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ABSTRACT OF DISSERTATION

PRECLINICAL EVALUATION OF LOBELINE FOR THE TREATMENT OF
ADHD: COMPARISON WITH PSYCHOSTIMULANT THERAPIES
This dissertation work investigated the effect of acute and repeated in vivo
administration of lobeline on dopamine transporter (DAT) and vesicular
monoamine transporter (VMAT2) function. The effects of lobeline were then
compared to the effects of acute and repeated in vivo administration of
methylphenidate and amphetamine to determine if lobeline produced similar
effects compared to these Attention Deficit Hyperactivity Disorder (ADHD)
medications. These medications are considered the first line of pharmacotherapy
for ADHD, although there is a growing concern associated with their potential for
abuse and other side effects. This merits the need for novel ADHD treatments
that have a safer side effect profile. If lobeline alters DAT and VMAT2 function in
the same way as methylphenidate or amphetamine, further investigation may be
necessary to evaluate lobeline as a potential treatment for ADHD. Kinetic
analysis of [3H]dopamine (DA) was utilized to determine the effect on DAT and
VMAT2 function in rat striatum. Results from the DAT experiments, revealed that
lobeline as well as amphetamine had no effect on DAT function. However,
methylphenidate increased DAT function after acute and 7-day treatment. None
of the drug treatment regimens altered Km. To determine if the methylphenidateinduced increase in DAT function was due to DAT trafficking, biotinylation and
Western blot analyses were performed. Acute administration of methylphenidate
did not alter surface DAT, however repeated administration of methylphenidate
for 7 days decreased intracellular DAT, suggesting that methylphenidate
redistributes DAT in a time-dependent manner. Similar results were found in the
VMAT2 experiments. Lobeline and amphetamine had no effect on VMAT2
function after acute or repeated administration. Amphetamine decreased the Km
after repeated administration for 7 days. Methylphenidate increased VMAT2
function after acute and repeated administration for 7 days. The overall results of
these experiments suggest that methylphenidate interacts with DAT and VMAT2
in a different manner than amphetamine and lobeline. In addition, since lobeline
and amphetamine had no effect on DAT and VMAT2 function, further
investigation is warranted to elucidate the underlying mechanisms of the
therapeutic actions of these agents. This additional information will aid in the
development of novel treatments for ADHD.
Keywords: lobeline, methylphenidate, amphetamine, striatum, ADHD, dopamine
transporter, vesicular monoamine transporter
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Chapter One

Introduction and Background
A.

Attention-Deficit Hyperactivity Disorder
Attention-Deficit Hyperactivity Disorder (ADHD) is defined in the

Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) as primarily
a childhood psychiatric disorder; however, 30-60% of childhood cases continue
into adulthood (American Psychiatric Association, 2000; Himelstein & Halperin;
2000). Historically, this disease was labeled a “mental restlessness or a disease
of attention”, specifically in 1798 by Sir Alexander Crichton, a Scottish author and
physician (Palmer & Finger, 2001). However, Sir George Fredrick Still, a British
pediatrician, is most well-known for describing in 1902 the clinical manifestations
of ADHD, based on his observations of over 40 children with serious problems of
sustained attention and self-control. Sir Still described the behavior of these
children as a “quite abnormal incapacity for sustained attention” (Still, 1902).
Over the years, the classification of this condition has evolved from hyperkinetic
reaction of childhood disorder to attention deficit disorder in 1980 to ADHD,
which includes the hyperactivity component of the behavior (American
Psychiatric Association, 1987).
1.

Prevalence

ADHD is a major clinical and public health problem due to its disruptive
nature in school-age children, and rising prevalence and impact on the economy
(Meijer et al., 2009). Research has shown that boys are 3 times more likely to
have ADHD compared to girls (Barkley et al., 1990; Faraone et al., 2003). The
world-wide prevalence of ADHD is 5-12% and 3-5% in children and adults,
respectively, in the United States, depending on the diagnostic criteria utilized
(Brown et al., 2001b; Faraone et al., 2003; Kessler et al., 2005; Kessler et al.,
2006; Polanczyk et al., 2007). The estimated mean annual cost for a
child/adolescent with ADHD in the United States is $14,576 which includes
health and mental healthcare costs ($2,636), education ($4,900), and crime and
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delinquency ($7,040) with a range of $12,005 to $17,458 (Pelham et al., 2007).
The overall cost of illness based on the 2000 census of 60 million school-aged
children was estimated to be $42.5 billion annually, of which $7.9 billion is health
and mental healthcare costs, $13.6 billion is educational cost, and $21.1 billion is
crime and delinquency costs (Pelham et al., 2007). Based on the prevalence in
adults, the estimated cost of ADHD is between $36-77 billion, which is close to
the costs associated with alcohol abuse ($85 billion); greater than the costs
associated with drugs of abuse such as cocaine and marijuana ($58 billion);and
greater than costs associated with depression ($43 billion) (Pelham et al., 2007;
Reinberg, 2004). Furthermore, the National Health Statistics Report estimated
that there were as many as 7 million ambulatory care visits for ADHD in 2006
(Schappert, 2008). In addition, a study that included 10 countries concluded that
adult ADHD was associated with 143.8 million lost days of productivity each year
(de Graaf et al., 2008) and another study reported a work loss cost of adults with
ADHD that is approximately $3.7 billion in the US (Birnbaum et al., 2005). Taken
together, it is clear that ADHD has a huge economic impact on the health and
economy for the US, as well as the world.
2.

Etiology

The etiology of ADHD is unknown; however, there has been an enormous
amount of research conducted on this topic. Generally, the overall conclusion is
that the etiology of ADHD is complex and involves a combination of factors.
These factors include genetics, prenatal exposure to tobacco smoking, or
alcohol, or to both tobacco smoking and alcohol simultaneously (Betel, 1995;
Dawson, 2000; Mayfield, 2008).
As stated above, an important factor is genetic predisposition. Twin and
adoption studies show that genes play a vital role in the familial transmission of
ADHD (Biederman & Faraone, 2005). For example, adoptive relatives are less
likely than biological relatives to have the disorder or associated symptoms
(Sprich et al., 2000). Numerous family studies have shown that there is a genetic
link to ADHD, such that 25-33% of parents of ADHD children have ADHD
themselves (Cormier, 2008). Specifically, variants of genes associated with
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dopamine (DA) neurotransmission have been investigated most commonly with
respect to the etiology of ADHD (Faraone & Khan, 2006). These polymorphic
genes include the DA D4 receptor gene (DRD4) (Benjamin et al., 1996; Gabriela
et al., 2009; Rubinstein et al., 1997; Tahir et al., 2000), the DA D5 receptor gene
(DRD5) (Hawi et al., 2005; Manor et al., 2004; Mill et al., 2004; Tahir et al.,
2000), and the DA transporter gene (Barr et al., 2001; Cook et al., 1995; Giros et
al., 1996; Hawi et al., 2009; Henriquez et al., 2008; Hiongwa et al., 2004).
Research has been conducted on ADHD using D4 knock-out (D4KO)
mice. D4KO mice are genetically altered mice that have had the D4 receptor
gene deleted. D4KO mice were found to have a 32% decreased basal locomotor
activity compared to wild-type (Rubinstein et al., 1997). In addition, this study
revealed that the D4KO mice were more sensitive to cocaine (15 and 30 mg/kg)
and methamphetamine (1 and 2 mg/kg) administration, as demonstrated by a
two-fold increase in stimulant response in D4KO mice compared to WT. These
results suggest that the DRD4 gene is involved in hyperactivity, an ADHD
hallmark symptom, as well as response to psychostimulants that are used as
treatments for ADHD.
To follow up on the results of this preclinical study employing D4KO mice,
relationships between the DRD4 exon III sequence variants and personality test
scores were evaluated in 315 mostly male siblings and other family members of
individuals with ADHD (Benjamin et al., 1996).

An association was found

between the DRD4 variants and the novelty seeking personality trait in relatives
of the ADHD individuals. Another study examined the association of the DRD4-7
repeat (DRD4-7r) allele with novelty seeking in a sample of 303 15-year old
adolescents (144 males and 159 females) using data from a high-risk community
sample (Becker et al., 2005).

Males with the DRD4-7r allele polymorphism

scored significantly higher with respect to the novelty seeking personality trait
(p=0.002) of the Junior Temperament and Character Inventory and no
association was found in females. However, a meta-analysis of 20 studies
conducted by Kluger et. al., 2002, found no association between the DRD4
polymorphism and novelty seeking. A meta-analysis combines the results of
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several studies that address a set of related research hypotheses. In its simplest
form, this is normally by identification of a common measure of effect size, for
which a weighted average might be the output of a meta-analyses. Here the
weighting might be related to sample sizes within the individual studies. More
generally there are other differences between the studies that need to be allowed
for, but the general aim of a meta-analysis is to more powerfully estimate the true
"effect size" as opposed to a smaller "effect size" derived in a single study under
a given single set of assumptions and conditions. It is only a statistical
examination of scientific studies, not an actual scientific study, itself.
Nevertheless, the presence of high variability of the association between
DRD4 polymorphism and novelty seeking suggests that there are unknown
causes for observing weak to moderate positive effects in some studies. This
issue could be addressed more fully by utilizing more advanced statistical
techniques, high-through output genotyping and large numbers of polymorphoric
markers such as single nucleotide polymorphisms.
With respect to the DRD5 gene polymorphism, a transmission
disequilibrium test (TDT) was used to evaluate the linkage of the DRD5 gene
variant and ADHD (Hawi et al., 2005). ADHD was associated with over
transmission of the variant paternal alleles of both DRD5 and DRD4 genes.
Another study using TDT found only a trend for an association with the DRD5
gene, but a significant increase in transmission of the DRD4-7r allele in ADHD
individuals (Tahir et al., 2000). Also, the role of DRD5 gene in ADHD individuals
was studied by genotyping ADHD families and searching for the 148 base pair
allele of DRD5 (Manor et al., 2004). A preferential transmission of this variant
DRD5 gene was confirmed using TDT with the Family Based Association Test,
suggesting that the DRD5 repeat polymorphism confers a small, but significant
(p=0.037) risk for ADHD (Manor et al., 2004). Taken together, the results of these
studies suggest that the DRD5 gene also plays a role as a genetic factor
contributing to ADHD, which needs to be further evaluated.
The DAT1 gene is another gene that has been found to be associated with
ADHD. The association between the presence of ADHD and the 480-bp DAT1
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allele was determined in 49 subjects with ADHD based on DSM-IV criteria using
the haplotype-based haplotype relative risk (HHRR) method to avoid effects
associated with the small sample of subjects with regards to
stratification (Cook et al., 1995).

population

This study found a significant association

between the 480-bp DAT1 allele and ADHD. As a preclinical correlate, a
disruption by homologous recombination of the mouse DAT gene knock-out
(DAT-KO) resulted in 3-fold greater spontaneous hyperactivity, demonstrated as
immediate hyperactivity when placed in a chamber with no treatment given,
compared to heterozygotes and WT mice. Since hyperactivity is a hallmark
symptom of ADHD, the DAT gene was suggested to be involved in the etiology of
ADHD (Giros et al., 1996). Another study investigated the variable number
tandem repeats (VNTR) polymorphism of DAT1, which is a location on the
genome where a short nucleotide sequence is organized as a tandem repeat,
where a pattern of 2 or more nucleotides is repeated and the repetitions are
directly adjacent to one another (Barr et al., 2001). To determine if the VNTR was
associated with ADHD; 333 subjects from 102 nuclear families were genotyped.
A linkage of the 480-bp allele of the DAT1 gene with ADHD was found,
suggesting that molecular analysis of the DAT gene may identify mutations that
increase the risk for ADHD.
The utilization of pharmacogenomics, which is a branch of pharmacology
involving the influence of genetic variation on drug response by relating gene
expression or polymorphisms with a drug’s efficacy or toxicity, may be a potential
method

in

developing

a

gene

therapy

for

ADHD.

For

example,

pharmacogenomics is used in cancer research to determine which patient will
have the best response to a certain treatment. Hopefully, in the same way
biochemical analysis of these mutations in specific patients could lead to the
development of more efficacious therapeutic treatment options for individuals
with ADHD.
In addition to DAT, the norepinephrine transporter (NET) gene is of
interest due to the efficacy of atomoxetine, a selective norepinephrine uptake
inhibitor, as a treatment for ADHD. In addition, NET is primarily responsible for
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the reuptake of DA in the frontal cortex due to the low density of DAT in this brain
region. In one study, 184 unrelated males (mean age 34.1 yrs) with adult ADHD
were assessed according to the International Classification of Diseases (ICD-10),
10th revision: Clinical Modifications, 6th (Greydanus et al., 2007), criteria for
ADHD (Retz et al., 2008). The results of this study found negative evidence of
an association between the NET gene and ADHD. However, this result could be
due to the fact that this was a study of adults in Germany with ADHD who may
have less severe ADHD symptoms compared to adolescents; such that the age
of the subjects and location of the study could play a role in the results. In
contrast, Kim et al., (2006, 2008) observed in two separate studies a significant
association between the polymorphism of the NET gene and ADHD, suggesting
that anomalous transcription factor-based repression of NET may increase risk
for the development of ADHD (Kim et al., 2006; Kim et al., 2008). Given the
controversial results found in the investigation of the NET gene in regards to the
etiology of ADHD, it is difficult to draw any conclusions as to its association with
ADHD.
Based on the evidence provided, genetics may play a vital role in the
etiology of ADHD. There is still much to be determined in regards to which
specific polymorphisms are more responsible for the development of ADHD,
however, future advances that will be made in this area will help gain a better
understanding of the role that genetics play in the etiology of ADHD.
Other studies have shown that environmental conditions such as prenatal
exposure to alcohol and tobacco smoking may be associated with the
development of ADHD in childhood (Linnet et al., 2003; Mick et al., 2002;
Milberger et al., 1996; Milberger et al., 1998). One study assessed 1,452 twin
pairs and found that maternal smoking shows an association with ADHD
symptoms in the offspring (Thapar et al., 2003). A meta-analysis on literature
published before 2005 revealed a pooled odds ratio indicating more than a 2-fold
increase in the risk for ADHD in individuals whose mothers smoked tobacco
during pregnancy (Langley et al., 2005), suggesting that maternal smoking during
pregnancy is a risk factor for ADHD.

With respect to alcohol exposure, one
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study assessed 68 children who were born into three separate groups, women
who reported not drinking during pregnancy, women who reported drinking
during pregnancy, and women who reported drinking an equivalent amount, but
who stopped after an educational intervention during the second trimester
(Brown et al., 1991). The results showed those children who were exposed to
alcohol throughout pregnancy showed deficits in the ability to sustain attention.
Another study analyzed a twin cohort consisting of 922 children with a history of
maternal alcohol use (Knopik et al., 2006). The study used a children-of-twins
design, which is a design that incorporates twins in order to explore the effects of
genetics and environmental variance on a phenotype. In addition, diagnostic
telephone interview data from high-risk families and control families targeted from
a large Australian twin cohort were employed. The calculated odds ratio
(OR=2.53) suggested that children exposed to prenatal alcohol were two-times
more likely to exhibit ADHD compared to those not exposed to prenatal alcohol.
The findings from the aforementioned studies imply that maternal alcohol and
tobacco use may play a key role in the etiology of ADHD.
Evidence has shown that these risk factors of maternal tobacco and
alcohol use may be important etiologies of ADHD. These risk factors may work in
concert with genetic factors, in that the exposure to nicotine and alcohol may
interact with genetic polymorphisms, making these children more at risk for
ADHD. In contrast, there are children who were not exposed prenatally to
nicotine or alcohol that have ADHD. With that in mind, further research is
necessary to fully address the complexity of the etiology of ADHD.
3.

Symptomology and Diagnosis

ADHD presents as a myriad of symptoms including the hallmarks,
hyperactivity, impulsivity and inattention, with 30-60% of childhood cases
extending into adulthood (American Psychiatric Association, 2000; Himelstein &
Halperin, 2000). The specific symptoms listed as diagnostic criteria for ADHD in
the DSM-IV-TR include:
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1)

Six or more of the following symptoms of inattention have

persisted for at least 6 months to a degree that is maladaptive and
inconsistent with the developmental level:
a)

Often fails to pay close attention to details or makes
careless mistakes in schoolwork, work, or other
activities

b)

Often has difficulty sustaining attention in tasks or
play activities.

c)

Often does not seem to listen when spoken to directly

d)

Often does not follow through on instructions and fails
to finish schoolwork, chores, or duties in the
workplace (not due oppositional behavior or failure to
understand instructions)

e)

Often has difficulty organizing tasks and activities

f)

Often avoids, dislikes, or is reluctant to engage in
tasks that require sustained mental effort (such as
schoolwork or homework)

g)

Often loses things necessary for tasks or activities
(i.e., toys, school assignments, pencils, books, or
tools)

2)

h)

Is often easily distracted by extraneous stimuli

i)

Is often forgetful in daily activities

Six

or

more

of

the

following

symptoms

of

hyperactivity/impulsivity have persisted for at least 6 months to a degree
that is maladaptive and inconsistent with the developmental level:
a)

Often fidgets with hands or feet or squirms in seat

b)

Often leaves seat in classroom or in other situations
in which remaining seated is required

c)

Often runs about or climbs excessively in situations in
which it is inappropriate (in adolescents or adults,
may be limited to subjective feelings of restlessness)
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d)

Often has difficulty playing or engaging in leisure
activities quietly

e)

Is often “on the go” or often acts as if “driven by a
motor”

f)

Often talks excessively

g)

Often blurts out answers before questions have been
completed

h)

Often has difficulty waiting

i)

Often interrupts or intrudes on others (butts into
conversations or games)

(American Psychiatric Association, 2000; Greydanus et al., 2007)
Some of the hyperactive-impulsive or inattentive symptoms that cause
impairment were present before 7 years of age. In addition, some impairment
from the symptoms is observed in 2 or more settings (i.e., at school, work, or at
home). Due to the complex symptomology, ADHD has been divided into three
subtypes: a) predominantly inattentive (known as Attention-Deficit Disorder
(ADD),

b)

predominantly

hyperactive/impulsive,

and

c)

combined

hyperactive/impulsive and inattentive subtypes, to help obtain a more accurate
diagnosis and treatment of the disorder (American Psychiatric Association,
2000). The inattentive subtype is characterized by inattention, distractibility,
disorganization, forgetfulness, and lethargy. The hyperactive-impulsive subtype
includes symptoms of interrupting, impatience, and fidgetiness. The combined
subtype is a combination of both the inattentive and hyperactive-impulsive
subtypes (Tamm et al., 2001). Dividing ADHD into these subtypes is helpful with
respect to treatment, because ADHD symptoms are unique to each patient
depending on their specific subtype and their individual response to the
medication. Russell Barkley, a renowned ADHD researcher believes that
methylphenidate is more effective in treating ADHD and that amphetamine is
better suited for the treatment of ADD. This is based on the mechanism of action
of amphetamine causing it to have a greater effect on norepinephrine than
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dopamine, therefore, having more of an effect on the inattentive symptom
(Barkley, 2001).
Impulsivity and sensation seeking are personality traits that have been
linked together for various reasons (Nower & Blaszczynski, 2006). Impulsivity is
defined as “the failure to resist an impulse, drive, or temptation to perform an act
that is harmful to the person or others” (American Psychiatric Association, 2000).
Sensation seeking is defined as “the seeking of varied, novel, complex and
intense sensations and experiences, and the willingness to take physical, social,
legal, and financial risks for the sake of such experiences (Zuckerman, 1994).
Adolescence appears to be a critical period of development for these traits. Two
systems that are involved in the development of adolescent behavior are the
subcortical socioemotional system and the cognitive control system (Nower &
Blaszczynski, 2006). The subcortical socioemotional system includes the ventral
striatum and the amygdala, which is responsible for emotion, novelty, and
reward. The cognitive control system includes the prefrontal cortex, which is
crucial for impulse control, emotion regulation, and decision-making. These
systems mature at different time points throughout the course of development.
For example, the socio-emotional system appears to become more sensitive in
early adolescence, during the same time of the onset of puberty. However, the
cognitive control system develops more gradually during the end of early
adulthood (Casey et al., 2005).

Therefore, adolescents may experience an

increased responsiveness to rewards, affective cues, and novelty while still
having immature capacities for impulse control and inhibition. A recent report
conducted in humans found that mean levels of impulsivity were found to decline
through adolescence and then plateau as youth reached their mid-20s; however,
mean levels of sensation seeking were found to increase profoundly until midadolescence, peaking around the age of 16 and then slowly decreasing through
the mid-20s. Various experimental methods have been developed to examine
impulsivity and sensation seeking in an animal model; however, most of these
methods have only used a single task as the predictor variable. A novel study
determined if measuring multiple behavioral tasks simultaneously would be
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useful for characterizing aspects of sensation seeking and impulsivity as
predictor variables for amphetamine self-administration (Marusich et al., 2011a).
This study found that combining these predictor variables into a multivariate
approached failed to produce any significant correlations among predictor and
outcome measures. The results imply that multivariate tests are possibly
insensitive as reliable predictors of drug self-administration, which could
represent a limitation of animal models for assessing drug abuse vulnerability, at
least for this particular study.
In conclusion, impulsivity and sensation seeking are human traits that are
multifaceted and require a great deal of skill to evaluate. Furthermore, assessing
these traits in an animal model is even more of a challenge based on the
difference in life span between and human and a rat. In addition, impulsivity and
sensation seeking are human traits that may not be fully modeled in laboratory
animals. Studies have shown a relationship between impulsivity and sensation
seeking, however more research is warranted to determine the extent of this
relationship.
Evaluation and diagnosis of ADHD are subjective because there are no
objective diagnostic measurements to test for ADHD. However, there are
numerous specific diagnostic criteria of ADHD available to assist clinicians in the
diagnosis. The overall desired outcome of assessment criteria is to determine if a
child or adult meets the qualifications for ADHD, which may rule out other
conditions (Liu & Leslie, 2003). Other medical, psychiatric, or developmental
disorders must be ruled out before the presence of developmentally
inappropriate levels of inattention and/or hyperactivity/impulsivity can be
diagnosed as ADHD (American Psychiatric Association, 2000). There are three
commonly used diagnostic tools, including the DSM-IV-TR, Classification of Child
an Adolescent Mental Diagnosis in Primary Care: Diagnosis and Statistical
Manual for Primary Care (DSM-PC), and the ICD-10 (Greydanus et al., 2007).
The American Psychiatric Association (APA) publishes the DSM-IV-TR and gives
the most detailed list of symptoms by classification with diagnostic codes and
criteria used to evaluate the disorder as stated previously. These methods for
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diagnosis were developed based on different settings that patients are evaluated
in, and generally are similar. Therefore, the most appropriate assessment
method is chosen based on setting. The DSM-PC, intended for primary care
environments, uses a developmental approach to diagnosis, and distinguishes
between variations, problems, and disorders. The ICD-10 uses the term
attention-deficit/hyperkinetic disorder, which is commonly used by insurance
companies (Greydanus et al., 2007). Questionnaires and rating scales, such as
the Connors ADHD Index and the DSM-IV Symptoms scales have been
suggested by the American Academy of Pediatrics (Forsback et al., 2004) as
guidelines to ensure accurate diagnosis (Tripp et al., 2006). The Connors ADHD
Index has various different versions based on who is taking the assessment
(Conners, 1999). For example, there is the Conners’ Parenting Rating Scale
Revised-Long Version (CPRS-R:L). This version contains 80 items with 10
different scales for the parents or caregivers to complete. The short version
(CPRS-R:S) contains only 27 items and 4 scales. There is also the ConnersWell’s Adolescent Self-Report Scale-Long Form (CASS:L). This self-report scale,
which is ideal for adolescents between the ages of 12 and 17, contains 87 items
and 8 scales. There is also an assessment for adults called the Conner’s Adult
ADHD Rating Scale-Self Report: Short Version (CAARS-S:S). It contains 26
items that quantitatively measure ADHD symptoms while looking at the
manifestations of ADHD in adults. Subjects read descriptive statements that they
may, or may not, be presently experiencing (i.e., I have trouble sitting still).
Subjects rate each statement on a four-point Likert scale ranging from “Not at all”
to “Very much”. CAARS subscales include: A = Inattention/Memory Problems, B
= Hyperactivity/Restlessness, C = Impulsivity/Emotional Reliability, D = Problems
with Self-Concept and E = Total ADHD Index. In summary, there are several
tools that clinicians can utilize to ensure accurate evaluation and diagnosis of
ADHD.
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4.

Neuroanatomical and Neurochemical Basis of ADHD
a.

Neuroanatomy

The neuroanatomical and neurochemical basis of ADHD is based on the
general consensus that there is a dysregulation of the catecholaminergic
neurotransmitter systems (Heal et al., 2008). Neuroimaging studies have
suggested that brain regions, including the prefrontal cortex (PFC) and the basal
ganglia (striatum, caudate nucleus and putamen)

are the regions with

dysregulation of neurotransmission in ADHD (Casey et al., 2007). The PFC and
striatum are the most widely studied regions regarding ADHD, because these
regions are involved in behavior, attention, motor control and cognition (Arnsten,
2006; Kieling et al., 2008). Specifically, motor control is modulated by the
nigrostriatal DA pathway projecting from the substania nigra to the basal ganglia
(Stanwood & Zigmond, 2000).

The mesolimbic pathway, projecting from the

ventral tegmental area (VTA) to the subcortical limbic regions (nucleus
accumbens, olfactory tubercle and amygdala) is associated with motivated
behavior (Ikemoto & Panksepp, 1999) and reinforcement (Schultz et al., 2000).
The mesocortical DA pathway projects from the VTA to the PFC and is involved
in cognitive function (Floresco & Magyar, 2006).
Noradrenergic neurons originate both in the locus coeruleus and the
lateral tegmental area. Norepinephrine containing cell bodies are only found in
the pons and medulla. However, the pontine norepinephrine-containing cells
which terminate in the nucleus locus coeruleus, give rise to extensive projections
to the hypothalamus, thalamus, limbic regions, and cortex. Medullary
norepinephrine cells project to the hypothalamus, locus coeruleus, and spinal
cord (Rinaman, 2011).
b.

Neurochemistry
i. DA synthesis and metabolism

Research on the neurochemical basis of ADHD has focused primarily on
dopaminergic neurotransmission and function (Figure 1). DA is transported by
DAT and pharmacological agents that influence the DA system via DAT have
been the most effective treatments for ADHD (Zhu & Reith, 2008). DA is a
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catecholamine involved in behavior and cognition; voluntary movement,
motivation and reward (Jaber et al., 1996). The synthesis of DA takes place in
DA neurons, starting with L-tyrosine which comes from the essential amino acid,
phenylalanine, which is derived from food. L-Tyrosine is converted to Ldihydroxyphenylalanie (L-DOPA) via an enzyme located in the cytosol called
tyrosine hydroxylase (TH), which is the rate limiting step in the synthesis of DA
(Cooper et al., 2003). The co-factors for tyrosine hydroxylase include
tetrahydrobiopterin, O2, and Fe2+ (Cooper et al., 2003). Enzyme activity is
regulated by phosphorylation at four different serine sites at the N-terminus and
through the end-product inhibition and through competition for the required
cofactors for the enzyme (Cooper et al., 2003). L-DOPA is then decarboxylated
by aromatic L-amino acid decarboxylase (also located in the cytosol), which
produces DA. The co-factor for this enzyme is pyridoxal 5-phosphate and is
regulated by induction of synthesis of new protein rather than changes in activity
(Squire LR, 1999). After DA is synthesized, it is stored in synaptic vesicles for
future release from the terminal into the synapse. An action potential causes
depolarization of the nerve terminal, which in turn causes the synaptic vesicles to
fuse to the synaptic membrane and release DA into the synaptic cleft (Cooper et
al., 2003; Squire LR, 1999).

Specifically, Na+ ions flow into the cell and K+

channels open allowing the flow of K+across the membrane causing the
membrane to become depolarized. There is a rise in Ca2+ concentration that
triggers the fusion of the vesicles with the plasma membrane and the release of
their contents into the synaptic cleft. This is the physiological process known as
exocytosis (Squire LR, 1999).
DA is inactivated by two enzymes, catechol-O-methyltransferase (COMT)
and monoamine oxidase (MAO) that are located in the postsynaptic neuron and
outer mitochrondrial membrane, respectfully. The pathway for the metabolism of
DA by MAO involves the conversion of DA to 3, 4-dihydroxyphenylacetaldehyde.
Then, this product is converted to dihydroxyphenylacetic acid (DOPAC) by
aldehyde dehydrogenase. Subsequently, DOPAC is converted by COMT to form
homovanillic acid (HVA). Another possible pathway is for DA to be converted to
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3-methoxytyramine (3-MT) by COMT. 3-MT is then converted to 3-methoxy-4hydroxyphenylacetaldehyde, which is then converted to homovanillic acid (HVA)
by aldehyde dehydrogenase.
ii. DA receptors
In the synapse, DA has access to both presynaptic and postsynaptic DA
receptors to which it binds. DA acts at both the D1-like (D1 and D5) and D2-like
(D2, D3, D4) receptor families (Arnsten, 2006). The amino acid (AA) sequence
for the entire family ranges from 387 AA (D4) – 477 AA (D5). The main structural
differences between the D1-like and D2-like receptors are the intracellular loop
between the 6th and 7th transmembrane domain (TMD) segments which are
larger in the D2-like receptors. D2 receptors have a smaller C-terminal in the
intracellular segments after the 7th TMD segment. There are two isoforms of the
D2 receptor, D2-long and D2-short. The D2-long receptor has 444 AA in rats and
443 AA in humans (Cooper et al., 2003). The D2-short has 415 AA in rats and
414 AA in humans. D1 receptors have a high density in striatum and nucleus
accumbens and their activation stimulates adenylate cyclase to produce cyclic
adenosine monophosphate (cAMP). D5 receptors are mostly located in
hippocampus and hypothalamus, but are found also in striatum and nucleus
accumbens to a lesser extent. The D5 receptor, which also stimulates adenylate
cyclase, is only located in the hippocampus, thalamus, and hypothalamus. D5
receptors have a 10-fold higher affinity for DA compared to D1 receptors (Cooper
et al., 2003).
The D2 receptor family includes the D2 subtype, which are both an
autoreceptor located presynaptically and a postsynaptic receptor. The release of
DA regulates the synthesis of DA by stimulating the DA receptors which can
modulate the synthesis of DA via a negative feedback, such that when there is a
decrease in DA, the DA receptors are stimulated to produce more DA (Cooper et
al., 2003). A greater number of D2 receptors are located on the postsynaptic
membranes, compared to presynaptic D2 receptors. Postsynaptic D2 receptors
are located in striatum, nucleus accumbens, olfactory tubercle, and neuron cell
bodies in substantia nigra and VTA D1 and D2 receptors have opposite effects
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on adenylate cyclase activity. Adenylate cyclase catalyzes the conversion of ATP
to c-AMP and pyrophosphate via a G-protein, which signals a downstream
cascade of events, including the activation of protein kinase A (PKA).
Recently,methylphenidate was suggested to modulate D2 receptors, thus
indicating the involvement of this receptor in the mechanism of action of
methlyphenidate (Volz et al., 2008). D3 receptors are localized in the nucleus
accumbens, olfactory tubercle, and hypothalamus. The D4 receptors are found in
frontal cortex, midbrain, and amygdala.
iii. DAT
After DA binds to its receptors, it is then transported back into the terminal
by DAT and is transported into vesicles by the vesicular monoamine transporter
(VMAT2) for repackaging and future exocytotic release (Hiongwa, 2004). DAT
plays a vital role in the function of DA. DAT is among the family of 12
transmembrane domain (TMD; Figure 2) neurotransmitter transporter sodium
symporter class (Saier, 1999), which also includes the norepinephrine transporter
(NET) and the serotonin transporter (SERT).

DAT is a Na+/Cl- dependent

transmembrane transporter protein also called the neurotransmitter sodium
symporter (NSS) that regulates the extracellular DA concentration (Amara &
Sonders 1998; Krause et al., 2003). DAT contains 620 amino acid residues, and
currently, there is no X-ray crystal structure of DAT. However, the recently
published crystal structure of Aquifex aedicus leucine transporter (LeuTAa), allows
researchers to have a suitable template for DAT because this prokaryotic
organism processes a NSS that is homologous to the human NSS (Yamashita et
al., 2005). LeuTAa produced crystals which were determined by multi-wavelength
anomalous dispersion (MAD), using crystals grown from selemethionine-labeled
protein and diffraction data measured to Bragg spacings of 1.9A°. A more recent
study employed a novel computational modeling approach, the Molecular
Operating Environment program MOE 2005.06 and to two other modeling
servers, using LeuT-Aa as a template, to expand upon the proposed molecular
structure of DAT. As shown in Figure 2, the DAT model that was developed
suggests, like the LeuTAa, that TMDs 3 and 8 combine with TMDs 1 and 6 to form
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the substrate binding pocket. In addition, this model implies favorable interactions
for substrate recognition between the 3rdTMD, and the valine amino acid, number
152 side chain and either the aromatic ring or the lipophilic hydrocarbon portion
of both DA and amphetamine (Indarte et al., 2008).
DAT antibodies, which were all used for immunolocalization of DAT in rat
brain at the light microscopic level, were characterized and developed by
immunoblot

analysis,

immunoprecipitation,

and

immunocytochemistry

to

specifically detect DAT proteins. DAT is mainly expressed in the striatum and
nucleus accumbens, but can also be found in the globus pallidus, cingulated
cortex, olfactory tubercle, amygdala, and midbrain (Ciliax et al., 1995).
DAT-like immunoreactivity has been detected in striatum, nucleus
accumbens, olfactory tuberacle, nigrostriatal bundle, which is a group of nerve
fibers and lateral habenula (Hersch et al., 1997). The specific localization of
DAT on the synaptic terminal has been studied using dual localization of DAT
and TH with electron microscopic immunocytochemistry in the rat ventral
pallidum (Pickel et al., 2004). Electron microscopy confirmed that the majority
of DAT and TH were located in axonal profiles in the ventral pallidum. These
findings were the first to provide structural evidence showing that DAT is
localized to the axonal profiles with a significantly higher mean area density in
the dorsolateral ventral pallidum than the ventromedial ventral pallidum. The
pallidum is important because it is a major element of basal ganglia, which
includes the striatum, which is also the region used in the studies of this
dissertation research.
There has been a wealth of research performed on DAT knock-out (KO)
mice as well (Fauchey et al., 2000; Gainetdinov & Caron, 2003; Giros et al.,
1996; Hall et al., 2009; Jones et al., 1999; Jones et al., 1998a; Rocha et al.,
1998). This research was performed in order to gain a better understanding of
the function of DAT and to determine how the dopaminergic system acts in the
absence of DAT. One report found that despite the decreased amount of DA in
tissue, DAT KO mice have more than normal levels of extracellular DA and
spontaneous hyperlocomotor activity (Rocha et al., 1998). One study reported
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that DAT KO mice display a 300-fold increase in extracellular lifetime of DA and
a 5-fold elevation in steady-state extracellular DA levels in striatum (Gainetdinov
& Caron, 2003). In addition, these mice do not display an increase in locomotor
activity typically seen upon administration of high doses of cocaine (Giros et al.,
1996).
D1 and D2 receptor levels have also been investigated in DAT KO mice.
Jones and colleagues found that in striatum, the D1 and D2 receptors were
decreased by approximately 50%; TH levels were increased even though
protein levels were down nearly 90%; and total tissue DA levels were only 5% of
normal, whereas extracellular DA was increased by at least 5-fold in striatum
(Jones et al., 1998a). Another study found that D1R mRNAs coding decreased
for D1R and D2R by 34% and 36%, respectively in caudate putamen of DAT
KO mice, which suggest that there are fewer D1R and D2R receptors in DAT
KO mice (Fauchey et al., 2000). DAT KO mice have several characteristics
found in individuals that have ADHD including hyperactivity, cognitive
impairment, and a calming response to psychostimulants (Jones et al., 1999).
A more recent study further explored the effect of DAT KO by investigating
the rewarding effects of cocaine and the ability of repeated cocaine
administration to induce conditioned locomotion (Hall et al., 2009). Conditioned
locomotion is the process by exposing animals to drug or stimuli over a period
of time and then comparing those animals with control animals to determine if
the drug or stimuli caused neurochemical changes, which are reflected by a
change in locomotor activity. DAT KO mice were significantly more active
compared to WT; however they did not have increased locomotion after acute
cocaine administration. NET and SERT affect the ability of cocaine to produce
conditioned locomotion. These results suggest that the ability of cocaine to
produce conditioned locomotion is dependent on NET or SERT, but not DAT.
In summary, the research on DAT KO mice has illuminated the
mechanisms by which DAT acts and its importance to the overall dopaminergic
system. This work may also have implications for the development of certain
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pharmacological agents for disorders that involve DAT, such as drug abuse and
ADHD.
Numerous studies suggest that DAT is regulated by several mechanisms
including, but not limited to internalization and recycling, also known as
trafficking, which involves phosphorylation and protein-protein interactions
(Kahlig & Galli, 2003; Loder & Melikian, 2003; Melikian, 2004; Torres et al.,
2003; Zahniser & Doolen, 2001).

Great efforts have been made towards

elucidating the molecular and cellular mechanisms involved in the trafficking of
DAT. Many different kinases, receptors and scaffolding proteins interact with
DAT and regulate its activity or modulate its trafficking and degradation. Second
messenger systems, such as protein kinase C (Boudanova et al., 2008), protein
kinase A (PKA), and calcium-calmodulin kinase II alter DAT function,
phosphorylation, and trafficking. Furthermore, DAT endocytosis is suggested to
be the cause of the sustained DAT down-regulation in response to PKC
activation (Eriksen, 2010). Another post-translational modification that may be
involved in PKC activation is ubiquitination, a post-translational enzymatic
modification that involves the ε-amino moiety of lysine residues in target cellular
proteins (Miranda & Sorkin, 2007; Miranda et al., 2005; Sorkina et al., 2006).
Although the underlying mechanisms of DAT trafficking are still not fully
understood, new technical methodologies such as fluorescently tagged
inhibitors and substrates have advanced our understanding of DAT trafficking.
For example, fluorescence resonance energy transfer (FRET) experiments with
cyan fluorescent protein-tagged DAT and yellow fluorescent protein tagged
ubiquitin demonstrated that ubiquitination was most abundant in endosomes
supporting that ubiquitination is a signal for endocytosis (Miranda et al., 2005).
Other kinase pathways including downstream effectors of insulin signaling such
as phosphatidylinositol-3-kinase and serine/threonine protein kinase, Akt have
been shown to also affect DAT surface expression (Carvelli et al., 2002).
In addition, [3H]DA uptake kinetics was assessed and the cellular
localization profiles of the hDAT expressed in both Sf9 and COS-7 cells via
immunofluorescent confocal microscopy following modulation of PKC and
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protein PKA-dependent pathways were evaluated (Pristupa et al., 1998). Acute
exposure of hDAT expressing Sf9 cells to the PKC activator PMA (1 µM),
reduced the Vmax (approximately 1 pmol/min/105 cells) for [3H]DA uptake by
approximately 40%, an effect which was blocked by the protein kinase inhibitor,
staurosporine. Vmax is defined as the maximal velocity of uptake. Pretreatment
of cells with staurosporine (500 nM) alone, however, increased [3H]DA uptake
by approximately 30%, an effect mimicked by the potent PKA inhibitor
Rp-cAMPS. Immunofluorescent confocal microscopy showed that PKC
activation rapidly internalized the hDAT from plasmalemmal membrane, but
PKC inhibition led to trafficking of hDAT to the cell surface. These results
suggest that the differential regulation of DAT transport capacity by both PKCand PKA-dependent pathways are not a result of modifications in DAT kinetics
and that DAT function may be regulated by second messenger systems,
possibly following activation of presynaptic DA receptors (Pristupa et al., 1998).
A recent report has also suggested that the PKC-induced DAT regulation
may depend on the membrane localization of the transporter in reference to raft
and non-raft DATs (Foster et al., 2008). Lipid rafts contain 3 to 5 times more
cholesterol than the surrounding bilayer. They are heterogeneous, dynamic
membrane microdomains enriched in cholesterol and glycosphingolipids, which
are wider than non-raft regions and resistant to solubilization by detergents.
Lipid rafts are associated with internalization and endocytic cargo delivery.
DATs are located between raft and non-raft microdomains in rat striatal tissue
and have the potential to effect dopaminergic neuronal activity (Foster et al.,
2008). Decrease of surface DAT was only found in non-raft DAT populations.
These results suggest that trafficking events regulate non-raft DATs and nontrafficking regulatory mechanisms occurs in raft DATs. These authors identified
the presence of DAT in cholesterol-rich membrane raft domains, which could
possibly serve as a platform for regulatory DAT activity, phosphorylation, and
subcellular interactions. Thus, DAT is distributed between membrane raft and
non-raft populations, where it is subject to specific regulatory controls that could
provide distinct modulation of DA clearance and efflux. More recently, Sorkina
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et al., (2009) found that the intracellular N-terminal tail of DAT has an inhibitory
influence on internalization, by promoting the presence of DAT on the cell
surface. In addition, DAT-mediated uptake activity is increased by replacing the
first 65 amino acids of the N-terminal tail of DAT with a DAT mutant. This was
shown by visual examination of human epithelial cervical cancer cells (HeLA)
and porcine aortic endothelial cells (PAE). A significant accumulation of the DAT
mutant was found in intracellular compartments (Sorkina et al., 2009). Another
study used the fluorescent DAT substrate ASP+ and live cell imaging
techniques, such as bioluminescence resonance energy transfer (Brett) to
identify the role of two D2R-linked signaling pathways, extracellular signalregulated kinases 1 and 2 (ERK1/2) and phosphodinositide 3 kinase (P13K).
These pathways mediate D2R activation and up-regulate DAT function based
on the observations that ASP+ rapidly accumulated in the cytoplasm of EM
(embryonic) cells (Bolan et al., 2007). This accumulation was intensified by the
D2R agonist quinpirole. In addition, eticlopride a D2R antagonist blocked
quinpirole-evoked increase in ASP+ accumulation. Furthermore, the MEK
inhibitor PD98059 prevented quinopirole-evoked ERK1/2 phosphorylation, but
the PI3K inhibitor LY294002 had no effect. These results suggest that D2SR
regulation of DAT requires coupling to Gi/G0 proteins and ERK1/2 activation.
DAT has also been reported to generate detectable currents during the
process of substrate transport (DeFelice & Blakely, 1996; Lester et al., 1994;
Sonders & Amara, 1996). One study used two-electrode clamp techniques with
hDAT expressed in Xenopus laevis oocytes to examine the electrophysiological
and pharmacological characteristics of DAT (Sonders et al., 1997). Oocytes
expressing hDAT were voltage-clamped at -60 mV and were superfused with 20
µM DA, which produced a downward displacement in the current trace
consistent with a net inward current. The inward current was suggested to be
the result of the translocation of DA+ and Na+ ions. However, 10-µM cocaine
produced an outward current, both on initial application and reapplication of
cocaine after DA superfusion of the same oocyte. These findings suggest that
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hDAT mediates at least two distinct steady-state ionic conductances that result
from transport-associated currents (Sonders et al., 1997).
A more recent study combined confocal imaging, whole-cell steady-state
and transient current recordings with HEK-293 cells transfected with a yellow
fluorescent protein-tagged hDAT to monitor DAT cell surface expression and
activity (Kahlig et al., 2004).

At -160 mV, amphetamine decreased hDAT-

mediated transient currents, and these currents were dependent upon
extracellular Na+. In addition, these currents corresponded to the amphetamine
decrease in DAT expression at the cell surface, measured by cell-surface
biotinylation. These findings suggest that DAT transient charge movements can
be used to evaluate relative changes in DAT cell surface expression.
DAT is considered the main target for stimulant action, and stimulants
interact directly with DAT (Gainetdinov & Caron, 2003; Krause et al., 2003;
Volkow et al., 2007). A plethora of research has been conducted on the
mechanisms by which DAT is regulated and expressed. The studies discussed
here have shown how DAT may be regulated by a number of different pathways
and signaling messengers. Some of these pathways include PKA and PKC,
which are involved in the internalization of DAT. Others have investigated DAT
structure and how its conformation plays a role in the regulation of DAT. In
addition, studies were performed to determine how trafficking plays a role in DAT
expression and function. Furthermore, others have investigated how ion currents
involved in the electrophysiological and pharmacological characteristics of DAT.
Collectively, these studies have provided a better understanding of how DAT is
regulated and expressed. Hopefully the knowledge gained from this research will
lead to pharmacological agents that can be used in the treatment of diseases
that involve DAT, such as ADHD.
iv. NET
The norepinephrine transporter (NET) is the primary target for the first and
only non-stimulant medication, atomoxetine, Strattera® approved by the U.S.
Food and Drug Administration (FDA) to treat ADHD (Wilens, 2006). In addition,
methylphenidate and amphetamine, the gold standard ADHD treatments, inhibit

22

NET function in addition to inhibiting DAT function (Bymaster et al., 2002; Han &
Gu, 2006). The major function of NET is to translocate norepinephrine, a
neurotransmitter involved in mood regulation, behavior, alertness and arousal,
from the extracellular space to within the noradrenergic presynaptic terminals
(Barker & Blakely, 1995; Pacholczyk et al., 1991; Zavosh et al., 1999; Zhou,
2004). NET is a member of the same family of transporters as DAT and is also a
Na+/Cl- dependent transmembrane transporter protein (Hu et al., 2009; Zhou,
2004).
NET contains 617 amino acid residues (Torres et al., 2003). Human NET
(hNET) has 10 cysteine residues, and two of these which are located in the
second intracellular loop are linked by a disulfide bond (Sucic & Bryan-Lluka,
2005). TMD 2 and the first intracellular loop are important in determining cell
surface expression of the transporter (Sucic & Bryan-Lluka, 2005). Residues 94111 of NET appear to not be involved in substrate interactions; however, these
residues are associated with interactions with various inhibitors (Sucic & BryanLluka, 2005). The regulation of NET involves extracellular and intracellular
signaling pathways including several associated proteins such as SNARE protein
syntaxin 1A, protein phosphatase 2A (PP2A), catalytic sub unit (PP2A-C), and
PP2A anchoring subunit (PP2A-Ar) (Miner et al., 2006; Sung & Blakely, 2007;
Sung et al., 2005).
Xu and colleagues found that NET knockout mice have reduced body
temperature and body weight and are supersensitive to psychostimulants;
however,

they

have

reduced

intracellular

norepinephrine,

increased

norepinephrine synthesis and elevated extracellular norepinephrine (Xu et al.,
2000). These findings suggests that NET plays a role in regulating body
temperature and body weight, and that the mechanism of action of the stimulant
class of drugs involves NET, since in its absence supersensitivity to stimulants
occurs. Focus on the development of selective NET inhibitors as a treatment for
ADHD has increased, because of the potential abuse liability of stimulant
medications, whereas NET inhibitors do not appear to have this side effect (Seu
et al., 2009).
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v. VMAT2
Another important transporter for DA function is VMAT2, which is the only
transporter that translocates cytoplasmic DA from the cytosol into synaptic
vesicles for storage, providing availability for future exocytotic release (Yelin &
Schuldiner, 2002). VMAT2 and VMAT1 are members of the solute carrier (SLC)
protein family encoded by separate genes VMAT1 (SLC18A1) located on
chromosome 8p21 and VMAT2 (SLC18A2) located on chromosome 10q25
(Adam et al., 2008; Eiden et al., 2004). VMAT2 is an integral membrane protein
with 12 putative transmembrane domains containing a large, hydrophobic, Nglycosylated loop between TMD1 and 2 facing the vesicle cytosol (Yao & Hersh,
2007; Yelin & Schuldiner, 2002). During embryonic development, both VMAT1
and VMAT2 are widely expressed in the CNS; however, by adulthood, VMAT2
predominates (Hansson et al., 1998). The decrease in VMAT1 expression has
been suggested to be due to the absence of VMAT1 gene expression. In
adulthood, VMAT1 is primarily expressed in neuroendocrine cells such as
chromaffin cells found in the adrenal medulla and enterochromaffin cells located
in the intestinal tract (Erickson et al., 1996; Peter et al., 1995; Weihe et al., 1994).
VMAT2 is expressed in at least 2 endocrine cell populations, and moreover, in
neurons. Adult mammalian monoaminergic neurons of the central nervous
system and sympathetic postganglionic neurons express VMAT2, not VMAT1
(Erickson et al., 1996; Peter et al., 1995; Weihe et al., 1994).
The pharmacology of VMAT1 and VMAT2 is distinct. Although they both
transport monoamines such as serotonin, DA, epinephrine and norepinephrine,
VMAT1 transports histamine, whereas VMAT2 transports histamine (Km~ 24 µM;
(Erickson et al., 1996; Merickel & Edwards, 1995). Km is defined as the
concentration of substrate at half of maximal velocity. In addition, VMAT1 has a
higher affinity for serotonin compared to VMAT2 (Brunk et al., 2006). VMAT2 is
responsible for the transport of neurotransmitters such as DA, serotonin,
norepinephrine, epinephrine, and histamine from the cytosol into synaptic
vesicles (Schuldiner et al., 1995). VMAT2 is an essential protein as indicated by
the finding that homozygous VMAT2 knockout mice do not survive after birth
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(Fon et al., 1997; Takahashi et al., 1997; Wang et al., 1997). Tetrabenazine, a
benzoquinolizine compound (Zheng et al., 2006), and reserpine, an alkaloid, are
considered classical VMAT2 inhibitors (Pletscher, 1977). Studies have shown
that VMAT2 binding is altered by psychostimulants (Brown et al., 2001a;
Fleckenstein & Hanson, 2003). For instance, methamphetamine administration
(15 mg/kg; 4 ip injections at 2 hr intervals) decreases (22%) striatal VMAT2
binding of [3H]dihydrotetrabenazine, assessed 14 days after treatment (Guilarte
et al., 2003). Also, methylphenidate (40 mg/kg, sc) redistributes VMAT2 within
the nerve terminals an hour after treatment, distributing VMAT2 between the
cytoplasmic

and

membrane-associated

vesicle

fractions.

In

contrast,

methylphenidate did not cause redistribution since a majority of DAT was present
in just the membrane-associated vesicle fraction, not the cytoplasm (Volz et al.,
2007).

In addition, lobeline, a novel alkaloid, inhibits [3H]DA uptake into rat

striatal vesicle preparations with an IC50of 0.88 ± 0.001 µM and

displaces

dihydrotetrabenazine binding with an IC50 of 0.90 ± 0.02 µM (Teng et al., 1998;
Teng et al., 1997). VMAT2 plays an important role in protecting the neurons
against damage from toxins, such as hydrogen peroxide, by maintaining a low
cytoplasmic

concentrations

of

neurotransmitter

via

translocating

neurotransmitters into synaptic storage vesicles (Liu & Edwards, 1997).

the
In

addition, GBR 12935, a potent DAT inhibitor, also blocks uptake into brain
synaptic vesicles (IC50 between 34-45 µM) compared to synaptosomes
(IC50between1-6µM) (Reith et al, 1994) .
5. Pharmacotherapies for ADHD
Once the diagnosis of ADHD has been established, the next step is to
choose the most appropriate treatment for the patient. Stimulants are considered
the first-line pharmacological treatment option for ADHD. These include various
dosage forms and formulations of methylphenidate and amphetamine, (Meijer et
al., 2009; Spencer et al., 1996). However, there are potential side effects
associated with these stimulants that can limit their use. These agents, along
with their side effects are discussed below in more detail.
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Pemoline, approved in 1975, was another stimulant used to treat ADHD
that increases DA transmission in the central nervous system (Zaczek et al.,
1989). However due to liver toxicity, pemoline was removed from the market in
2005 (Greydanus et al., 2007; Olfson, 2004). The most recent medication
approved for ADHD is a long-acting form of guanfacine (Intuniv®; Figure 3), a
non-stimulant, approved in September, 2009. Another non-stimulant approved to
treat ADHD is atomoxetine (Strattera®; Figure 3). Atomoxetine is considered a
second-line therapeutic agent since it is not as effective as stimulants (Michelson
et al., 2003; Michelson et al., 2002; Michelson et al., 2001; Newcorn et al., 2008).
These non-stimulant medications are a good alternative for parents with
concerns about giving their children stimulants and for those patients that cannot
tolerate or do not respond to stimulants. There are also drugs that are used offlabel to treat ADHD for the reasons stated above. These agents include tricyclic
antidepressants, bupropion, clonidine, and modafinil.
Stimulants produce pharmacological effects by inhibiting DAT and/or NET,
which results in an increase in the amount of DA and norepinephrine in the
synaptic cleft, which enhances neurotransmission in these systems (Greydanus
et al., 2007). Additionally, stimulants are associated with untoward effects that
include, but are not limited to insomnia, cardiac events, decreased appetite,
abdominal pain, headache, weight loss, tics, depression, and growth delays
(Bymaster et al., 2002; Cormier, 2008; Greydanus et al., 2007). Furthermore, the
possibility of abuse and diversion have become major concerns with the use of
stimulant medications (Bymaster et al., 2002; Cormier, 2008; Greydanus et al.,
2007; Holman, 1994; Olfson, 2004), even though the AAP guidelines recommend
a trial of at least three types or formulations of stimulant medication before
considering different agents (Cormier, 2008). This recommendation is to ensure
that each patient is treated as an individual, because there is such a high degree
of variability of response to these medications. Thus, the issue with stimulants is
apparent because they are considered the first line therapy for ADHD, even
though the possibility of abuse is present.

26

a. Methylphenidate
i. Historical Background
Originally, methylphenidate was approved to treat chronic fatigue,
lethargy, depressive states, disturbed senile behavior, psychosis associated with
depression, and narcolepsy. In 1968, methylphenidate was approved to treat
ADHD, and is a gold standard treatment for ADHD (Folsom et al., 1956; Leonard
et al., 2004). The landmark study, conducted in the early 1990s, by the National
Institute on Mental Health Multimodal Treatment study of children with ADHD
(MTA), which found that methylphenidate treatment was superior to behavioral
therapy for children with ADHD, which led to its widespread use (Heal et al.,
2008; National Institute, 2001). Thus, the pharmacotherapeutic use of stimulants
became the first line pharmacological therapy for ADHD.
ii. Formulations
Methylphenidate, a piperazine substituted phenylisopropylamine (Figure
3), was first synthesized in 1944 by Dr. Leandro Panizzon and marketed by CibaGeigy pharmaceutical company as Ritalin (Leonard et al., 2004). There are
various trade names for methylphenidate depending on the formulation and
dosage form. For instance, dl-threo-methylphenidate has the following trade
names; Ritalin®, RitalinSR ®, MetadateCD ®, Concerta® and Daytrana®. The initial
formulations were short-acting (3-4 hrs), which was a limitation for school-aged
children, who would need medication administered multiple times per day
(Greydanus et al., 2007).

Ritalin SR® and Concerta® were developed to

overcome this pharmacokinetics problem, since they have similar duration of
actions, with Ritalin SR® being 8-9 hours and Concerta® being 10-12 hours
(Biederman & Faraone, 2005). Daytrana®, which was approved in 2006, is a
transdermal methylphenidate preparation and has a 9-12 hour duration of action
(Greydanus et al, 2007). D-threo-Methylphenidate (dexmethylphenidate) has a
higher affinity for DAT than l-threo-methylphenidate (Heal & Pierce, 2006; Patrick
et al., 1987). Thus, dexmethylphenidate was developed as an immediate release
formulation and as an extended release formulation (Focalin® and Focalin XR®).
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iii. Pharmacokinetics and mechanism of action
The half-life of methylphenidate is 2-4 hours depending on the formulation.
Its bioavailability is between 11-53% (Chan et al., 1983). Its onset of action is
approximately 2 hours after administration (May & Kratochvil, 2010).
Furthermore,

a

clinical

study

in

which

healthy

subjects

were

given

[11C]methylphenidate intravenously (iv), found that the peak concentration of
methylphenidate in the brain was achieved in 4-10 minutes and peak
concentration of oral methylphenidate did not occur until 60 minutes after
administration (Volkow et al., 1995). Methylphenidate is metabolized primarily
through deesterification in humans to ritalinic acid, which is inactive.
The mechanism of action of methylphenidate involves binding to DAT and
inhibiting its function, which leads to a greater concentration of DA in the
synaptic cleft to bind to both postsynaptic and presynaptic DA receptors, thus
augmenting dopaminergic neurotransmission. Surgical lesions of the medial
forebrain bundle or intracerebroventricular administration of 6-hydroxydopamine
(6-OHDA) were utilized to determine effects on [3H]threo-(+/-)-methylphenidate
and [3H]DA uptake. After both of these procedures a reduction in the specific
binding of [3H]threo-(+/-)-methylphenidate to membranes of rat striatum was
observed, which was highly correlated with the decrease in [3H]DA uptake.
However, intracerebroventricular administration of 5, 7-hydroxytryptamine,
AF64A, or chronic parenteral administration of reserpine did not alter the
number of [3H]threo-(+/-)-methylphenidate binding sites. These results suggest
that localization of the specific [3H]threo-(+/-)-methylphenidate sites in striatum
is on dopaminergic nerve terminals (Janowsky et al., 1985). Another report
found that the highest specific [3H]methylphenidate binding was in caudate
putamen, olfactory tubercle, nucleus accumbens, bed nucleus of the stria
terminalis,

and

median

eminence;

in

contrast

to

[3H]amphetamine,

[3H]methylphenidate binding was not high in brainstem; however, the Bmax was
not included in this report (Unis et al., 1985). Although methylphenidate has
high affinity for DAT (Ki = 160-340 nM), it also has high affinity for NET (Ki = 40238 nM) and a lower affinity for serotonin transporter (SERT;Ki= 1000-22,000
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nM) (Andersen, 1989; Easton et al., 2007; Kuczenski & Segal, 1997; Richelson
& Pfenning, 1984).
Inhibition of DAT function leads to concerns regarding the use and
diversion of methylphenidate for recreational purposes. In fact, methylphenidate
and cocaine have similar affinity for DAT, with cocaine having a Ki of 555-640
nM for DAT (Gatley et al., 1996; Schweri et al.,1985; Ukairo et al., 2005).
Methylphenidate is prescribed for ADHD and has a high potential for being
diverted for recreational use (Klein-Schwartz, 2002; Kollins et al., 2001; McCabe
et al., 2005; McCabe et al., 2006; Parran & Jasinski, 1991; Setlik et al., 2009;
Sussman et al., 2006; Teter et al., 2003; Weyandt et al., 2009; Wilens et al.,
2008).

However, methylphenidate may have a lower abuse potential than

cocaine due to its pharmacokinetics, such that methylphenidate has a longer
half-life than cocaine, 90 minutes and 20 minutes, respectively (Volkow et al.,
1999). Cocaine has a faster onset of action than methylphenidate, which likely
attributes to the euphoric feeling of “high”. An animal study using rats,
(Izenwasser et al., 1990) examined the pharmacological effects of cocaine and
methylphenidate and other monoamine uptake inhibitors on DA uptake. This
study showed that methylphenidate and cocaine had similar Km values (100
nM) in striatum, nucleus accumbens, olfactory tubercle, and medial prefrontal
cortex; however, cocaine inhibited [3H]DA uptake to a lesser extent than
methylphenidate. This suggests that there is a possible additional effect of
cocaine that contributes to the potent reinforcing characteristics of this drug.
Another study found that cocaine and methylphenidate have similar potency in
the septum-caudate synaptosomes for inhibiting serotonin uptake based on the
IC50 values of 70 µM and 118 µM, respectively. These results imply that the
effect of cocaine on serotonin uptake may play a role in its increased abuse
liability, compared to methlyphenidate (Taylor & Ho, 1978).
Positron

emission

tomography

(PET)

studies

utilizing

[11C]methylphenidate in human subjects showed that occupation of 50% of DAT
sites by [11C]methylphenidate in striatum is required to elicit a therapeutic effect,
and that the estimated oral dose of methylphenidate required to occupy 50% of
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DAT sites corresponded to 0.25 mg/kg (Volkow et al., 1998). In other work, the
temporal and spatial distribution of [11C]methylphenidate was determined, and
the result compared to those obtained previously with [11C]cocaine (Volkow et
al., 1999). DAT occupancies were measured with PET using [11C]cocaine, as
the DAT ligand, in 8 healthy subjects (average age of 32, 4 men and 4 women)
for the methylphenidate study and 17 active cocaine abusers for the cocaine
study (average age of 35, 12 men and 5 women). The 8 healthy subjects were
injected with 4-8 mCi of [11C]cocaine and then scanned four times over a 3 day
period. The first scan was the placebo scan to establish a baseline and the
other three scans were performed after intravenous methylphenidate doses
(0.025, 0.1, 0.25, and 0.5 mg/kg). The subjects for the cocaine studies were
scanned four times over a 2-day period, with the first scan being a placebo to
achieve a baseline and the second scan was done 2 hours after the first, and
the rest were performed after a range of intravenous doses of cocaine (0.05,
0.1,0.3, and 0.6 mg/kg). Cocaine was co-administered with [11C]cocaine, while
methylphenidate was given 5-8 minutes prior to [11C]cocaine. The results from
this study showed that methylphenidate has a slightly higher potency at DAT
than cocaine in the human brain, based on the ED50 of 0.07 mg/kg and 0.13
mg/kg, respectively. Also, a double dose of cocaine was required to induce DA
increases equivalent to those induced by methylphenidate utilizing PET and
[11C]raclopride, which is a D2R antagonist. The potencies of methylphenidate
and cocaine were compared to other DAT blockers, including but not limited to
norcocaine, mazindol, lidocaine, procaine, and WIN 35,065-3. These DAT
blockers have 50-100 fold higher affinities than cocaine. These results show
that the potencies of methylphenidate and cocaine are similar. Based on these
observations, the difference in the abuse liability of these agents is not solely
based on the pharmacological potencies at DAT. Pharmacokinetics may also
play an important role in the abuse potential of these two drugs (Volkow et al.,
1999). In another study by some of the same authors, PET was used to
measure temporal and spacial distribution of [11C]methylphenidate and
[11C]cocaine (Volkow et al., 1995). Eight healthy male subjects between the
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ages of 20 and 51 years of age were scanned with [11C]methylphenidate. The
scans were done two hours apart. Three subjects underwent two repeated
scans to test for re-test reproducibility. Four subjects underwent a baseline scan
and a second scan 10 minutes after administration of methylphenidate (0.5
mg/kg, iv) to assess specific to nonspecific binding. One subject was scanned
with both [11C]methylphenidate and [11C]cocaine to compare the distribution
and kinetics of these two compounds in the same individual. The authors did not
mention how they were able to tell the difference between the compounds,
however based on their different pharmacokinetics; it may have been possible
to distinguish the two compounds. In the same study, two baboons were
scanned to evaluate if methylphenidate and cocaine compete for the same
binding sites in brain. One animal underwent a baseline scan with [11C]cocaine
and a second scan with [11C]cocaine 5 minutes after administration of cold
methylphenidate (0.5 mg/kg, iv). The other animal underwent a baseline scan
with [11C]methylphenidate and a second scan with [11C]methylphenidate 5
minutes after administration of cold cocaine (0.2 mg/kg, iv). In the human
studies, the uptake of [11C]methylphenidate into brain was 7.5 ± 1.5% (mean ±
SD) of the injected dose, and was comparable to the uptake of cocaine, which
was 7.5 ± 3.0% (mean ± SD) of the injected dose. Maximal concentrations of
methylphenidate were observed in striatum, however low levels were detected
in

the

cortex

and

cerebellum.

Furthermore,

pretreatment

with

cold

methylphenidate 5 minutes prior to the administration of [11C]cocaine and
pretreatment with cold cocaine 5 minutes prior to administration of
[11C]methylphenidate significantly decreased binding of the corresponding
tracer, but only in striatum, not in cerebellum. These results indicate that
methylphenidate and cocaine compete for the same binding sites in the
striatum.
The distribution of methylphenidate was very similar to that of cocaine.
Although the brain regional distribution of [11C]methylphenidate was identical to
that of [11C]cocaine, and these drugs competed for the same binding sites, they
differed markedly in their pharmacokinetics. Clearance of [11C]methylphenidate
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from striatum (90 minutes) was significantly slower than clearance of
[11C]cocaine (20 minutes). For both drugs, fast uptake, 4-10 minutes for
[11C]methylphenidate and 2-4 minutes for [11C]cocaine in striatum paralleled the
experience of the "high” reported by the subjects. For methylphenidate, the
“high” decreased rapidly despite that a significant amount of drug was still
bound in striatum. In contrast, for cocaine, the decline in the feeling of “high”
paralleled its fast rate of clearance from striatum. Therefore, the “high” appears
to be associated with the fast uptake of methylphenidate and cocaine into brain,
and the slow clearance of methylphenidate from brain may serve as a limiting
factor in promoting its frequent self-administration (Gatley et al., 1996; Volkow
et al., 1999). Thus, the pharmacokinetics alter the pharmacology, specifically
the abuse liability of methylphenidate.
A recent study found that methylphenidate (0.3 mg/kg/infusion) is a
relatively robust reinforcer for all strains, SHR, WKY, and SD based on the
results

that

these

strains

acquired

methylphenidate

self-administration

(Marusich et al., 2011b). Another study also conducted in the SHR strain found
the same result in regards to methylphenidate self-administration, such that this
strain acquired methylphenidate (0.25 mg/0.1ml infusion) self-administration as
well (Pena et al., 2001).

In addition, this study also showed that

methylphenidate induced conditioned place preference (CPP) in SHR, however
there was no difference found between the SHR and WKY in regards to CPP,
suggesting that SHR may not be more sensitive to the rewarding effects of
methylphenidate. These studies provide evidence that methylphenidate has the
potential to be abused.
Evidence has been provided that methylphenidate also interacts with
VMAT2, the only transporter that translocates cytoplasmic DA from the cytosol
into synaptic vesicles for storage, providing availability for future exocytotic
release (Yelin & Schuldiner, 2002). Pre-clinical studies have demonstrated that
unlike amphetamine, the effects of methylphenidate on brain catecholamines
were completely inhibited by reserpine, suggesting that methylphenidate
interacts with a reserpine-sensitive pool of DA (Scheel-Kruger, 1971).
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Methylphenidate rapidly and reversibly increases VMAT2 binding and vesicular
uptake of DA (Sandoval et al., 2003). Rotating disk electrode (RDE) methods
were utilized to measure the initial velocities of inwardly directed vesicular DA
transport in vesicles purified from rat striata. VMAT2 immunoreactivity was used
to measure the amount of VMAT2 protein. Methylphenidate (40 mg/kg, s.c.),
which is considered a high dose for this animal model, was found to decrease
VMAT2 immunoreactivity in membrane-associated vesicle fraction and increase
VMAT2 immunoreactivity in the cytoplasmic vesicle fraction in nerve terminals
by a 2-fold difference compared to control. In addition, membrane-associated
vesicles were able to sequester 5-9 fold more DA than cytoplasmic vesicular
associated vesicles (Volz et al., 2007).

In another study using RDE, both

eticlopride, the D2 receptor antagonist, and scopolamine, the muscarinic
receptor antagonist, blocked methylphenidate-induced K+ stimulated DA
release

(Volz

et

al.,

2008).

These

results

suggest

that

effects

of

methylphenidate are mediated by both D2 and muscarinic receptors.
In addition to the effects of methylphenidate on the neurotransmitter
transporters, PET studies using human subjects have investigated the effects of
methylphenidate on DA release and how it relates to appetitive stimuli in the
response. DA neurons fire in response to salient events. Salient events are
defined as relevant events that require a response from the subject. Salient
events have been hypothesized to contribute to the therapeutic effects of
methylphenidate. Subjects were given methylphenidate (20 mg/kg, po) or
placebo and then shown a salient stimuli (visual and olfactory presentation of
food) or neutral stimuli, which was the description of family genealogy. No
increase in DA was found in the placebo group shown the salient stimuli,
demonstrating that the salient stimulus alone does not increase DA. Moreover,
methylphenidate increased DA in striatum in response to the salient stimuli, but
not to the neutral stimuli, suggesting that the methylphenidate-induced increase
of DA in the striatum was dependent upon stimulus context (Volkow et al.,
2005). This could impact therapy because the increase in the amount of DA in
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the striatum is, in part, based on the stimulus a patient reacts to, which may be
lead to an increase in the abuse liability of methylphenidate.
In

conclusion,

a

wealth

of

research

has

been

performed

on

methylphenidate and the mechanism by which it produces its pharmacological
effect. Research, thus far, has found that methylphenidate inhibits DAT function,
thereby causing an increase in extracellular DA. However, methylphenidate
interacts with other systems within the brain, which may also contribute to its
pharmacological effect. Additional work is needed to further study the effects
methylphenidate to obtain a more comprehensive understanding of its underlying
mechanisms.
b.

Amphetamine
i. Historical background

Lazar Edeleano, a Romanian chemist studying in Germany, was the first to
synthesize amphetamine (Figure 3) in 1887 (Edeleanu, 1887). In 1927, Gordon
Alles first reported the stimulant effects of sympathomimetics. In 1937, Charles
Bradley, reported the therapeutic effects of dl-amphetamine in children with
neurological and behavioral problems (Alles, 1933; Bradley, 1937). The
pharmaceutical company, Smith, Kline, and French, marketed amphetamine as
Benzedrine® in 1932, and this drug was used for decongestion as an inhaled
dosage form (Rasmussen, 2006). Benzedrine® was sold without a prescription,
and over 50 million Benzedrine® tablets were sold during the initial 3 years of
availability as an oral dosage form (Sulzer et al., 2005). The Spanish Civil War
marked the beginning of the military using amphetamine to promote alertness in
the troops (Sulzer et al., 2005). Also, the alerting properties of amphetamine
were exploited by American troops during World War II, especially those in the
air force during extended bombing missions. Today, amphetamine is still used by
the air force in some cases in which prolonged attention is required (Caldwell et
al., 2003).
The escalation in the use of amphetamine abuse during the early periods
of its over the counter availability, led to the decision in 1939 to make it only
available by prescription (Sulzer et al., 2005). During the subsequent period of
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time, the recognized therapeutic uses of amphetamine increased, such that by
1946, it had more than 30 indications, including the treatment of schizophrenia,
opiate addiction, sea sickness, and radiation sickness (Brett, 1946; Miller &
Hughes, 1994). Even though amphetamine was considered a prescription-only
drug, its diversion for recreational use continued. In 1972, in an attempt to
discourage its diversion, the United States Justice Department enforced legal
quotas of amphetamine production (Sulzer et al., 2005). D-amphetamine
appears to have a similar dose-related profile of effects in humans to
methamphetamine, which suggest their equivalence for abuse (Kirkpatrick et al.,
2011).
ii. Formulations
There are various dosage forms of amphetamine available today. The
most prescribed is Adderall®, which is a complex formulation of mixedamphetamine salts consisting of ¼ dextroamphetamine saccharate, ¼
dextroamphetamine sulfate, ¼ racemic dextro/levo amphetamine aspartate
monohydrate, and ¼ racemic dextro/levo amphetamine sulfate, resulting in a
3:1 ratio of d-amphetamine to l-amphetamine. Adderall®is available as
immediate-release

and

extended-release

formations

(Adderall

XR®).

Dextroamphetamine (Dexedrine®) is an immediate release formulation and is
marketed also in a capsule formulation for controlled release called Dexedrine
SR®. The most recent development in the amphetamine series for the treatment
of ADHD is lisdexamfetamine (Vyvanse®) and was FDA-approved in 2007 for
the treatment of ADHD in children, and subsequently approved in 2008, for
ADHD treatment in adults (Cowles, 2009). Lisdexamfetamine, a prodrug, is a
novel agent designed to lower the potential for abuse, since it must be
catabolized to the active compound dextroamphetamine which provides the
pharmacological effect.
iii. Pharmacokinetics and mechanism of action
The

pharmacokinetics

of

amphetamine

is

similar

to

that

of

methylphenidate. The onset of action is 30-60 minutes and the duration of
action for immediate release is 4-6 hours and 10-12 hours for extended release
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mixed-amphetamine salts (MAS-XR). An even longer duration of 16 hours is
seen with the MAS-triple-bead formulation (Greydanus et al., 2007).
The mechanism of action of amphetamine is complex. Amphetamine
produces a redistribution of DA from synaptic vesicles to the cytoplasm by
reducing the vesicular pH gradient. VMAT2 mediated transport involves a
vacuolar-type H+ pumping, which creates a pH gradient across the vesicle
membrane. When amphetamine is transported into the vesicle, it reduces the
synaptic vesicle pH gradient required for monoamine storage, thus reducing
concentration of monoamines inside the vesicle (Sulzer & Rayport, 1990). In
addition, amphetamine inhibits DA uptake at DAT and reverses the transport of
DA causing its release into perisynaptic area and into the extracellular space,
whereas cocaine and methylphenidate bind to DAT and only inhibit DA uptake
at DAT, i.e., do not release DA (Bannon et al., 2000; Seiden et al., 1993;
Solanto, 2002; Sonders et al., 1997). The mechanism of action of amphetamine
is

dependent

on

the

amphetamine

concentration,

whereby

at

lower

concentrations amphetamine is exchanged for DA via DAT, but at higher
concentrations amphetamine can diffuse across the plasmalemmal membrane
independently of DAT (Mack & Bonisch, 1979).

Amphetamine is widely

accepted to elicit its pharmacological effect by: 1) binding to neurotransmitter
transporters and reversing the transport of

neurotransmitters such as DA,

norepinephrine, and serotonin from inside the presynaptic terminal to the
extracellular space which facilitates their release and 2) inhibiting monoamine
oxidase (MAO) (Seiden et al., 1993).
With

respect

to

the

effect on the plasmalemmal transporters,

amphetamine has affinity (Ki) for NET (30 - 100 nM), followed by DAT (30 - 600
nM), and lastly SERT (1000 - 40,000 nM; (Easton et al., 2007; Han & Gu, 2006;
Heal et al., 1998; Kula & Baldessarini, 1991; Richelson & Pfenning, 1984;
Rothman et al., 2001).

Extensive research has been conducted on the

interaction of amphetamine with these transporters; however, most of the focus
has been on the interaction with DAT. Amphetamine binds to the extracellular
surface of DAT, competing with its substrate (e.g., DA), thus decreasing DA
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uptake into the neuron (Seiden et al., 1993).

Once inside the neuron,

amphetamine is released from DAT, leaving DAT unoccupied. DA binds to the
internally facing DAT protein and is reverse transported to the outside or
extracellular space, where it is released, and the result is an increase in the
extracellular concentration of DA (Levi & Raiteri, 1993; Sulzer et al., 1995).
A study by Cass and colleagues used in vivo electrochemistry to
determine the effects of locally applied raclopride, a D2 receptor antagonist, and
SCH-23390, a D1 receptor antagonist, on the clearance of locally applied DA in
the striatum, nucleus accumbens, and medial prefrontal cortex of rats. Raclopride
or SCH-23390 was applied locally prior to the pressure injection of DA.
Raclopride increased the amplitude and time course of DA signals, suggesting
significant inhibition of DAT. However, SCH-23390 had no effect of DA signals.
These results were interpreted to indicate that D2, not D1 receptors, modulate
the activity of DAT (Cass & Gerhardt, 1994). Another study confirmed these
results by employing continuous amperometry and cyclic voltammetry and
determined that amphetamine (10µM)-induced stimulation of DA overflow from
striatal slices was inhibited (47%) by sulpiride, a D2 receptor antagonist (Schmitz
et al., 2001), suggesting that the response to amphetamine may be indirect and
involve D2 autoreceptor activation following DA release.
Amphetamine is a substrate for DAT. Amphetamine accumulation into
striatal synaptosomes is saturable, temperature-dependent, and ouabainsensitve, indicating that it is a substrate for transport (Zaczek et al., 1991).
Similarly, a study investigating the effects of uptake blockers and substrates on
transporter-associated ion currents found that amphetamine induced currents,
whereas methylphenidate blocked transporter-associated current, indicating that
amphetamine is a substrate for DAT (Sonders et al., 1997).

More recently,

studies using neuronal cultures and heterogeneous cells stably expressing hDAT
showed that amphetamine produces DA efflux via two mechanisms that involve a
rapid channel-like configuration with a millisecond firing rate of DA neurons and
the other consisting of a slower, exchange-like mechanism of DA release (Kahlig
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et al., 2005). Thus, results from these studies provide evidence that
amphetamine is a substrate for DAT.
Amphetamine also modulates DAT cellular expression. The role of PKC
in DAT modulation has been widely investigated because DAT is regulated by
activation of protein kinase, which decreases DAT cell surface expression after
amphetamine administration (Pristupa et al., 1998; Vaughan et al., 1997; Zhang
et al., 1997). This stems from findings that phosphorylation of the N-terminus of
DAT, which may be PKC dependent, causes an amphetamine-induced DA efflux
(Khoshbouei et al., 2004). If phosphorylation is needed for internalization and
PKC causes phosphorylation, then PKC may play a vital role in the regulation of
DAT (Copeland et al., 1996; Huff et al., 1997; Vaughan et al., 1997; Zhang et al.,
1997).
Specifically, amphetamine has been shown to increase striatal PKC and
PKC activation stimulates DAT-mediated release of DA and triggers rapid
internalization of DAT from the plasmalemmal membrane (Giambalvo, 1992;
Kantor & Gnegy, 1998). For example, amphetamine acutely decreased cell
surface expression of human DAT (hDAT) in cell lines, which was concomitant
with a loss of DAT function (Saunders et al., 2000). In addition, HEK-293 cells
transfected with a yellow fluorescent protein-tagged hDAT were employed to
determine if loss of transporter activity was due to a modification in DAT function
independent of cell surface redistribution or due to a reduction in the number of
active transporters at the plasma membrane resulting from DAT trafficking
(Kahlig et al., 2004). Confocal imaging combined with electrophysiology of the
HEK cells revealed that after 1 hr exposure to 10 µM amphetamine, a reduction
in hDAT function resulted and was directly related to the redistribution of hDAT
from the plasma membrane. Thus, the decrease in DA uptake was associated
with an increase in intracellular hDAT.
In other work, Gnegy and coworkers investigated the effects of
amphetamine on DAT expression at very early time points using biotinylation in
rat striatal synaptosomes. Within 3 seconds of application of 3 µM amphetamine,
there was an increase in synaptosomal DAT surface expression was observed
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lasting less than 2.5 min, which was prevented by cocaine pretreatment and
associated with increased delivery of DAT to the plasmalemmal membrane
(Johnson et al., 2005a).
The innovative work of Zahniser and colleagues showed that the hDAT
oligomerizes (Sorkina et al., 2003). hDAT was fused with yellow or cyan
fluorescent protein and transfected and expressed in PAE, human embryonic
kidney (HEK) 293 cells, and an immortalized dopaminergic cell line 1RB3AN27 to
examine the oligomeric state and trafficking of DAT in different compartments of
different types of living cells (Sorkina et al., 2003). Fluorescence resonance
energy transfer (FRET) was used to determine the location of these specific
compartments. FRET involves a donor chromophore in its electronic excited
state that transfers energy to an acceptor chromophore through nonradiative
dipole-dipole coupling in near field region. The excited chromophore emits a
virtual photon that is instantly absorbed by a receiving chromophore. The FRET
signals were strongest in the endosomes, which provides evidence of the
involvement

of

vesicles,

where

amphetamine

caused

the

intracellular

accumulation of hDAT on endosomal vesicles. Based on the results that a DAT
mutant was retained in the endoplasmic reticulum after biosynthesis, suggests
that DAT oligomers are formed in the endoplasmic reticulum and are maintained
both at the cell surface and during trafficking between the plasma membrane and
endosomes.
Another target for amphetamine action is VMAT2. An early study used
isolated chromaffin granules and [3H]reserpine-binding measurements to
determine amphetamine interaction with VMAT2 (Rudnick & Wall, 1992).
Amphetamine analogs such as 3,4-methylenedioxymethamphetamine (235 µM)
and

fenfluramine

(30

µM)

inhibited

50%

of

maximal

binding;

but

3

parachloroamphetamine (800 µM) inhibited less than 10% of [ H]reserpine
binding. These results were interpreted to suggest that parachloroamphetamine
effects on isolated chromaffin granules were only due to an alteration in pH,
whereas methamphetamine and fenfluramine exerted effects both by altering the
pH gradient and vesicular transport, which was also measured (Rudnick & Wall,
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1992). This study demonstrates that there is a way to determine if a compound
solely changes the pH versus directly interacts with the transporter.
Although, amphetamine interacts with VMAT2 (Brown et al., 2002;
Gonzalez et al., 1994; Johnson, 1988; Mosharov et al., 2003); at this point in
time, the focus in the literature has switched from amphetamine to
methamphetamine, coinciding with the more wide spread abuse of the latter.
One study found that 10-15 min of application of 10 µM amphetamine induced a
15-fold increase in cystosolic DA in synaptosomes, strongly suggesting
redistribution of vesicular storage from the vesicle to the cytosol (Mosharov et
al., 2003). Amphetamine displaced [3H]tetrabenazine binding, a VMAT2 ligand
with a nM affinity (Teng et al., 1998), which suggests amphetamine may increase
cytoplasmic DA concentrations by inhibiting vesicular DA uptake (Ary &
Komiskey, 1980; Gonzalez et al., 1994; Philippu & Beyer, 1973).
Yet, another target of amphetamine action is MAO. Thus, amphetamine
also alters DA intracellular and extracellular concentrations by inhibiting MAO.
MAO is one of the enzymes which metabolize catecholamines in brain. Thus, by
inhibiting MAO, amphetamine increases the amount of cystolic DA available for
reverse transport by DAT (Sulzer et al., 2005).
An alternative hypothesis regarding amphetamine-evoked DA release
involves the physicochemical properties of amphetamine, as alluded to above.
Amphetamine is a weak base, with apKa of 9.9. This has been suggested also to
play a role in the release of dopamine from the terminal into the extracellular
space (Sulzer & Rayport, 1990).

The weak base theory suggests that

amphetamine enters the cell through both transport and diffusion, diffuses across
the vesicular membrane, accumulates in vesicles, disrupts the proton gradient by
binding to free protons, and thereby, increases the pH inside the vesicles, which
is normally around 5.5 (Johnson, 1988). This disruption in pH decreases the
driving force that provides energy for the accumulation of DA in the vesicle,
causing the vesicle to release the stored DA. This DA release from the vesicle
results in an increase of cytoplasmic DA available for reverse transport by DAT,
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ultimately producing an increase in DA in the extracellular space (Sulzer et al.,
1993; Sulzer & Rayport, 1990).
In summary, there has been a plethora of work conducted on amphetamine
and its underlying multi-faceted mechanisms of action, which likely work in
concert to ultimately increase the extracellular concentrations of DA and other
neurotransmitters to produce its pharmacological effects including its therapeutic
effects on ADHD. Despite the tremendous efforts to understand how
amphetamine works in brain, further studies are needed to gain additional insight
into the action of this very complicated pharmacotherapy. This dissertation work
will compare the effects of amphetamine and methylphenidate, two gold standard
treatments for ADHD, on DAT and VMAT2 function in rat striatum.
6.

Alternative Therapies

Alternative therapies for ADHD include tricyclic antidepressants (TCA), such
as desipramine and nortriptyline (Biederman & Spencer, 1999; Spencer et al.,
1996; Wilens et al., 1996; Wood et al., 2007). These agents are somewhat
effective in the treatment of ADHD, because they have affinity for NET, DAT and
SERT (Wong et al., 1995). Desipramine has been reported to have a Ki of 3.8
nM for NET, 179 nM for SERT, but over 10,000 nM for DAT (Bymaster et al.,
2002). Nortriptyline has been reported to have a Ki of 4.4 nM for NET, 18.5 nM
for SERT, and 1140 nM for DAT (Owens et al., 1997). Unfortunately, these
antidepressants have considerable side effects. For example, nortriptyline is
associated with dry mouth (19% of subjects), constipation (11% of subjects), and
headache (9% of subjects). Desipramine produces loss of appetite (25% of
subjects), insomnia (19% of subjects), and dry mouth (10% of subjects), all of
which have deterred the wide spread use of TCAs for ADHD (Prince et al., 2000;
Spencer et al., 2002).
Another antidepressant, which is not a TCA, but is used in the treatment of
ADHD is bupropion (Wellbutrin®). Bupropion is also used as smoking cessation
agent (Zyban®).This is of interest because lobeline has been investigated as a
smoking cessation aid. Both bupropion and lobeline interact with nicotinic
systems (Damaj et al., 1997; Dwoskin & Crooks, 2002; Yamada et al., 1985).
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Bupropion is an aminoketone antidepressant (Figure 3), that interacts with
noradrenergic, dopaminergic, and nicotinic systems. Bupropion is thought to
inhibit DA uptake in the mesolimbic DA system thereby, aiding in smoking
cessation (Jorenby et al., 2006). However, bupropion is considered an adjunctive
treatment for ADHD, because it is less effective than stimulants in eliminating
symptoms of ADHD when used alone (Greydanus et al., 2007; Olfson, 2004;
Wilens, 2006; Wilens et al., 2005; Wilens et al., 2001).
In addition, the antihypertensive medications, clonidine (Figure 3) and
guanfacine (Figure 3), have been shown to be effective in the treatment of
ADHD. A number of studies have shown that clonidine improved the hyperactivity
and impulsivity symptoms, but not the inattention symptoms associated with
ADHD (Connor et al., 1999; Heal et al., 2008; Nair & Mahadevan, 2009; Rains et
al., 2006; Scahill et al., 2001). With respect to guanfacine, one study employing
25 children between the ages of 7-16 years with ADHD found that this
therapeutic agent improved hyperactivity by 27%, improved teacher ratings on
the hyperactivity/impulsivity scale by 36% and the teacher ratings on the ADHD
scale by 32%, as well as the total tic severity scale by 39% (Boon-yasidhi et al
2005).

Compared to clonidine, guanfacine may be more beneficial clinically

because it has a longer duration of action (Greydanus et al., 2007). The major
side effects of clonidine are sedation and hypotension (Greydanus et al., 2007;
Olfson, 2004). In addition, comparisons of clonidine and guanfacine revealed that
that guanfacine caused less somnolence than clonidine (21% vs. 35%,
respectively; (Wilson et al., 1986).
With respect to the mechanism of action, clonidine acts centrally as an
agonist at both α1 and α2 adrenergic receptors (Wilens, 2006).

Clonidine is

thought to improve neuropsychological function associated with the PFC by
inhibiting norepinephrine release through stimulation of α2 autoreceptors that are
located presynaptically on noradrenergic neurons. This action is suggested to
explain the effect of clonidine on impulsivity and cognition in ADHD (Arnsten &
Dudley, 2005; Arnsten & Li, 2005).
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Guanfacine is thought to act similar to clonidine, however, this drug is
actually more selective for a subtype of α2 adrenergic receptors. There are 2
main subtypes of adrenergic receptors, which are α and β. Both of these
subtypes have several subtypes. Theα-receptors have the subtypes α1 and α2.
The α2-receptors have three highly homologous subtypes, which are α2A, α2B and
α2C-receptors. Theα2A-receptors inhibit norepinephrine uptake in the PFC, which
produces improvements in working memory, attention, and enhancement of
impulse control. There is a high density of norepinephrine in PFC and locus
coeruleus. Since guanfacine is a selective agonist of theα2A subtype of
norepinephrine receptor, with a reported wide range of Kd (0.1-100 nM), it effects
the neural transmission of norepinephrine (Greydanus et al., 2007; Khalid et al.,
2002; Wilens, 2006). Guanfacine inhibits norepinephrine release in this area,
thereby increasing the blood flow to PFC. This effect is thought to improve the
attention deficits associated with ADHD (Kolar et al., 2008). A preclinical study
employing nonhuman primates revealed that guanfacine (0.2 mg/kg, im)
increased blood flow in the PFC as determined by single photon emission
computed tomography (Loo et al., 2003; Avery et al., 2000). Specifically, a
significant 5.8% increase in the mid-dorsolateral PCF and an 8.5% increase in
the caudal dorsolateral PFC were found. Cognitive function was evaluated using
the delayed response task and three of the four subjects demonstrated 18%
improvement in the task. Therefore, guanfacine may be an acceptable treatment
for ADHD, without the adverse side effects associated with stimulants.
Another therapeutic agent that has been investigated for the treatment of
ADHD is modafinil, an analeptic medication approved for the treatment of
narcolepsy (Boellner et al., 2006; Greenhill et al., 2006; Hou et al., 2005;
Swanson et al., 2006; Wilens, 2006).

Modafinil is structurally different from

methylphenidate and amphetamine (Figure 3). In a discrimination study using
rhesus monkeys, modafinil dose-dependently substituted for cocaine in 6 out of 7
monkeys. These results suggest that modafinil shares discriminative stimulus
effects with cocaine which alludes to the abuse potential of modafinil (Newman et
al., 2010). One of the most recent clinical studies was a six week double-blind,
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randomized trial that included 46 children between the ages of 6-15, who were
given 200-300 mg/day of modafinil (depending on weight-200 if < 30kg and 300
if > 30kg) (Kahbazi et al., 2009). Modafinil significantly reduced parent ADHD
rating scores, which was the primary outcome measure compared to baseline
being -22 ± 8.9 (mean ± SD) and -8.2 ± 6.2 for modafinil and placebo,
respectively. Modafinil significantly reduced the secondary outcome measure
(teacher ADHD rating scores) compared to baseline being -23 ± 8.2 (mean ± SD)
and -7.7 ± 5.0 for modafinil and placebo, respectively. No subjects discontinued
treatment with modafinil during the study due to side effects. Side effects
associated with modafinil include dry mouth (8.7%), insomnia (8.7%), and
decreased appetite (15%) being most common. Limitations of this trial included a
small n and no reasons were given as to why one subject dropped out of the
modafinil group and 2 subjects dropped out of the placebo group.
With respect to mechanism of action, modafinil alters the balance of
GABA and glutamate in brain, resulting in activation of hypothalamus, which is
thought to improve the symptoms of narcolepsy (Ferraro et al., 1996; Kahbazi et
al., 2009; Keating & Raffin, 2005; Lin et al., 1996; Wilens, 2006). The complex
mechanism of action of modafinil has not been fully elucidated. Modafinil has at
least four possible targets in the treatment of narcolepsy that are components of
the

wakefulness-promoting

hypothalamic/perifornical

area,

orexin-containing
the

neurons

histamine-containing

of

the

neurons

lateral
of

the

tuberomammillary nucleus of the posterior hypothalamus, the noradrenergic
neurons of the pontine locus coeruleus (LC), the mesencephalic dopaminergic
neurons, and a group of sleep-promoting GABA and galanin-containing neurons
of the ventrolateral preoptic nucleus of the hypothalamus (Hou et al., 2005).
Cocaine and amphetamine-regulated transcript (CART) is also a potential
modulator for alertness, which is found in the hypothalamus as well (Keating et
al., 2010).

In addition, it is localized in neurons of the nucleus accumbens,

synaptic terminals of the ventral tegmental area and the substantia nigra, partially
engaging the mesolimbic DA circuits. This involvement may have influence upon
reward/motivation and locomotion. One of the targets of modafinil is the lateral
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hypothalamic/perifornical area, where CART is expressed. This interaction
between modafinil and CART suggests that modafinil may improve ADHD
symptoms, especially those related to alertness and hyperactivity, which is the
pathway that involves CART.
With regards to ADHD, modafinil elevates DA and norepinephrine levels in
PFC and in rostromedial hypothalamus (de Saint Hilaire et al., 2001). Modafinil
may activate noradrenergic neurons in the LC associated with the arousal
without affecting the extra LC noradrenergic neurons involved in cardiovascular
regulation (Hou et al., 2005). The papillary control of modafinil is of interesting
because it is comparable with LC phasic responses to task relevant events
(Beatty,

1982;

Richer

&

Beatty,

1987),

suggesting

the

potential

for

LC/norepinephrine system involvement in optimizing cognitive task performance
(Aston-Jones & Cohen, 2005). Furthermore, a study demonstrated that a low
dose of yohimbine, an α-2 antagonist, potentiated the modafinil-induced
wakefulness and activity (Lin et al., 1992). However, at high doses yohimbine
attenuated the modafinil-mediated effects on activity (Duteil et al., 1979). These
findings suggest that there is evidence that the adrenergic system may play a
role in the mechanism of action of modafinil.
In addition, modafinil effects have been evaluated in ADHD. Contrasting
results from various studies have been reported when investigating if modafinil
improves the symptoms of ADHD. However, the variables of these studies such
as dose, length of administration, age of subjects, and test measurements need
to be taken into consideration. For example, a study including 20 adult ADHD
subjects were given a single dose of 200 mg modafinil, which was associated
with significant improvements in performance on digit span, visual recognition
memory, spatial planning, and Stop-Signal Reaction Time (SSRT; (Turner et al.,
2004). Conversely, a two-week study including 22 adult ADHD patients in which
the modafinil-treated group was given a titrated dose over 4-7 days that
averaged dose of 207 mg/day, found no treatment effects of modafinil on the
Stroop or Digit Span tests (Taylor & Russo, 2000). Nevertheless, the majority of
the modafinil studies have shown that modafinil is effective in treating the
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symptoms of ADHD in children, adolescents and adults. In addition, modafinil is
well tolerated at the dosages used (Biederman et al., 2006; Biederman et al.,
2005; Greenhill et al., 2006;, Rugino & Copley, 2001; Rugino & Samsock, 2003).
The only FDA-approved (in 2002) non-stimulant medication for ADHD is
the selective NET inhibitor, atomoxetine (Cormier, 2008; Heal et al., 2008;
Olfson, 2004; Wilens, 2006). Atomoxetine has been shown to be effective in
children, adolescents and adults with ADHD. Atomoxetine may not be as
effective as the gold standard stimulants, as indicated by a study showing
improvement of only 45% in ADHD ratings compared to a 56% improvement with
methylphenidate (Michelson et al., 2003; Michelson et al., 2002; Michelson et al.,
2001; Newcorn et al., 2008). Due to the untoward side effects of atomoxetine,
the FDA requires a black box warning which states the potential for suicidal
ideation (0.4%). In addition, the atomoxetine black box label was updated in 2004
to include information about the cases of serious liver injury. From January 2005
to March 2008, six post market cases of serious liver injury with atomoxetine
were reported to the FDA (Diak & Senior, 2009). Furthermore, based on the
FDA receiving six additional reports of serious liver injury in patients taking
atomoxetine, the label was revised again in 2007. The Warnings and Precautions
section of the label advises prescribers about the risk of severe liver injury with
this drug (Diak & Senior, 2009; Lim et al., 2006). Thus, the use of atomoxetine
has its own unique concerns to be aware of when employed as a treatment for
ADHD that must be balanced with therapeutic benefit (Cormier, 2008; Greydanus
et al., 2007). The most common side effects of atomoxetine are sedation (6% of
subjects), abdominal pain (11% of subjects), decreased appetite (14% of
subjects), and headache (18% of subjects; (Newcorn et al., 2008). Although,
atomoxetine is not considered to be a first line agent, it is still a treatment option
for ADHD, particularly in patients who do not tolerate or respond to stimulants.
Between 2002 and 2007, 3.3 million patients received a prescription for
atomoxetine in the US (Diak & Senior, 2009).
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With regards to mechanism of action, atomoxetine has a high affinity for
NET (Ki value of 2-5 nM) and lower affinity for other neurotransmitter transporters
(Gehlert et al., 1995; Tatsumi et al., 1997; Wong et al., 1982). One study
reported a Ki value of 1.9 nM for atomoxetine for NET (Wong et al., 1982).
Another study extended that finding by determining that a tomoxetine inhibited
binding of radioligands ([3H]paroxetine, [3H]nisoxetine, [3H]WIN 35,428) to clonal
cell lines transfected with human NET, SERT or DAT with Ki values of 5.0, 77
and 1450 nM, respectively, thus demonstrating over a 10-fold selectivity for NET
over SERT and DAT (Bymaster et al., 2002). In the same study, microdialysis in
male Sprague Dawley rats showed that local perfusion of 0.34 µM atomoxetine
via dialysis probe into PFC significantly increased extracellular norepinephrine
and DA to a maximum effect of 175 ± 33 and 190 ± 15% of basal concentration,
respectively. In addition, atomoxetine (0.3, 1, 3 mg/kg, ip) produced a 3-fold
increase in extracellular levels of norepinephrine in PFC, but did not alter
extracellular serotonin levels. Atomoxetine also produced a 3-fold increase in
extracellular DA in PFC, but no changes in striatum or nucleus accumbens
(Bymaster et al., 2002), suggesting that it will not have drug abuse liability. In
contrast, methylphenidate (3 mg/kg, ip) increased extracellular DA in striatum
and nucleus accumbens to the same degree, whereas atomoxetine did not alter
the amount of DA in these regions of the brain. However, methylphenidate
increased extracellular norepinephrine and DA equally in PFC compared with
atomoxetine. Furthermore, the latter study found that the expression of neuronal
activity marker Fos was increased 3.7-fold in PFC by atomoxetine administration,
but was not increased in striatum or nucleus accumbens, consistent with the
regional distribution of increased extracellular DA. This study did not evaluate
methylphenidate’s effect on Fos expression. However, a previous study found
that an oral administration of methylphenidate (2.5 mg/kg) given to cats
increased Fos expression in striatum (Lin et al., 1996). The atomoxetine-induced
increase of catecholamines in PFC, a region involved in attention and memory,
may mediate the therapeutic effects of atomoxetine in ADHD and may be
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associated with the improvements in executive function and other cognitive
functions (Wilens, 2006).
7.

Investigational Treatments

The current treatment options for ADHD have been discussed, however
due to the adverse side effects of some of these medications, along with the lack
of effectiveness of others, has spurred the development of novel therapeutic
options for ADHD. According to the National Institute of Mental Health, there are
clinical trials underway to investigate new candidate pharmacotherapies.
One particular clinical trial is entitled Betahistine: Novel Therapeutic in
Attention Deficit Hyperactivity Disorder. Betahistine is an antivertigo drug, which
was first registered in Europe in 1970 for the treatment of Méniére’s disease.
Betahistine has a high affinity for H3 receptors and a low affinity for H1 receptors.
However, the mechanism of action of Betahistine is related to its ability to
increase the levels of neurotransmitters in the brainstem (Barak, 2008). This
study started in January of 2009 with an estimated completion date of December
of 2009 (NIH, 2010).
Another ongoing clinical trial is an open-label multicenter sequential group,
phase 1 study in 6-11 year old patients with ADHD (NIH, 2010). The agent being
investigated is JNJ-310001074. However, there was no available literature on the
pharmacology of this compound and how it relates to ADHD. An additional trial
on this compound is ongoing in Wisconsin, where the investigators are
evaluating the efficacy and safety/tolerability of 3 different doses of JNJ310001074 compared to placebo.
There is one clinical trial investigating a medication that has already
received approval from the FDA for another condition. This medication, called
varenicline (Chantix®), was approved for the treatment of smoking cessation in
May of 2006 (NIH, 2010). Varenicline interacts with specific nicotinic receptors.
Nicotinic receptors are a complex system of different subunits that are a part of
the super-family of ligand-gated ion channels (Xiong et al., 2007). These
complexes are incorporated within the cell membrane and are composed of
pentameric groups of α (α2-10) and β (β2-4) subunits. The subtypes contain only
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one subunit type and are therefore called homomeric. Most of the subtypes are
heteromeric, i.e., containing both an α (α2-10) and β (β2-4) subunit (Symons et
al., 2010). The most common subtypes in the brain include the homo-oligomeric
α7 and the heteromeric α4β2. The composition of the subtype can determine its
sensitivity of a receptor for nicotine. Varenicline binds more potently to the α4β2
subtype of the nicotinic acetylcholine receptor compared to α7subunit>3500 fold;
(Mihalak et al., 2006), without producing a full nicotinic effect on dopamine
release. Therefore, it is considered a partial agonist of the α4β2 subtype. In
addition, varenicline inhibits the ability of nicotine to stimulate the central nervous
mesolimbic DA system. The purpose of this clinical trial is to determine if
varenicline can improve the symptoms of ADHD and also decrease the amount
of smoking in this population. A secondary outcome is to assess the tolerability
and response to varenicline more fully in this population.
The most promising candidate for the treatment of ADHD is a new
chemical entity, called AZT3480 (TC-1734; (NIH 2010). This compound, which
is a partial agonist for the nicotinic acetylcholine receptor, is selective for the
α4β2 subtype of the nicotinic acetylcholine receptor. As of May 2009, it has
been evaluated in six Phase 2 clinical trials in various neurocognitive disorders,
including ADHD. It has been evaluated in about 1,350 subjects from Phase 1
and Phase 2 trials and has exhibited consistently a favorable tolerability profile
(Dunbar et al., 2007). Preliminary results show that AZT3480 met the primary
outcome measure in a Phase 2 clinical trial in adult ADHD. The most common
side effects that have been reported include dizziness and headache (Gatto et
al., 2004). As of July of 2009, there were plans to conduct a vigorous drug
development program for AZT3480.
One novel clinical candidate for the treatment of ADHD and the focus of
our research is the alkaloid lobeline. The rationale for the potential utility of
lobeline as a treatment option for ADHD is that it interacts with the same
transporter proteins, DAT and VMAT2, as methylphenidate and amphetamine,
which are the gold standard treatments for ADHD. In addition, it also has a high
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affinity (Ki of 4-30 nM) for central nicotinic receptors as well (Broussolle et al.,
1989; Damaj et al., 1997; Lippiello & Fernandes, 1986; Yamada et al., 1985).
8.

Lobeline as a Candidate for ADHD Pharmacotherapy
a. Historical background and clinical uses:

Lobeline (Lob; Figure 3), an alkaloidal component of Lobelia inflata, is a
novel compound that has been investigated in the treatment of drug abuse,
including but not limited to, methamphetamine, nicotine, cocaine, opioid, and
alcohol abuse (Dwoskin & Crooks, 2002; Farook et al., 2009; Miller et al., 2007;
Polston et al., 2006). The first report of Lobelia inflata being used for medicinal
purposes occurred in 1813, when Reverend D. Cutler referred to the alkaloid as
a effective remedy for asthma (Millspaugh, 1974). In 1938, Proctor was the first
to document the pharmacological effects of an alkaloid extract of the plant and
reported on its use as an expectorant, asthma treatment, anti-spasmodic, emetic,
diuretic, respiratory stimulant, and for narcotic overdose. The seeds of the plant
contain the highest amount of lobeline, the principal alkaloid. Lobeline was
named after Matthias de Lobel who was a French botanist and physician
(Dwoskin & Crooks, 2002). Wieland identified the chemical structure of lobeline
and subsequently synthesized it in 1925 (Wieland H, 1925).
Lobeline has also been considered as a therapeutic agent for smoking
cessation dating back to 60 years ago (Dwoskin & Crooks, 2002). Lobeline was
first reported by Dorsey, in 1936 as a smoking cessation agent (Dwoskin &
Crooks, 2002). Although a review on the clinical studies using lobeline stated
that lobeline had no effect on smoking (Stead & Hughes, 2001), others believe
that if a new dosage form of lobeline was developed with improved
bioavailability, lobeline would be an efficacious smoking cessation agent
(Schneider & Olsson, 1996). Poor compliance due to the multiple dosing and
side affects such as nausea, dizziness, vomiting, and hypertension could have
contributed to the lack of efficacy. The evidence supporting the utility of lobeline
as a smoking cessation agent may be inconclusive, but nevertheless, the
interest in lobeline to reduce smoking is ongoing (Buchhalter et al., 2008). Due
to this interest, a recent study was published in 2010 that had an objective of
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evaluating the safety and efficacy of sublingual lobeline on smoking cessation
(Glover et al., 2010). This was a multicenter Phase 3 trial involving 3 separate
sites and a total of 750 smokers (250 from each site). The results of this study
showed that the efficacy for lobeline was not significant (p= 0.62) compared to
placebo. Based on these results, the authors concluded that lobeline does not
appear to be an efficacious smoking cessation aid. It would be interesting to
learn if another dosage form of lobeline would be more effective in smoking
cessation by reducing the adverse effects, since the sublingual tablet does not
seem to have any significant effect.
b. Pharmacokinetics and Mechanism of action
Research examining the pharmacokinetics of lobeline is very scarce. In a
previous study in rats (Reavill et al., 1990), lobeline (4mg/kg, sc) had a reported
lipophilicity of 1.68 at a ph of 7.4. The plasma concentration at this dose was
74.3 ng/ml and the brain concentration was 237 ng/ml. These results imply that
lobeline has the ability to penetrate the blood-brain barrier by both carrier and
lipid mediation. In addition, the authors suggest that based on the behavioral
data demonstrating that lobeline did not produce a nicotine-like effect in doses
as large as 6.4 mg/kg, that other receptors other than nAChRs may mediate the
effects of lobeline (Reavill et al., 1990a).

However, previous research has

revealed similarities in the pharmacology of nicotine and lobeline, which resulted
in lobeline being classified as a nicotinic agonist. Lobeline may have the similar
effects of nicotine on cognition, based on studies utilizing radial-arm maze and
spatial discrimination water maze, which showed that lobeline improved
performance and learning in rats (Decker et al., 1993; Levin & Christopher,
2003). However, there is no common pharmacophore or apparent structural
likeness of lobeline to nicotine (Dwoskin & Crooks, 2002). Some of the reasons
why lobeline was considered a nicotinic receptor agonist were because lobeline
caused tachycardia, hypertension, hyperalgesia, improvement of learning and
memory, and in anesthetized rats it causes bradycardia and hypotension; which
are all pharmacological effects of nicotine (Decker et al., 1993; Hamann &
Martin, 1994; Olin et al., 1995; Sloan et al., 1988). In addition, studies have
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shown that nicotine improves cognition. One study involved 62 male nonsmokers, who were randomized into two groups, a low attention group and a
high attention group (Poltavski & Petros, 2006). Based on the results from the
Wisconsin Card Sorting Test, classic Stroop Test and the Conner’s Continuous
Performance Test (CPT), transdermal nicotine improved attention in the low
attention group and decrease working memory in the high attention group. This
suggests that nicotine optimizes rather than just improving cognitive function.
Another study investigated transdermal nicotine in healthy non-smoking adults
with no attentional deficits (Levin & Simon, 1998). Based on the results from the
Profile of Mood States Test, nicotine significantly improved self-perceived vigor.
Using the CPT, it was found that nicotine significantly reduced the number of
errors of omission. Taken together, these results suggest that nicotine not only
reduces attentional impairment, it also can improve attentiveness in normal adult
non-smokers. A more recent study (Potter & Newhouse, 2008) used the Stop
Signal Reaction Time to measure the effect of nicotine on cognition. The results
showed that nicotine had a significant positive effect on this task without
changes in the Go reaction time or accuracy. These data suggest that
cholinergic agents like nicotine, may be potential pharmacotherapies for the
cognitive deficits associated with ADHD.
However, lobeline also has effects that are different from nicotine. For
instance, nicotine is reported to be self-administered by rats (Corrigall & Coen,
1989; Goldberg et al., 1981; Rasmussen & Swedberg, 1998; Sorge & Clarke,
2009); however lobeline is self-administered in mice and is not self-administered
by rats (Harrod et al., 2003; Rasmussen & Swedberg, 1998). Chronic nicotine
treatment results in an increase in locomotor activity (Clarke, 1990; Clarke &
Kumar, 1983; Fung & Lau, 1988) and produces conditioned place preference
(Fudala et al., 1985; Risinger & Oakes, 1995; Shoaib et al., 1994), but lobeline
does not produce these effects (Dwoskin & Crooks, 2002). Even though one
study reported that lobeline generalized to nicotine in a drug discrimination assay
(Geller et al., 1971), additional studies have not been able to reproduce this
finding (Reavill et al., 1990b; Romano & Goldstein, 1980; Schechter &
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Rosecrans, 1972). Lobeline also produces transient, small cardiovascular effects,
such as increase in heart rate, and with chronic use, it acts as a depressant of
the sympathetic and parasympathetic ganglia as well as the adrenal medulla
(Sloan et al., 1988), with side effects including decreased breathing rate and
hypothermia.
Due to the complexity of the pharmacological actions of lobeline, further
investigation is necessary to evaluate other potential effects of lobeline in
addition to its nicotinic receptor agonist effects. Lobeline has high affinity for the
nAChR (Ki = 4-30 nM; (Broussolle et al., 1989; Damaj et al., 1997; Lippiello &
Fernandes, 1986; Reavill et al.,1990b; Yamada et al., 1985). Furthermore, in a
study using in vitro [3H]nicotine binding assays in rat brain, lobeline displaced
binding of [3H]nicotine with a Ki value of 4.4 ± 2.2 nM (Damaj et al., 1997). This
finding confirms that lobeline has a high affinity for nicotinic receptors, but does
not indicate if lobeline is an agonist or antagonist at these sites. However, using
a frog oocyte expression system with a two-electrode voltage-clamp, 0.1 and 1
mM lobeline produced only a small current when applied for 10 sec to oocytes
expressing the α4β2 subtype, suggesting that lobeline is

not acting as an

agonist at this subtype of nAChR (Damaj et al., 1997).

Moreover, 10 µM

lobeline antagonized 50% of the current-induced by 3 µM nicotine, although
antagonism is not observed in vivo in mice (Damaj et al., 1997).

Also,

pretreatment with mecamylamine and dihydro-β-erythroidine at a dose of 10
µg/mouse, sc, 5 min before lobeline (40µg/mouse) did not decrease lobelineinduced motor impairment, but these compounds did inhibit effects of nicotine,
including lethality, seizures, and cardiovascular effects. Taken together, the
results of this study suggest that lobeline interacts with a different mechanism
than nicotine. Furthermore, the interaction of ligands with their receptors depends
on a number of factors including receptor localization, subtype specificity, and
potency of antagonist (Damaj et al., 1997).
A series of studies investigated the action of lobeline as a nicotinic
antagonist. The subsequent studies that investigated the action of lobeline,
concluded that lobeline is a nicotinic antagonist (Clarke & Reuben, 1996;. Teng
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et, al 1998; Teng et al., 1997; Terry et al., 1998). Specifically, lobeline evokes
86

Rb+ efflux from striatal synaptosomes with low efficacy (Terry et al., 1998). This

86

Rb+ efflux assay is a chemical method of investigating ion flux, whereby the

86

Rb+ acts like K+. If there is an increase in

86

Rb+ efflux, then the compound in

question acts as an agonist. In this case, lobeline produced low

86

Rb+ efflux,

suggesting that it acts as an antagonist instead of an agonist.
In addition, lobeline-induced [3H]DA release is independent of extracellular
calcium concentration and is not sensitive to mecamylamine, which indicates that
the lobeline-evoked DA release is not mediated by nAChRs, and that lobeline
does not act as an agonist nAChRs (Clarke & Reuben, 1996; Teng et al., 1998;
Teng et al., 1997). Importantly, a study using in vivo brain microdialysis was
used to investigate the influence of lobeline on DA and DOPAC overflow in the
core of nucleus accumbens in freely-moving rats pretreated with nicotine (0.4
mg/kg, sc) once daily for 5 days. Lobeline (4.0 and 10 mg/kg) inhibited nicotineevoked [3H]DA overflow when administered 10 minbefore nicotine, but not after
60 min (Benwell & Balfour, 1998). In addition, the low dose of lobeline had no
effect at either time point in this study. The effect of lobeline on nicotine-evoked
[3H]DA overflow was investigated using striatal slices (Miller, 2000). Striatal slices
were superfused with lobeline for 30 min and 1 of 4 concentrations of nicotine
was added to the buffer containing lobeline and superfusion continued for an
additional 60 minutes. The results showed that lobeline blocked nicotine-evoked
[3H]DA overflow from rat striatal slices (Benwell & Balfour, 1998; Miller et al.,
2000), which suggests that lobeline is an nicotinic antagonist.
In addition, lobeline interacts with the same transporter proteins, DAT and
VMAT2, at which psychostimulant drugs of abuse and treatments for ADHD
interact (Miller et al., 2003). Lobeline inhibits [3H]DA uptake into vesicles with
an IC50 of 0.88 µM and inhibits the binding of [3H]dihydrotetrabenazine, a
VMAT2 ligand, to vesicular membranes with an IC50 of 0.90 µM (Teng et al.,
1998; Teng et al., 1997). Lobeline inhibits [3H]DA uptake into synaptosomes
with an IC50 value of 80 µM (Teng et al., 1997). Results from this same study
also demonstrated that lobeline increased DOPAC efflux, and did not increase
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endogenous DA release (Teng et al., 1997). The increase in DOPAC suggests
that lobeline does not inhibit MAO like amphetamine does. In addition, lobeline
is more potent inhibiting DA uptake in vesicles (IC50= 0.88 µM) than releasing
DA, whereas amphetamine is equipotent in inhibiting and promoting DA release
(EC50~2.22 µM;(Teng et al., 1998). Both of these effects of lobeline may explain
at least in part why lobeline is not self-administered.
Taken together, the evidence from the above studies indicates that the
overall mechanism of action of lobeline is a combination of interactions with
different targets, the outcome of which is a diminished extracellular concentration
of DA. Specifically, lobeline inhibits nAChR, DAT and VMAT2 function. The
outcome of the interaction with VMAT2 would be expected to decrease the
vesicular DA pool and increases the cystosolic DA, although this has not been
determined directly. The proposed increase in cryptozoic DA would be expected
to be metabolized by MAO, leading to an increase in extracellular DOPAC, which
has been observed (Teng et al., 1997).
9. Animal Models for ADHD
The development of an appropriate animal model to evaluate potential
new agents for ADHD is based on the behavioral, neurochemical, and
neuroanatomical profile of ADHD individuals. A valid ADHD animal model should:
1) mimic the clinical symptoms and presentation of individuals with ADHD (face
validity), 2) show the underlying neurochemical changes in ADHD,

thus

confirming the theoretical underlying etiology for ADHD (construct validity) and 3)
predict an appropriate response to the effective, currently available, ADHD
treatments (van der Kooij & Glennon, 2007). Another factor to consider is the
age of the rats in the animal models, since ADHD is primarily found in children
and adolescents (American Psychiatric Association, 2000), but also persists into
adulthood (Kessler et al., 2006). There are many ADHD animal models; however
no one model satisfies all the criteria of an animal model for ADHD. Current
models have been developed by either creating a lesion in the brain or by
manipulation of the genome.
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a. Neonatal 6-OHDA
The first studies to model ADHD used 6-hydroxydopamine (6-OHDA)
administered to neonatal rats to produce hyperactivity, which was expressed
temporarily from postnatal day (PND) 12-22 (Shaywitz et al., 1976). 6-OHDA
(20 µg/µl; intracereoventricularly) is toxic to dopaminergic and noradrenergic
neurons, decreasing DA and norepinephrine content and neurotransmission in
brain. DA decreased in the frontal cortex by 76%, in striatum by 96%, and in
nucleus accumbens by 84%. Norepinephrine levels decreased by 13% in frontal
cortex and by 39% in nucleus accumbens (Archer et al., 1988). This model
resulted in learning and memory deficits, which are consistent with ADHD
symptoms (Archer et al., 1988). Autoradiographic studies have demon strated
the involvement of the DA D4 receptor in the effects of neonatal 6-OHDA in this
model of ADHD (Avale et al., 2004; Zhang et al., 2002; Zhang et al., 2001).
These latter findings are consistent with clinical observations that there is a
higher incidence of ADHD when a polymorphism, in which a direct repeat in the
48-base-pair sequence in the DA D4 receptor gene exists (Benjamin et al., 1996;
Van Tol et al., 1992). Additional research has shown that the indolamine in
addition to the noradrenergic neurotransmitter systems appear to be involved in
the pathology of ADHD due to the observations that NET inhibitors, such as
desipramine and nisoxetine and 5-HT inhibitors citalopram and fluvoxamine
reduced hyperactivity in 6-OHDA (100 µg) lesioned juvenile male rats, but the DA
inhibitors had no effect on hyperactivity in 6-OHDA (100 µg) lesioned juvenile
male rats (Davids et al., 2002). These results suggest that the neonatal 6-OHDA
rat is not a good model for ADHD. The neonatal 6-OHDA lesion model using rats
also has excellent predictive validity because in one study methylphenidate (0.25
mg/kg, sc) reduced hyperactivity in 6-OHDA lesioned rats (Shaywitz et al., 1978).
However, it takes more than predictive validity for an animal model to be
considered a good model for ADHD. In another study, methylphenidate (1 and 4
mg/kg, sc) and amphetamine (0.25 and 1 mg/kg, sc) both decreased
hyperactivity in neonatal 6-OHDA lesioned rats (Luthman et al., 1989).
Moreover, a study evaluating the effect of atomoxetine (1 mg/kg) on neonatal 6-
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OHDA lesioned rats found that this non-stimulant also was effective in reducing
motor hyperactivity in this animal model (Moran-Gates et al., 2005). Taken
together, these studies provide evidence that the neonatal 6-OHDA lesioned rat
model is not the best animal model for ADHD. Furthermore, this model has
limitations because there is a lack of evidence showing that ADHD medications
improve learning and memory deficits, not just hyperactivity.
b. Neonatal alternative models
Alternative ADHD animal models include the neonatal hypoxia rat model
and the neonatal bromodeoxyuridine (BrdU) rat model. The neonatal hypoxia rat
model was developed by immersion of rats in 100% nitrogen for 25 min at
various stages of development ranging from 30 min after birth (Davids et al.,
2002), PND 2 (Dell'Anna et al., 1991), PND 4 (Shimomura & Ohta, 1988), or at
PND 10 (Decker et al., 2003).

This animal model also produces permanent

deficits in learning and memory (Gramatte & Schmidt, 1986).

Although

amphetamine decreased hyperactivity, stimulants have not been thoroughly
investigated for effects on improving learning and memory (Speiser et al., 1983).
However, based on the limited research of this model, its predictive validity as a
ADHD model is not clear (van der Kooij & Glennon, 2007).
The neonatal BrdU rat model incorporates BrdU administration (50 mg/kg
body weight, ip, every 12 hours for 2.5 days) to dams during gestational days
between 9 and 15 (van der Kooij & Glennon, 2007). This treatment produces
behavioral problems, impaired sexual behavior, deficits in learning and memory,
and hyperlocomotion in the male offspring of these dams (van der Kooij &
Glennon, 2007). Nevertheless, no construct validity has been examined in this
model and research has shown that methylphenidate (1 or 4 mg/kg, s.c.) has no
effect in the BrdU rat model (Muneoka et al., 2006), which also questions the
predictive validity of this model. In addition, this model also has a hyposexuality
aspect that is not associated with ADHD. In conclusion, the overall validity of the
neonatal BrdU rat model for ADHD remains questionable based on the above
evidence.
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c. Genetic models
There are also established genetic rat models of ADHD. These models
include the spontaneously hypertensive rat (Schmitt et al., 2008), the WistarKyoto derived hyperactive rat (WKHA), and the Naples high (and low) excitability
rat (Krause et al) models. The SHR model, the most commonly studied animal
model of ADHD, was developed in the 1960’s by inbreeding individuals in the
WKY strain that showed high systolic blood pressure, which resulted in
hypertension in subsequent generations (Okamoto & Aoki, 1963).

The SHR

model satisfies many of the criteria for a valid model of ADHD because these rats
display hyperactivity, impulsivity, poor performance stability, poor sustained
attention, and spatial working memory deficits (De Bruin et al., 2003; Hernandez
et al., 2003; Ueno et al., 2002) when compared to WKY (Tsai & Lin, 1988; van
den Bergh et al., 2006).
However, hypertension is not associated with ADHD patients, leading to
potentially confounding interpretations as to the results obtained with this model,
i.e., the role that hypertension plays in contributing to the effects. In addition, the
predictive validity of this model in identifying novel treatments is questionable
because amphetamine and methylphenidate have been shown to increase
hyperactivity in this rat model, which is the opposite result that is observed
clinically (Amini et al., 2004; McCarty et al., 1980; Wultz et al., 1990). The age of
these rats in this model may also be a concern to some investigators, because
the rats between 10-12 months old, which is considered an adult rat (Spear,
2000), yet ADHD is diagnosed in adults and is an ongoing issue in the adult
population as well. Conversely, a more current study found that methylphenidate
(1.5 mg/kg, po) lowered the amount of errors in the attentional set-shifting task in
the SHR rat model using 9 week old rats (Kantak et al., 2008). This same study
sought to advance the SHR animal model of ADHD toward medication
development by utilizing 3 behavioral tests to assess the validity of this model
with respect to the deficiency in learning and memory associated with ADHD,
using 9 week old rats versus adult rats (Kantak et al., 2008). Specifically, the
function of the orbitofrontal cortex, the dorsal striatum, and the prelimbic cortex
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were evaluated using the odor-delayed win-shift task (Di Pietro et al., 2004), the
win-stay task (Kantak et al., 2001), and the attentional set-shift task (Birrell &
Brown, 2000). The odor-delayed win-shift task training phase involves the rats
discriminating among four odors in four arms and keeping online the memory of
the odors for which the reinforcer was already received. The rats were given
eight training trials per day for 4 days to learn to dig in an unscented sand cup for
a hidden fruit loop reinforcer. The turn bias used a T-configuration for the maze
and the rats were started from the less familiar stem arm and had to choose the
correct strategy to advance to the extradimensional set-shifting trials conducted
the following day. The food well of each choice arm was baited with a single
pellet and a visual cue was randomly placed on the left wall of the one of the
choice arms before each trial. If a rat made an incorrect choice, the
discrimination trials continued until it was able to reach five consecutive correct
reinforced choices.
In addition, Kantak and colleagues included a genetic control in this latter
study, the WKHT strain, which is a Wistar-Kyoto-derived strain of rat inbred for
hypertension, but not exhibiting the hyperactivity. This important aspect provided
the first direct test of the impact of hypertension in these ADHD-relevant learning
paradigms. Furthermore, in the experiments the authors used 9-week old rats, an
age which is considered more comparable with adolescence. The results from
the odor-delayed win-shift task revealed that the over the entire task there was
no strain differences in the cumulative number of working memory errors or
reference memory errors made over the 20 test phase sessions. However, the
methylphenidate-treated SHR strain completed the test phase 78% faster than
the vehicle-treated WKY strain. This suggests that methylphenidate elevates
some of the working memory deficits. The SHR strain latencies to traverse the
arm and recover a food pellet in the win-stay task were 42% faster than the WKY
strain and the WKHT strain was 20% faster than the WKY strain. This indicates
that the learning deficits of the SHR strain are not associated with a lower
motivation level compared to the other two control strains. The model was
validated by the findings that methylphenidate(1.5 mg/kg, po, 30 min
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pretreatment) significantly improved latencies in the win-stay task, where the
methylphenidate-treated SHR finished the task 66% faster than the vehicletreated WKY strain. These results demonstrate that methylphenidate treatment
was effective in enhancing the performance of the SHR, thus allowing them to
complete the task faster than the vehicle-treated WKY. With the attentional setshifting task, the vehicle-treated SHR strain had 23% more errors compared with
the vehicle-treated WKY. Methylphenidate-treated WKY strain had 30% less
errors compared to the methylphenidate-treated SHR strain. These findings
demonstrate that methylphenidate eliminates strain differences in attention. The
WKHT strain performed similarly to the WKY, suggesting that the hypertension is
not associated with the hyperactivity found in the SHR rat model. The overall
results of this study support the use of the SHR as a valid model for ADHD,
particularly with respect to the neurocognitive deficits associated with this
disease, and that the WKY is an appropriate control strain to compare with the
SHR when neurocognitive endpoints are evaluated.
The SHR strain and the WKY strain were crossbred in order to develop a
strain without the hypertension associated with the SHR model. This led to the
development of the WKHT rat having hypertension but no hyperactivity and the
WKHA rat model, which had no hypertension but had hyperactivity (Hendley &
Ohlsson, 1991). In regards to face validity, in the absence of hypertension, this
model has abnormal attentional processing, impulsivity, and learning deficits. The
WKHA model also had a low predictive validity. This conclusion was
demonstrated by the results of a study that administered methylphenidate (5
mg/kg) to WKHA rats and found that their locomotor activity increased by 200%
(Drolet et al., 2002). Based on these results, the increase in locomotor activity
decreases the predictive validity because methylphenidate should not increase
locomotor activity, but decrease it. Furthermore, more research is needed to
investigate the construct validity of this model because the role of the DA
receptors and DAT is still unclear. In conclusion, these observations limit the
usefulness of the WKHA model as an ADHD animal model.
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The Napel High Excitability (NHE) rat model has been investigated as an
ADHD model because of the different exploratory activity in the Làt maze, a
commonly used method of testing locomotor activity and habituation in a novel
situation. This model was based on reactivity to novelty, not baseline activity
level (Sadile et al., 1993). NHE rat model has an advantage over the SHR model,
because the NHE strain does not have hypertension (Cerbone et al., 1993), and
does not have the limitation of evaluating the effect of hypertension. The face
validity of this model needs to be improved because even though it demonstrates
hyperactivity and attention deficits, no impulsivity has been observed. In addition,
the predictive validity of this model still needs to be investigated. In reference to
construct validity, one study evaluated mesencephalic TH expression in coronal
sections as determined by immunohistochemistry in the NHE rat model (Viggiano
et al., 2003). Results showed a larger neuron size in the VTA. These results
suggest that the mesolimbic and nigrostriatal DA pathway are normal, but the
mesocortical DA pathway is hyperfunctional and hyperinnervated. However, a
larger VTA neuron size in ADHD has not been reported, thus limiting its construct
validity. In addition, the size of the neuron can not be the only factor involved in
the functional of the pathway. The NHE could be potential ADHD animal model
because it demonstrates the aspects of ADHD including hyperactivity and deficits
in tasks requiring visuospatial attention (Aspide et al., 1998; Papa et al., 2000).
Nevertheless, further study is necessary to determine how ADHD medications
affect this rat model and if this model demonstrates the other symptoms of
ADHD, such as impulsivity. The age of the animal is not a limitation because this
model used adult rats and as stated earlier, adults suffer with ADHD as well. In
conclusion, this model should not be considered a suitable model for ADHD until
additional research is performed such as investigating the construct validity in
more detail in order to validate the model more appropriately.
There are also models of ADHD which employ mice, rather than rats.
Some of these models include the hyperactive-wheel turning mice, the coloboma
mutant mice, and the DAT-KO mice. The hyperactive wheel-running mouse only
demonstrates hyperactivity in regards to face validity (Rhodes et al., 2001). As
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far as construct validity, altered dopaminergic function regarding the D1 and DAT
may be involved in producing the hyperactivity (Rhodes et al., 2001). The
predictive validity is weak because only amphetamine has been shown to
attenuate the hyperactivity (Rhodes et al., 2001). The coloboma mutant mice
model was developed by neuron irradiation in mice (Searle, 1966). This model
has been used as a ADHD model because it possesses a weak face validity in
that it displays spontaneous hyperactivity (Hess et al., 1992) and delayed
development (Heyser et al., 1995). However, impulsivity has not been observed.
It is suggested that the neurochemical basis of this model is produced by
elevated noradrenaline levels in striatum and nucleus accumbens of the
coloboma mouse (Jones et al., 2001). The predictive validity is questionable
because amphetamine blocks the hyperactivity, however methylphenidate
increases hyperactivity (Hess et al., 1996). Based on the lack of validity of these
two models, they are not recommended as suitable ADHD models. Due to the
lack of research of these models, a greater focus has been placed on DAT-KO
mice.
Since DAT is the major regulator of DA clearance and DAT-gene
alterations have been associated with ADHD, DAT-KO mice were developed
(Cook et al., 1995; Gill et al., 1997). In support of the validity of this model, DATKO mice have been found to display hyperactivity and spatial learning deficits
(Gainetdinov & Caron, 2001; Gainetdinov et al., 1999). Methylphenidate and
amphetamine attenuate the hyperactivity observed in the DAT-KO mice, also in
support of the validity of the model. However, a disadvantage of this model is that
the target of psychostimulants, DAT is missing, which makes it more difficult to
assess the predictive validity. There is the possibility that not all the DAT has
been knocked out which depends on the process used to develop the DAT-KO
mice (NIH, 2010).

The pups born from the embryos that had the altered

embryonic stem cells injected into them do not have the DAT completely knocked
out because there is also normal tissue present as well. In order to produce a
homozygous line of knockout, crossbreeding is required where each copy from
respective chromosomes is knocked out in the present tissue (NIH, 2010).
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Nevertheless, a study utilizing fast scan cyclic voltammetry of extracellular striatal
DA levels, show impaired DA clearance in DAT-KO mice x 300 times compared
to controls. These results demonstrate that the DAT gene was knocked-out. A
more logical explanation is that these psychostimulants are interacting with other
neurotransporters, such as NET and 5-HT, to elicit their effects. This leaves open
the question of the involvement of other targets for the action of effective
pharmacotherapies for ADHD.
In order to eliminate some of the disadvantages associated with the DATKO mice mode, such as premature death, growth retardation, and the absence of
DAT, the DAT-knock-down (DAT-KD) mouse model was created. This line was
developed by breeding heterozygous mutants in a 129 Su/J genetic background
(Zhuang et al., 2001). Both the DAT-KO/KD models respond to amphetamine
and methylphenidate, thus supporting the predicative validity of the models for
ADHD. However, more research is needed to find the construct validity marker
such as D4 receptor involvement. In reference to the face validity, both models
possess hyperactivity, impulsivity, and attention deficits. Another advantage of
the DAT-KD model is that it expresses a small percentage of DAT, thus allowing
it to have a more acceptable predictive validity because pharmacotherapies
targeting DAT can be evaluated. The age of the mice used in these models is not
clear, however the model suggest that the mice are adolescents since some do
not live to adulthood.
In conclusion, there are several potential ADHD animal models from which
to choose. Nonetheless, ADHD animal model needs to demonstrate the
symptoms associated with ADHD (face validity), confirm an underlying theory of
ADHD (construct validity), and possess the appropriate response to ADHD
treatments (predictive validity). There is no perfect animal model for ADHD, but
the most promising models include the neonatal 6-OHDA lesion model and the
DAT/KO-KD mice model based on their ability to meet the aforementioned
criteria.
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10.

Specific Aims and Hypotheses

The work discussed in this dissertation was based on the hypothesis that
DAT and VMAT2 are the primary targets for the pharmacological effects of
ADHD psychostimulants, methylphenidate, and amphetamine. DAT is generally
thought to be a major target for these agents; however, it may not be the only
target. In addition, these pharmacotherapies have untoward effects such as
abuse liability, which limits their use and demonstrates the need for additional
ADHD treatment options. Lobeline may be a potential treatment option for
ADHD because it interacts with the same transporters as methylphenidate and
amphetamine, but does not have abuse liability.
The specific hypotheses for this project were:
1) Lobeline will decrease DAT function after acute and repeated in
vivo administration, as shown by a decrease in Vmax, based on results
from previous in vitro studies performed in our lab
2) Lobeline will have a greater effect on VMAT2 function after acute
and repeated in vivo administration as shown by the parameters of Vmax
and Km, based on results from previous in vitro studies
3) DAT trafficking is the underlying mechanism behind the
modulation of DAT function as shown by an increase of DAT to the
neuronal cell surface of the striatum.
a. Specific Aims
Specific Aim 1) Determine the effect of lobeline after acute and repeated
in vivo administration on DAT function using [3H]DA uptake assay.
Specific Aim 2) Determine the effect of lobeline after acute and repeated
in vivo administration on VMAT2 function using [3H]DA uptake assay.
Specific Aim 3) Determine if the underlying mechanism of modulation of
DAT function is due to DAT trafficking, using biotinylation and western blot
analysis.
The effects of lobeline were compared to the effects of methylphenidate
and amphetamine for all experiments.
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Figure 1. Schematic of a DA nerve terminal.
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Figure 2. 3D-Image of a DA transporter. Used with permission by Dr. Zhan.
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Figure 3. Structures
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Chapter Two

Effect of Acute and Repeated In Vivo Administration of Lobeline,
Methylphenidate, and Amphetamine on Dopamine Transporter Function
A.

Introduction

ADHD is a childhood disorder that can, in some cases, persist into
adulthood (Madras et al., 2005) and is associated with behavioral dysfunctions
including three major components, hyperactivity, impulsivity, and inattention.
Estimations are that ~15% of school age children (Scahill et al., 1999) and 5-10%
of adults have ADHD, which translates into at least 8 million adults having ADHD.
(Swanson et al., 1998a). This suggests that ADHD is not just a childhood
disorder, but a disorder of all ages. The striatum, which contains high
concentrations of DA, is suggested to be involved in executive function and
motor response associated with ADHD (Dinn et al., 2001; Volkow et al., 2001;
Wilens, 2008).
The etiology of ADHD is unknown; however DAT, which is located on the
DA nerve cell membrane, is believed to play a major role in the pathophysiology
of ADHD (Easton et al., 2007). DAT is the primary regulator of extracellular DA
concentration (Gainetdinov & Caron, 2003). DAT is thought to be involved in the
mechanism of action of stimulants, which are the gold standard options to treat
ADHD (i.e., methylphenidate and amphetamine). This is supported by work that
shows that stimulants that block DAT are effective treatments for ADHD (Volkow
et al., 2002); thus, DAT is a pharmacological target for ADHD therapeutic agents.
Methylphenidate inhibits the reuptake of DA into the synaptic terminal,
thus increasing the amount of DA in the synaptic cleft (See Introduction;
(Greydanus et al., 2007).

Amphetamine increases the amount of DA via a

different mechanism, whereby it releases DA from the terminals by causing a
reversal of DAT (Jones et al., 1998b). Due to the potential for abuse associated
with these stimulants, there are concerns about the use of these agents.
Additional concerns include cardiovascular effects, abnormal growth, and
suppressed appetite (Gibson et al., 2006).
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Lobeline may be a suitable candidate for the treatment of ADHD. When
lobeline was evaluated in behavioral studies, lobeline was not self-administered
by rats, nor did it substitute for d-methamphetamine, which suggest that it has no
abuse liability (Harrod et al., 2003). Lobeline is the major alkaloidal component
of the Indian tobacco plant, Lobelia inflata, and is similar to nicotine in some
ways. For example, both have a high affinity for the nicotinic receptor despite the
structural differences of nicotine and lobeline (Dwoskin & Crooks, 2002). Based
on in vivo studies, lobeline does not stimulate locomotor activity (Miller et al.,
2003) and acts as a nicotinic antagonist, in vitro, (Miller et al., 2001) and in vivo
(Miller et al., 2003). Lobeline binds to and inhibits (IC50 value ≈ 40-100 µM) DAT,
inhibiting DA uptake in vitro (Miller et al., 2004; 1998, Teng et al., 1997).
The concerns of the use of stimulant medications clearly indicates that
more effective treatment options with less side effects are needed for ADHD.
Based on in vitro experiments where lobeline inhibited DAT function, lobeline
may be an option (1998, Teng et al., 1997). However, the effect of in vivo
administration of lobeline needs to be determined. In order to determine if the
mechanism of action of lobeline on DAT function is similar to either
methylphenidate

or

amphetamine,

the

effects

of

methylphenidate

and

amphetamine on DAT function were also investigated after in vivo administration.
Therefore, the goal of the present study was to elucidate the effect of acute and
repeated in vivo administration of lobeline and to determine if this effect was
observed in a dose-dependent manner. In addition, the effect of lobeline on DAT
function was compared to the effect of methylphenidate and amphetamine
administered in vivo. Such experiments are helpful in providing more insight into
the mechanism of action of all these agents.
B. Methods
Materials.
[3H]DA (3,4-ethyl-2[N-[3H]dihydroxyphenylethylamine Specific Activity 28
Ci/mmol) was purchased from PerkinElmer Life Sciences Inc. (Boston, MA). LAscorbic acid, bovine serum albumin (BSA), catechol, α-D-glucose, N-(2hydroxyethyl)piperazine-N’-(2-ethanesulfonic
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acid)

(HEPES),

nomifensine

maleate, pargyline hydrochloride, sucrose, methylphenidate hydrochloride,
amphetamine hydrochloride, and 3-hydroxytyramine hydrochloride DA were
obtained from Sigma Chemical Co. (St. Louis, MO). Lobeline was purchased
from ICN Biomedicals (Costa Mesa, CA). All other chemicals used in the in vitro
assay buffers were purchased from Fisher Scientific (Pittsburgh, PA).
Subjects.
Adult male Sprague-Dawley rats (200-220g body weight upon arrival)
were obtained from Harlan Inc. (Indianapolis, IN). Adult male rats were used
because as stated earlier, ADHD is found in adult humans as well as adolescents
(Swanson et al., 1998b). Animals were housed two per cage with free access to
food and water in the Division of Lab Animal Resources, University of Kentucky.
Experimental protocols were in concordance with the NIH 1996 Guide for the
Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee at the University of Kentucky.
Drug Administration.
Lobeline, methylphenidate, and amphetamine were administered by
subcutaneous (sc) injection in a volume of 1 ml/kg body weight and expressed as
the salt weights. In order to remain consistent with previous studies, the
subcutaneous route was selected. Groups of rats were injected acutely with
either saline (control), lobeline (1, 3, and 10 mg/kg), methylphenidate (2.5, 5, 20,
and 40 mg/kg), or amphetamine (0.1, 0.25, 1, and 5 mg/kg). The striatum was
obtained 20 min after the last injection for the lobeline group, 60 min for the
methylphenidate group and 30 min for the amphetamine group. Separate groups
of rats were injected repeatedly for either 7 or 14 days once daily with saline,
lobeline (3.0 mg/kg), methylphenidate (2.5, 5, and 20 mg/kg), or amphetamine
(0.25 and 5 mg/kg). The doses for the repeated experiments were chosen based
on the effect observed during the acute experiments. If no effect was observed in
the acute experiments, doses were chosen based on results of previously
reported behavioral studies (Harrod, 2003; Miller, 2001).
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Lobeline dose range and time point after injection was chosen based on
previous behavioral studies in which the effect of lobeline (1, 3, and 10 mg/kg) on
methamphetamine self-administration was determined. Results showed that
lobeline (3 mg/kg) inhibited methamphetamine self-administration 20 min after
administration (Harrod et al., 2001). Methylphenidate dose range and time point
were chosen based on experiments assessing [3H]DA uptake, 60 min after
administration and behavioral studies which concluded that doses of 2.5 and 5.0
of methylphenidate were more clinically relevant (Kuczenski & Segal, 2001;
Wooters et al., 2006). Amphetamine dose range and time point were based on
behavioral studies showing that low doses of amphetamine (0.25-0.75 mg/kg)
improved stimulus detection performance in rats 30 min after injection (Grilly,
2000).
Striatal Synaptosomal Preparation and [3H]DA Uptake Assay (DAT
Function).
[3H]DA uptake assays were conducted using previously published
methods (Zhu et al., 2004). Briefly, striata were dissected and homogenized with
10-12 passes of a Teflon pestle homogenizer in 20 mL of ice cold 0.32 M
sucrose buffer containing 5 mM sodium bicarbonate (pH 7.4). Homogenates
were centrifuged at 2000 g for 10 min (4°C). Supernatants were centrifuged at
20,000 g for 15 min (4°C). Pellets were resuspended in 2.4 ml of ice-cold assay
buffer (125 mM NaCl, 5 mM KCl, 1.5 mM MgSO4, 1.25 mM CaCl2, 1.5 mM
KH2PO4, 10 mM glucose, 25 mM HEPES, 0.1 mM ethylenediaminetetraacetic
acid (EDTA), 0.1 mM pargyline and 0.1 mM L-ascorbic acid, saturated with 95%
O2/5% CO2, pH 7.4). Protein concentrations were determined using the Bradford
assay (Bradford, 1976). Striatal synaptosomes (20 µg protein in 50 µl) were
incubated in an oxygenated environment for 5 min at 34°C. [3H]DA (1 nM - 5µM)
was added to the samples. Total assay volume was 500 µl. Nonspecific uptake
was determined in the presence of 10 µM nomifensine. Incubation continued for
10 min at 34°C and was terminated by the addition of 3 ml ice-cold assay buffer
containing 1 mM pyrocatechol. Samples were filtered through Whatman GF/B
glass fiber filters (presoaked with 1 mM pyrocatechol
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for at least 3 h) and

washed three times with ice-cold assay buffer containing 1 mM pyrocatechol,
using a Brandel cell harvester (Model MP-43RS; Biochemical Research and
Development Laboratories Inc., Gaithersburg, MD). Radioactivity was determined
using a liquid scintillation spectrometer (Model B1600TR, Perkin-Elmer Life
Sciences, Downers Grove, IL).
C.

Data Analysis.

A one-way ANOVA with each dose of drug serving as an independent
group revealed that [3H]DA uptake was not different among the saline groups
across the dose range for each drug (Table 1, 2, and 3). Therefore, the data for
the saline-control groups were pooled for statistical analysis and graphical
presentation, which also explains the wide range of n.
Kinetic parameters Vmax(pmol/min/mg) and Km(µM)) for [3H]DA uptake
were determined using GraphPad Prism software (GraphPad Prism,

version

5.02; GraphPad Software, San Diego, CA). Vmax is the maximum velocity at
which the substrate is 100% bound and Km is the concentration of the substrate
at half of the Vmax. Data are expressed as mean values ± S.E.M. To analyze the
kinetic parameters, separate unpaired Student t-tests were performed on the
Vmax and Km for [3H]DA uptake of the drug-treated group for each drug at each
dose and saline-control groups. Log transformed Km values were used for
statistical analyses using the SPSS (Statistical Packages for the Social Sciences;
standard version 17, SPSS Inc., Chicago, IL). To determine the methylphenidate
(20 mg/kg) response on DAT cell surface expression, separate student t-tests
were conducted on DAT immunoreactivity from each of the cell fractions (total,
non-biotinylated and biotinylated) between methylphenidate-treated and saline
control groups. Differences were considered significant at p< 0.05.
D.

Results

Effects of Acute and Repeated In Vivo Methylphenidate Administration on
DA Transporter Function
Kinetic analysis of [3H]DA uptake was performed on synaptosomes after
acute in vivo administration of methylphenidate. Specific [3H]DA uptake for the
saline-control groups for methylphenidate 2.5, 5.0, 20.0, and 40.0 mg/kg doses
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were 16.7 ± 1.5, 12.8 ± 2.1, 17.4 ± 3.9, and 10.8 ± 2.5 pmol/mg/min, respectively.
Methylphenidate (5.0, and 20 mg/kg) increased (~60%) Vmax (23.5 ± 1.6 and 23.3
± 2.7 pmol/mg/min) for [3H]DA uptake compared to pooled saline-control (14.5 ±
1.3 pmol/mg/min, Table 1), respectively. The current results show an increase
(~60%) of DAT function, with acute methylphenidate (5.0 and 20 mg/kg) having a
significantly higher Vmax compared to control (Fig. 4A). Acute in vivo
administration of methylphenidate had no effect on Km values (Table 6).
Repeated methylphenidate administration for 7 days at 2.5 and 20 mg/kg
doses had a Vmax of 25.1 ± 0.9 and 27.3 ± 2.0 pmol/mg/min, respectively, which
increased (36% and 48%, respectively) DAT function compared to pooled salinecontrol with a Vmax of 18.5 ± 1.3 pmol/mg/min (Fig. 5A). No significant effect was
observed for the 5.0 mg/kg dose after 7 days or after 14 days (Fig. 5A).
Repeated methylphenidate in vivo administration had no effect on Km values
(Table 6).
Effects of Acute and Repeated In Vivo Amphetamine Administration on DA
Transporter Function
Acute in vivo administration of amphetamine had no effect on DAT
function (Fig. 7). Seven-day repeated in vivo administration of amphetamine had
no effect on DAT function (Fig. 8). Fourteen-day-repeated in vivo administration
of amphetamine had no effect on DAT function (Fig. 9). Specific [3H]DA uptake
for the saline-control groups for acute amphetamine 0.1, 0.25, 1.0, and 5.0 mg/kg
doses were 18.6 ± 1.0, 27.0 ± 4.9, 15.3 ± 1.1, and 14.6 ± 0.7 pmol/mg/min,
respectively, with no effect onKm (Table 7). Specific [3H]DA uptake for repeated
amphetamine 0.1, 0.25, 1.0, and 5.0 mg/kg doses were 15.9 ± 2.2, 17.7 ± 1.4,
14.3 ± 1.1, and 15.9 ± 0.9 pmol/mg/min, respectively, compared to the pooled
saline-control group with a Vmax of 19.1 ± 1.7 pmol/mg/min (Table 2).
Effects of Acute and Repeated In Vivo Lobeline Administration on DA
Transporter Function
Kinetic analysis of synaptosomal [3H]DA uptake after acute and repeated
(7 or 14 days) in vivo administration of lobeline showed no effect on Vmax or Km
values (Fig. 10-12;Table 8). Specific [3H]DA uptake for the saline-control groups
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for lobeline 1.0, 3.0, and 10.0 mg/kg doses were 16.4 ± 2.3, 20.8 ± 2.3, and 13.1
± 1.8 pmol/mg/min, respectively. Specific [3H]DA uptake for acute lobeline 1.0,
3.0, and 10.0 mg/kg doses were 13.3 ± 0.9, 20.3 ± 1.5, and 13.3 ± 1.7
pmol/mg/min, respectively, compared to16.3 ± 1.3 pmol/mg/min for the pooled
saline-control group (Table 3). The 3 mg/kg dose had the highest effect of all the
doses with a Vmax of20.3 ± 1.5 pmol/mg/min; however, this effect was not
significant.
E.

Discussion

In the present study, the effects of in vivo administration of lobeline were
determined and compared to the effects of methylphenidate and amphetamine
using kinetic analysis of [3H]DA uptake into striatal synaptosomes. This work
investigating in vivo drug administration, extends previous work in our laboratory
demonstrating that in vitro lobeline inhibits DAT function (Teng et al., 1997).
However, the results from these studies show that lobeline (1, 3, and 10 mg/kg)
has no effect on DAT function 20 min after in vivo administration. There are a
number of possible explanations for this observation.
First, the concentration of lobeline after in vitro administration may be
higher than the final concentration after in vivo administration. In vitro
experiments involve the direct application of the drug in question to the striatal
slice of tissue or synaptosomes; however with in vivo administration that is not
the case because the drug is injected into the whole animal. Furthermore, when
a drug is given in vivo, the drug is exposed to various processes that could
decrease the amount of drug available to elicit its pharmacological effect such as
absorption, distribution, metabolism, and elimination. Previous research has
provided evidence that the ability of any compound to alter monoamine uptake in
vitro does not necessarily predict its ability to modulate monoamine transporters
after in vivo administration (Fleckenstein et al., 1999).
Another plausible explanation for the lack of effect with lobeline could be
that the time point may not have been appropriate. The time point of 20 minutes
post injection, was based on behavioral effects, such as the lobeline-induced
decrease in methamphetamine self administration in rats, observed after in vivo

75

administration. A way to address this issue would be to conduct a time-course
curve to determine if the effect of lobeline is seen at any other time point besides
20 min post injection, such as every 5-10 minutes.
A third possible explanation for not observing an effect with lobeline, may
be that the brain region examined was not the region where the effect was taking
place. Even though the striatum is very dense in DA, the PFC is an important
region also involved in ADHD, where DA is present to a lesser degree (Arnsten,
2006; Casey et al., 2007; Kieling et al., 2008).
Acute in vivo administration of methylphenidate showed an increase in
DAT function at 5 and 20 mg/kg, but showed no effect with the 40 mg/kg dose.
While surprising, this result is consistent with previous results showing that a
single 40 mg/kg s.c. injection of methylphenidate caused little or no change in
synaptosomal DA uptake (Fleckenstein et al., 1999; Sandoval et al., 2002). This
present study also extends the work of Fleckenstein by including a doseresponse curve as well as 7 and 14 day repeated daily injections. The 7-day
response curve showed an increase of 36% by the 2.5 mg/kg methylphenidate
dose and the 20 mg/kg dose showed an increase of 48%. It has been shown that
methylphenidate indirectly acts as a DA agonist (Wilens, 2008).

This may

explain the increase of DAT function because if methylphenidate acts as a DA
agonist, it could activate both presynaptic and postsynaptic D2 DA receptors.
This action could indirectly cause an increase in DAT function that removes the
DA in the synaptic cleft, which would decrease the activation of the D2 DA
receptors. Furthermore, methylphenidate has a more direct and less complicated
mechanism of action when compared to amphetamine and lobeline, which could
also explain the increase of DAT function compared to lobeline and
amphetamine, whereas both have a more complex mechanism of action.
After 7 days of repeated in vivo methylphenidate administration, the 2.5
and 20 mg/kg doses showed a significant increase in Vmax, while the 5.0 mg/kg
dose had no effect. However, after 14-days of repeated in vivo administration of
methylphenidate (2.5, 5.0 or 20 mg/kg) the effect was no longer present.
Methylphenidate administration did not alter the Km, which suggests that
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methylphenidate competes with DA at DAT in a noncompetitive manner. It could
also be possible that methylphenidate increased the number of receptors in order
to enhance DAT function.
Acute and repeated in vivo administration of amphetamine did not alter
DAT function in these studies. Previous investigations have shown that
amphetamine causes a biphasic effect on DAT trafficking and acts rapidly to
control DAT in the plasmalemmal membrane (Johnson et al., 2005a).
Intracellular amphetamine produces DAT trafficking (Kahlig et al., 2003). Since
amphetamine causes DAT trafficking, one would expect to see a difference in
DAT function after in vivo administration of amphetamine. However, consistent
with our results, Johnson et al., found that amphetamine did not alter [3H]DA
uptake following a 1-min incubation (Johnson et al., 2005b). This suggests that
the chosen time point plays a critical role when determining if an effect is present.
It is possible that the DAT response was not observed with the time point that
was chosen. In addition, DAT may not be the primary target responsible for
pharmacological actions of amphetamine based on its complex mechanism of
action, which includes acting as a DAT substrate. The results also showed the
amphetamine did not alter Km, which may imply that amphetamine also competes
with DA at DAT in a noncompetitive manner.
The current results suggest that lobeline acts more similar to
amphetamine compared to methylphenidate, with respect to the effects observed
on DAT function. Since there was no effect of amphetamine at DAT, we
reevaluated the doses used in these experiments by searching the literature.
Amphetamine administered at 0.25 mg/kg appears to be an adequate dose to
observe a behavioral effect since it increased choice accuracy in rats (Grilly et
al., 1998). Another study of amphetamine administration (0.25, 0.75, and 1.25
mg/kg, s.c.) prior to behavioral testing, observed an increase in accuracy at 0.25
mg/kg however, a decrease in accuracy at 1.25 mg/kg (Grilly et al., 1989).
Based on a recent review by Grilly and Loveland, 0.1-0.4 mg/kg of amphetamine
was considered a low dose, 0.4-1.0 mg/kg a moderate dose, 1.0-3.0 mg/kg a
high dose, and ≤3.0 mg/kg was considered a very high dose (Grilly & Loveland,
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2001). Furthermore, Kuczenski and colleagues have done extensive research
with amphetamine and found using microdialysis, the maximal concentration of
amphetamine was achieved 30 minutes after administration (Kuczenski et al.,
1997). Thus, the dose range of 0.1-5.0 mg/kg of amphetamine, which was used
in the current studies, offers a complete dose-response.
The results of this study suggest

that amphetamine, lobeline and

methylphenidate influence DAT differently at the time points and doses used in
this study, since the drugs have been shown to target DAT (Greydanus et al.,
2007; Thanos et al., 2007). However, there are limitations to this current study
that need to be addressed. The first limitation is the choice of the time point. The
time points were based on behavioral observations, and may not be the optimal
time points to observe the pharmacological effects ex vivo. A complete timecourse of the pharmacological effect is necessary to determine the best time
point for each drug after in vivo administration. However, the data in these
studies could be a result of the difference in their mechanisms of action. The
interaction of methylphenidate at DAT may depend on the release of DA in the
synaptic cleft, whereas amphetamine induces release of vesicular DA from the
synaptic terminal (Schiffer et al., 2006).

This could possibly explain our

observations of an increase in Vmax by methylphenidate and no effect by
amphetamine. Another limitation is the fact that we are evaluating the effect on
DAT using synaptosomes. This limits the findings to only effects found in the
synaptosomes, while other effects may be present in other areas, such as in
vesicles as well.
The common lack of effect with in vivo administration of lobeline and
amphetamine on DAT function is consistent with the fact that both are weak
bases and very lipophilic compounds (Teng et al., 1997). The IC50 value
determined in previous studies suggest that the synaptic vesicular DA transporter
is significantly more sensitive to lobeline versus the plasma membrane DA
transporter, which provides additional evidence as to why in vivo VMAT2
experiments need to be conducted (Teng et al., 1997).
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Overall, the results of the present study, present evidence that
methylphenidate effects DAT function after in vivo administration in a different
manner than that of lobeline and amphetamine, suggesting that more research is
necessary to further understand the mechanisms of actions of these agents.
In conclusion, there is evidence to warrant more investigation of lobeline
to determine its effects on VMAT2, due to the lack of effect on DAT function after
in vivo administration of amphetamine and lobeline. This may propose that
another target may be involved in the mechanisms of actions of these drugs,
such as VMAT2. Lobeline binds to and inhibits (IC50 value ≈ 1 µM) the function of
the VMAT2, which is the only transporter protein that transports DA from the
cytoplasm into the vesicle (Eyerman & Yamamoto, 2005; Teng et al., 1998;
Wilhelm et al., 2004; Zheng et al., 2006). Therefore, additional experiments need
to be conducted to determine the effects of in vivo administration of lobeline,
methylphenidate, and amphetamine on VMAT2 function. Ultimately, studies of
this nature may aid in the discovery of new treatment options for ADHD that
improve behavioral symptoms while reducing detrimental drug side-effects by
providing more information as to how certain compounds interact with the targets
in question.
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TABLE 1. Acute saline-treated control groups did not differ between MPD
doses for DAT experiments. Acute independent saline-treated controls did not
vary between MPD doses during DAT experiments based on results of a oneway ANOVA (F3,21 = 1.110, p>0.05), with the Vmax as the dependent variable.
This demonstrates that the saline-treated control groups did not differ over time
or between treatment groups. aData are presented as mean ± S.E.M for n = 4-8
rats/group.
ACUTE
MPD (mg/kg)

Vmax
pmol/min/mg

MPD 2.5 (n= 7)

17 ± 1.5

MPD 5 (n= 8)

13 ± 2.1

MPD 20 (n= 6)

17 ± 3.9

MPD 40 (n= 4)

11 ± 2.5

POOLED MEAN

15 ± 1.3a
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TABLE 2. Acute saline-treated control groups did not differ between AMPH
doses for DAT experiments. Acute independent saline-treated controls did not
vary between AMPH doses during DAT experiments based on results of a oneway ANOVA (F3,12 = 3.010, p>0.05), with the Vmax as the dependent variable.
This demonstrates that the saline-treated control groups did not differ over time
or between treatment groups. aData are presented as mean ± S.E.M for n = 4-5
rats/group.

ACUTE
AMPH (mg/kg)

Vmax
pmol/min/mg

AMPH 0.1 (n= 5)

19 ± 1.0

AMPH 0.25 (n= 5)

27 ± 5.0

AMPH 1.0 (n= 5)

15 ± 1.1

AMPH 5.0 (n= 4)

15 ± 0.7

POOLED MEAN

19 ± 1.7a
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TABLE 3. Acute saline-treated control groups did not differ between LOB
doses for DAT experiments. Acute independent saline-treated controls did not
vary between LOB doses during DAT experiments based on results of a one-way
ANOVA (F2,16 = 2.221, p>0.05), with the Vmax as the dependent variable. This
demonstrates that the saline-treated control groups did not differ over time or
between treatment groups. aData are presented as mean ± S.E.M for n = 3-8
rats/group.

ACUTE
LOB (mg/kg)

Vmax
pmol/min/mg

LOB 1 (n= 8)

16 ± 2.3

LOB 3 (n= 3)

21 ± 2.3

LOB 10 (n= 8)

13 ± 1.8

POOLED MEAN

16 ± 1.9a
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TABLE 4. Repeated 7-day saline-treated control groups did not differ
between drug treatments for DAT experiments. Repeated 7-day independent
saline-treated controls did not vary between drug treatments during DAT
experiments based on results of a one-way ANOVA (F3,17 = 0.5413, p>0.05), with
the Vmax as the dependent variable. This demonstrates that the saline-treated
control groups did not differ over time or between treatment groups. aData are
presented as mean ± S.E.M for n =4-6 rats/group.

7-Day
Drug Treatment

Vmax
pmol/min/mg

MPD (n=4-6)

18 ± 1.9

AMPH (n=6)

20 ± 2.3

LOB (n=5)

18 ± 1.8

POOLED MEAN

18 ± 1.8a
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TABLE 5. Repeated 14-day saline-treated control groups did not differ
between drug treatments for DAT experiments. Repeated 14-day
independent saline-treated controls did not vary between drug treatments during
DAT experiments based on results of a one-way ANOVA (F2,10 = 3.021, p>0.05),
with the Vmax as the dependent variable. This demonstrates that the salinetreated control groups did not differ between treatment groups. aData are
presented as mean ± S.E.M for n = 5-6 rats/group.
14-Day
MPD (mg/kg)

Vmax
pmol/min/mg

MPD (n=6)

22 ± 3.3

AMPH (n=6)

19± 3.0

LOB (n=5)

12 ± 0.7

POOLED MEAN

23 ± 3.3a
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Figure 4. A. Acute MPD increased DAT function in striatal synaptosomes.
Rats were injected acutely once daily with MPD (0 (n = 24), 2.5 (n = 7), 5.0 (n =
7), 20 (n = 8), and 40 (n = 6) mg/kg, s.c.; open bars). Synaptosomes were
prepared 60 min post-injection. Control (0; black bar) represents saline-treated
control group. Acute MPD (5 and 20 mg/kg) increased striatal [3H]DA uptake 60
min after administration (*p<0.05 for the 5 mg/kg group and **p<0.01 for the 20
mg/kg group compared to control).Vmax is represented in pmol/min/mg. Data are
presented as mean ±S.E.M for n = 6-25 rats/group. Data were pooled for control
groups, Figure 4. B. Comparison of saturation analysis of control and acute
MPD (5 and 20 mg/kg). Specific uptake for MPD (0, 5 and 20 mg/kg) increased
by ~60% compared to control.
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Figure 5. A. Repeated 7-day MPD increased DAT function. Rats were injected
repeatedly once daily for 7 days MPD (0 (n = 10), 2.5 (n = 4), 5.0 (n = 5), and 20
(n = 5) mg/kg, s.c.; open bars). Synaptosomes were prepared 60 min postinjection. Control (0; black bar) represents saline-treated control group. Repeated
MPD (2.5 and 20 mg/kg for 7 days) increased [3H]DA uptake (*p<0.05 for 5 and
20.0 mg/kg group compared to control).Vmax is represented in pmol/min/mg.
Data are presented as mean ±S.E.M for n = 4-10 rats/group. Data were pooled
for control group, Figure 5. B. Comparison of saturation analysis of control
and acute MPD (2.5 and 20 mg/kg). Specific uptake for MPD (0, 2.5 and 20
mg/kg) increased by 36% and 48%, respectively, compared to control.
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Figure 6. Repeated 14-day MPD did not alter DAT function. Rats were
injected repeatedly once daily for 14 days MPD (0 (n = 9), 2.5 (n = 3), 5.0 (n =3),
and 20 (n = 5) mg/kg, s.c.; open bars). Synaptosomes were prepared 60 min
post-injection. Control (0; black bar) represents saline-treated control group.
Repeated MPD (2.5, 5.0, or 20 mg/kg for 14 days) did not alter [3H]DA uptake.
Vmax is represented in pmol/min/mg. Data are presented as mean ±S.E.M for n
= 3-9 rats/group. Data were pooled for control group, Table 5.
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Figure 7. Acute AMPH did not alter DAT function. Rats were injected acutely
once daily with AMPH (0 (n = 19), 0.1 (n = 4), 0.25 (n = 5), 1.0 (n = 5), 5.0 (n = 5)
mg/kg, s.c.; open bars). Synaptosomes were prepared 30 min post-injection.
Control (0; black bar) represents saline-treated control group. Acute AMPH had
no effect on striatal [3H]DA uptake 30 min after administration. Vmax is
represented in pmol/min/mg. Data are presented as mean ±S.E.M for n = 5-19
rats/group. Data were pooled for control group, Table 2.
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Figure 8. Repeated 7-day AMPH did not alter DAT function. Rats were
injected repeatedly once daily for 7 days AMPH (0 (n = 6), 0.25 (n = 5) and 5.0 (n
= 5) mg/kg, s.c.; open bars). Control (0; black bar) represents saline-treated
control group. Repeated AMPH (7 days) did not alter striatal [3H]DA uptake.
Vmax is represented in pmol/min/mg. Data are presented as mean ±S.E.M for n
= 5-6 rats/group. Data were pooled for control group, Table 4).
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Figure 9. Repeated 14-day AMPH did not alter DAT function. Rats were
injected repeatedly once daily for 14 days AMPH (0 (n = 6), 0.25 (n = 6) and 5.0
(n =4) mg/kg, s.c.; open bars). Control (0; black bar) represents saline-treated
control group. Repeated AMPH (14 days) did not alter striatal [3H]DA uptake.
Vmax is represented in pmol/min/mg. Data are presented as mean ± S.E.M for n
= 4-6 rats/group. Data were pooled for control group, Table 5.
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Figure 10. Acute LOB did not alter DAT function. Rats were injected acutely
once daily with LOB (0 (n = 19), 1.0 (n = 7), 3.0 (n = 3), and 10.0 (n = 6) mg/kg,
s.c.; open bars). Synaptosomes were prepared 20 min post-injection. Control (0;
black bar) represents saline-treated control group. Acute LOB did not alter
[3H]DA uptake 20 min after injection. Vmax is represented in pmol/min/mg. Data
are presented as mean ± S.E.M for n=3-19 rats/group. Data were pooled for
control group, Table 3.
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Figure 11. Repeated 7-day LOB did not alter DAT function. Rats were
injected repeatedly once daily for 7 days with LOB (0 (n = 5), 3.0 (n = 5) mg/kg,
s.c.; open bars) Synaptosomes were prepared 20 min post-injection. Control (0;
black bar) represents saline-treated control group. Repeated LOB for 7 days did
not alter [3H]DA uptake 20 min after injection. Vmax is represented in
pmol/min/mg. Data are presented as mean ± S.E.M for n = 5 rats/group. Data
were pooled for control group, Table 4.
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Figure 12. Repeated 14-day LOB did not alter DAT function. Rats were
injected repeatedly once daily for 14 days with LOB (0 (n = 5), 3.0 (n = 5) mg/kg,
s.c.; open bars). Synaptosomes were prepared 20 min post-injection. Control (0;
black bar) represents saline-treated control group. Repeated LOB for 14 days
did not alter [3H]DA uptake. Vmax is represented in pmol/min/mg. Data are
presented as mean ± S.E.M for n = 5 rats/group. Data were pooled for control
group, Table 5.
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Table 6. Km values for [3H]DA uptake at DAT were not altered by
acute, 7-day, or 14-day MPD treatment regimens.

ACUTE
MPD
(mg/kg)
0
2.5
5
20
40

Km
(Mick et
al)
16±3.7
14±2.1
25±3.5
22±2.9
22±4.8

7-DAY
MPD
(mg/kg)
0
2.5
5
20

Km
(Mick et
al)
21±1.8
24±1.1
12±2.4
27±1.2

a

14-DAY
MPD
(mg/kg)
0
2.5
5
20

Km
(Mick et
al)
14±1.0a
11±2.4
14±5.4
11±2.1

Data are presented as mean ± S.E.M for n= 4-25 rats/treatment group. ANOVA
(F4,47 = 2.67, p>0.05) revealed that Km values were not different among
independent control groups across the given treatments, and thus, these data for
the saline-treated groups for each treatment group were pooled for statistical
analysis.
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Table 7. Km values for [3H]DA uptake at DAT were not altered by
the acute, 7-day, or 14-day AMPH treatment regimens.
ACUTE
AMPH
(mg/kg)
0
0.1
0.25
1
5

Km
(Mick et
al)
18±2.9
16±3.7
10± 0.9
9.0±1.2
16±2.2

7-DAY
AMPH
(mg/kg)
0
0.25
5

Km
(Mick et
al)
16±1.4
10±1.7
14±1.9

a

14-DAY
AMPH
(mg/kg)
0
0.25
5

Km
(Mick et
al)
13±1.9a
12±2.3
10±2.3

Data are presented as mean ± S.E.M for n= 4-19 rats/treatment group. ANOVA
(F4,32 = 1.67,p>0.05 revealed that Km values were not different among
independent control groups across the given treatments, and thus, these data for
the saline-treated groups for each treatment group were pooled for statistical
analysis.
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Table 8. Km values for [3H]DA uptake at DAT were not altered by
the acute, 7-day, or 14-day LOB treatment regimens.
ACUTE
Lobeline
(mg/kg)
0
1
3
10

7-DAY
14-DAY
Km
Km
(Mick et Lobeline (Mick et Lobeline Km (Mick
et al)
al)
al)
(mg/kg)
(mg/kg)
19±2.5
0
19±1.9
0
20±3.4a
16±4.6
3
20±1.5
3
22±4.7
24±2.8
12±3.7

a

Data are presented as mean ± S.E.M for n= 3-19 rats/treatment group. ANOVA
(F3,32 = 1.80, p>0.05) revealed that Km values were not different among
independent control groups across the given treatments, and thus, these data for
the saline-treated groups for each treatment group were pooled for statistical
analysis.
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III. Chapter Three
Effect of Acute and Repeated In Vivo Administration of Methylphenidate on
Dopamine Transporter Trafficking

A.

Introduction

DAT plays a vital role in regulating the dopaminergic signaling in the
synaptic cleft and in maintaining a releasable storage of DA (Eriksen et al., 2010;
O'Malley et al., 2010). Numerous studies have shown that various factors such
as kinase activators, phosphatase inhibitors, and transported substrates are
involved in regulating DAT trafficking between the plasma membrane and
endosomal compartments (Eriksen et al., 2010; Kahlig & Galli, 2003; Loder &
Melikian, 2003; Merickel & Edwards, 1995; O'Malley et al., 2010; Torres et al.,
2003).

DAT is the primary target for certain psychostimulants which are

commonly abused (Thomsen et al., 2009). Second messenger systems and
psychostimulants can alter function, phosphorylation, and trafficking of DAT. For
example, protein kinase C beta, which is a kinase important for DAT trafficking,
was found to co-localize with DAT in mesencephalic neurons (O'Malley et al.,
2010). Methylphenidate which is a psychostimulant as well, was the only drug to
alter DAT function after acute and repeated in vivo administration in the present
studies. Based on these results, we investigated if the effect of methylphenidate
involved DAT trafficking.
B.

Methods

Materials
Methylphenidate hydrochloride was obtained from Sigma Chemical Co.
(St. Louis, MO). All other chemicals used in the in vitro assay buffers were
purchased from Fisher Scientific (Pittsburgh, PA).
Subjects
Adult male Sprague-Dawley rats (200-220g body weight upon arrival)
were obtained from Harlan Inc. (Indianapolis, IN). Adult male rats were used
because as stated earlier, ADHD is found in adult humans as well as adolescents
(Swanson et al., 1998b). Animals were housed two per cage with free access to
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food and water in the Division of Lab Animal Resources, University of Kentucky.
Experimental protocols were in concordance with the NIH 1996 Guide for the
Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee at the University of Kentucky.
Drug Administration
Methylphenidate (20 mg/kg) was administered by subcutaneous (sc)
injection in a volume of 1 ml/kg body weight and expressed as the salt weights.
Groups of rats were injected acutely

with either saline (control) or

methylphenidate (20 mg/kg). The striatum was obtained 60 min for the
methylphenidate group. Separate groups of rats were injected repeatedly 7 days
once daily with saline or methylphenidate (20 mg/kg).
Biotinylation and Western Blot Assay (DAT Cellular Localization)
Cell surface biotinylation experiments were performed as described
previously

(Zhu

et

al.,

2005).

Synaptosomes

from

striatum

(500

µg

protein/sample) were incubated for 1 h at 4°C with sulfo-NHS-biotin, a
biotinylation reagent, and continual shaking in 500 µl of 1.5 mg/ml sulfo-NHSbiotin in PBS/Ca/Mg buffer (138 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 9.6 mM
Na2HPO4, 1 mM MgCl2, 0.1 mM CaCl2, pH 7.3). After incubation, samples were
centrifuged at 8,000 g for 4 min at 4°C. To remove the free biotinylation reagent,
the resulting pellet was resuspended 3 times with 1 ml of ice-cold 100 mM
glycine in PBS/Ca/Mg buffer, and centrifuged at 8,000 g for 4 min at 4°C.
Resuspension and centrifugation steps were repeated using the same
parameters. Final pellets were resuspended in 1 ml of ice-cold 100 mM glycine in
PBS/Ca/Mg buffer and incubated with continual shaking for 30 min at 4°C.
Subsequently, samples were centrifuged at 8,000 g for 4 min at 4°C, and the
resulting pellets were resuspended in 1 ml ice-cold PBS/Ca/Mg buffer and
centrifuged again. Resuspension and centrifugation steps were repeated twice
more using the latter parameters. Final pellet was lysed by sonication for 2-4 s in
300 µl Triton X-100 buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1.0% Triton
X-100, 1 µg/ml aprotinin (protease inhibitor), 1 µg/ml leupeptin (protease
inhibitor), 1 µM pepstatin (protease inhibitor), 250 µM phenylmethysulfonyl
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fluoride (serine protease inhibitor), pH 7.4) followed by incubation and continual
shaking for 20 min at 4°C. Lysates (300 µl) were centrifuged at 21,000 g for 20
min at 4°C. Pellets were discarded, and 100 µl of the supernatants were stored
at -20°C for determination of total immunoreactive DAT. Remaining supernatant
was incubated with continuous shaking in the presence of monomeric avidin
beads (Pierce Biotechnology, Inc, Rockford, IL) in Triton-X100 buffer (100
µl/tube) for 1 h at room temperature. Subsequently, samples were centrifuged at
17,000 g for 4 min at 4°C, and supernatants (containing non-biotinylated,
intracellular protein) were stored at -20°C. Resulting pellets containing the avidinabsorbed biotinylated proteins (cell-surface) were resuspended in 1 ml of 1.0%
Triton X-100 buffer and centrifuged at 17,000 g for 4 min at 4°C, and the pellet
was resuspended and centrifuged twice. Final pellets consisted of the
biotinylated proteins adsorbed to monomeric avidin beads. The biotinylated
proteins were eluted by incubating with 50 µl Laemmli buffer (62.5 mM Tris-HCl,
20% glycerol, 2% sodium dodecyl sulfate (SDS), 0.05% β-mercaptoethanol and
0.05% bromophenol blue (Bio-Rad Hercules, CA), pH 6.8) for 20 min at room
temperature. The samples were stored at -20°C.
To obtain the immunoreactive DAT protein in the three separate fractions:
total, intracellular and cell surface, samples were thawed and subjected to gel
electrophoresis and Western blotting. Briefly, proteins were separated by 10%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) for 90 min at 150 V, and
subsequently,

transferred

to

Immobilon-P

transfer

membranes

(Cat

#

IPVH00010, 0.45 µm pore size; Millipore Co., Bedford, MA) in transfer buffer (50
mM Tris, 250 mM glycine, 3.5 mM SDS) using a Mini Trans-Blot Electrophoretic
Transfer Cell (Bio-Rad Laboratories Ltd., Hercules, CA) for 110 min at 72 V. The
transfer membranes were incubated with blocking buffer (5% dry milk powder in
PBS containing 0.5% Tween 20) for 1 h at room temperature, followed by
incubation with goat polyclonal DAT antibody (sc-1433; 1:1000 dilution in
blocking buffer) overnight at 4 ºC. All specific antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Transfer membranes were washed
5 times with washing buffer (PBS containing 0.5% Tween 20) at room
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temperature, and then incubated with rabbit anti-goat DAT antibody (sc-7210;
1:4000 dilution in blocking buffer) for 1 h at 22°C. Bands were detected using
enhanced

chemiluminescence

and

developed

on

Hyperfilm

(ECL-plus;

Amersham Biosciences UK Ltd., Little Chalfont Buckinghamshire, UK). After
detection and quantification of DAT protein, each membrane was stripped in 10%
of Re-blot plus mild antibody stripping solution (Chemicon, Temecula, CA) for 20
min at room temperature and reprobed for detection of PP2A (FL-309) and βactin. PP2A and β-actin were used as control proteins for monitoring biotinylation
and protein loading between methylphenidate- and saline-treated samples.
C.

Data Analysis

Multiple autoradiographs were obtained using different exposure times,
and immunoreactive bands within the linear range of detection were quantified by
densitometric scanning using Kodak Image Station software (Carestream Health,
New Haven, CT). Band density measurements, expressed as relative optical
density, were used to calculate levels of DAT in total, non-biotinylated and
biotinylated fractions. The net density measurements were calculated by
substracting the background from the raw density value. Specifically, total DAT
levels in the biotinylated and non-biotinylated fractions were calculated based on
the density of DAT-immunoreactive bands in an aliquot of synaptosomal extract
multiplied by total volume of extract and divided by the total volume of
synaptosomal

extract

subjected

to

SDS-PAGE.

To

determine

the

methylphenidate (20 mg/kg) response on DAT cell surface expression, separate
student t-tests were conducted on DAT immunoreactivity from each of the cell
fractions (total, non-biotinylated and biotinylated) between methylphenidatetreated and saline control groups. Differences were considered significant at p<
0.05.
D.

Results

Effects of Acute and Repeated In Vivo Methylphenidate Administration on
DA Transporter Trafficking
The biotinylation and western blot assay revealed that methylphenidate
(20 mg/kg)given acutely, decreased intracellular DAT expression with no change
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in total or surface DAT expression (Fig. 13B), although not significantly.
However, in vivo administration of methylphenidate (20 mg/kg) after 7 days
significantly decreased intracellular DAT expression, leaving only 20% of
intracellular DAT (19.8 ± 3.3%) compared to control without changing the total or
surface DAT expression (Fig. 14B). PP2A, an intracellular protein, was the
control for monitoring biotinylation during experiments. One would expect to find
more PP2A in the intracellular section, which is the non-biotinylated section, than
in the biotinylated section since the biotinylated section is the section on the
surface of the membrane. If more PP2A was found in the biotinylated section,
this would suggest that cell leakage has occurred, thus implying that the
biotinylation inefficient. However, these present results show that there is more
PP2A in the non-biotinylated section, therefore indicating that there was very little
cell leakage during the biotinylation experiment. β-actin was the control for
protein loading for the samples used in the biotinylation experiments. The level of
β-actin should remain consistent through all the samples to ensure that the same
amount of protein was added to each sample. Our results showed that the levels
of β-actin were constant throughout the samples, thus confirming that the level of
protein used in the biotinylation experiments did not vary between samples.
E.

Discussion

The results from this experiment suggest that the methylphenidate inducedincrease in DAT function was not independent of trafficking, since a significant
decrease in intracellular DAT was observed. However, this phenomenon where
methylphenidate did not alter total DAT expression has been observed previously
with other compounds. For example, one report found that nicotine increased
Vmax for [3H]DA uptake, however no increase in cell surface DAT expression was
seen (Middleton et al., 2007). Furthermore, another study reported that insulin
increased NET function without a change in transport cellular localization
(Apparsundaram et al., 2001). Methylphenidate may have caused the
phosphorylation of DAT, thus making DAT unrecognizable to the DAT antibodies
used in the western blot analysis. Ubiquitination, another enzymatic process that
involves the ε-amino moiety of lysine residues in target cellular proteins, has the
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ability to affect DAT cell surface expression and membrane trafficking of
transporters (Schmitt and Reith, 2010).
Another possible explanation could be the involvement of PKA and PKC.
Activation or inhibition of PKC, PI3K, and members of the MAPK family can
cause transport membrane redistribution, although specific kinases responsible
for

direct

phosphorylation

are

still

unknown.

One

report

found

that

methylphenidate had no effect on PKC activator-induced down-regulation of DAT
function (Gorentla & Vaughan, 2005), however results from a previous study
showed that methylphenidate decreased PKA levels when given repeatedly for
five days (Crawford et al., 1998). These results demonstrate that the mechanism
behind the regulation of DAT by methylphenidate is still under debate and further
investigation is needed to gain a clearer picture of how methylphenidate
regulates DAT. In addition, Wagner et al observed a significant increase in Vmax
in rats with a controlled cortical impact (CCI) that received a daily injection of
methylphenidate (5 mg/kg) for 14 days, but there was no change in total tissue or
membrane bound DAT expression compared to the CCI rats that received saline
(Wagner et al., 2009). These findings demonstrate that methylphenidate has the
ability to increase the Vmax without altering total of surface DAT expression, which
is consistent with the results of this current study.
To our knowledge, no work has been conducted on how methylphenidate
alters DAT expression. However, Fleckenstein’s group examined the effect of
methylphenidate on VMAT2 immunoreactivity (Sandoval et al., 2003). They
found that a single injection of methylphenidate (40 mg/kg, sc) redistributes
VMAT2 immunoreactivity. Specifically, methylphenidate increased VMAT2
expression in the vesicular subcellular fraction, but a decrease was found in the
plasmelemmal membrane fraction, with no change in the whole synaptosomal
fraction, which included the vesicular subcellular fraction and the plasmelemmal
membrane fraction. Our current findings demonstrating that methylphenidate did
not alter total surface DAT coincides with this report where methylphenidate had
no effect on the whole synaptosomal fraction, but altered the vesicular
subcellular fraction and the plasmalemmal membrane fraction. Even though this
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study was done with VMAT2, it provides support that methylphenidate can
redistribute transporter expression. In summary, there is evidence that
collectively suggests that multiple pathways exist to regulate neurotransmitter
transport function (Jayanthi et al., 2005) and our results indicate that
methylphenidate may regulate transporter function by altering transporter
expression.
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Figure 13. Acute MPD did not alter intracellular DAT expression. Rats were
injected acutely with MPD (20 mg/kg; open bar) and fractions of striatal
synaptosomes were obtained 60 min after MPD (Clarke & Kumar, 1983). Control
(Sal; black bar) represents saline-treated control group. A) Representative
immunoblots of total synaptosomal fraction (Total), intracellular fraction (nonbiotinylated, Non-biot), and cell surface fraction (biotinylated, Biot) for DA, β-actin
and PP2A. β –actin was used as a control for protein loading and PP2A was
used to assess efficiency of biotinylation. B) DAT immunoreactivity is presented
as percentage of the saline-treated control. DAT immunoactivity for saline
controls for total, non-biot, and biot were 3.5 ± 1.04, 6.3 ± 2.79, and 73.0 ± 61.53,
respectively. Data expressed as mean ±S.E.M of densitometry values of DAT
immunoreactivity plotted as arbitrary units for n = 5 rats/group. Acute MPD 20
mg/kg did not alter DAT expression.
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Figure 14. Repeated 7-day MPD decreased intracellular DAT expression.
Rats were injected once daily with MPD (20 mg/kg; open bar) for 7 days and
fractions of striatal synaptosomes were obtained 60 min after MPD (20 mg/kg)
injection (s.c.). Control (Sal; black bar) represents saline-treated control group.
A) Representative immunoblots of total synaptosomal fraction (Total),
intracellular fraction (non-biotinylated, Non-biot), and cell surface fraction
(biotinylated, Biot) for DAT and β-actin. β –actin was used as a control for protein
loading and PP2A was used to assess efficiency of biotinylation. B) DAT
immunoreactivity is presented as percentage of the saline-treated control. DAT
immunoactivity for saline controls for total, non-biot, and biot were 3.2 ± 0.91,
16.0 ± 1.79, and 24.2 ± 5.87, respectively. Data expressed as mean ±S.E.M of
densitometry values of DAT immunoreactivity plotted as arbitrary units for n = 5
rats/group. Repeated MPD 20 mg/kg for 7 days decreased intracellular fraction
(non-biotinylated). * indicates difference from saline-treated control group,
p<0.001.
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IV. Chapter Four
Effect of Acute and Repeated In Vivo Administration of Lobeline,
Methylphenidate, and Amphetamine on Vesicular Monoamine Transporter
Function

A.

Introduction

Even though the etiology of ADHD is unknown, DAT has become the major
target of interest for pharmacotherapies to treat ADHD (Easton et al., 2007). The
striatum, which contains high dopamine concentrations, is suggested to be
involved in executive function and motor response associated with ADHD (Dinn
et al, 2001; Volkow et al., 2001; Wilens et al., 2008). Stimulants used to treat
ADHD (i.e., methylphenidate and amphetamine) interact with DAT (Volkow et al.,
2002). But they also interact with VMAT2, which is also an important transporter
protein that is responsible for transporting cytoplasmic DA into vesicles for
storage and release into the synaptic cleft (Schuldiner, 1994). VMAT2 plays a
vital role in protecting the cells against damage from toxins, such as hydrogen
peroxide, by maintaining the low cytoplasmic concentrations of neurotransmitters
via initiating their reuptake into storage vesicles (Liu & Edwards, 1997). Recent
studies have shown that VMAT2 function is altered by psychostimulants (Brown
et al., 2001a; Fleckenstein & Hanson, 2003).
Methylphenidate inhibits the reuptake of dopamine (DA) into the synaptic
terminal, thus increasing the amount of DA in the synaptic cleft (Greydanus et al.,
2007). Recent studies have found that methylphenidate alters VMAT2 transport
and rapidly and reversibly increases VMAT2 binding and vesicular uptake of
dopamine (Sandoval et al., 2003; Sandoval et al., 2001). Amphetamine elicits its
pharmacological effect in three ways: 1) by binding to and reversing the transport
of neurotransmitters such as dopamine, norepinephrine, and serotonin, 2) by
facilitating release of neurotransmitters of these same neurotransmitters, and 3)
by inhibiting MAO (Jones et al., 1998b; Seiden et al., 1993). One study found that
10 µM amphetamine induced a 15-fold increase in cystosolic dopamine with 10-
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15

min

of

application,

strongly

suggesting

redistribution

of

vesicular

catecholamine (Mosharov et al., 2003). An experiment by Gonzalez and others,
revealed that amphetamine displaced the VMAT2 ligand tetrabenazine with a
relatively low (µM) affinity for VMAT2, which suggest amphetamine may be a
substrate of VMAT2 as well (Gonzalez et al., 1994). Another study suggests that
the response to amphetamine is indirect and the apparent inhibition of VMAT2
involves D2 autoreceptor activation following dopamine release (Brown et al.,
2002). Due to the potential for abuse (Bymaster et al., 2002; Cormier, 2008;
Greydanus et al., 2007; Holman, 1994; Olfson, 2004) and other additional side
effects including cardiovascular effects, abnormal growth, and suppressed
appetite (Gibson et al., 2006) associated with these stimulants, there are
concerns about the use of these agents. There is an obvious need for additional
treatment options that possess a less unfavorable side effect profile.
However, lobeline, evaluated in behavioral studies, was not selfadministered by rats, nor did it substitute for d-methamphetamine, which suggest
that it has no abuse liability, (Harrod et al., 2003).

Lobeline is the major

alkaloidal component of the Indian tobacco plant, Lobelia inflata and is similar to
nicotine in some ways. For example, both have a high affinity for the nicotinic
receptor despite their structural differences (Dwoskin & Crooks, 2002). Lobeline
does not stimulate locomotor activity (Miller et al., 2000) and acts as a nicotinic
antagonist (Miller et al., 2001). Lobeline, in addition to, methylphenidate and
amphetamine also interacts with DAT. Lobeline also binds to and inhibits (IC50
value ≈ 40-100 µM) DAT, inhibiting DA uptake (Miller et al., 2004; Teng et al.,
1997). In vitro studies, have found that lobeline inhibits [3H]DA uptake into
vesicles with an IC50 value of 0.88 µM and inhibits the binding of
[3H]dihydrotetrabenazine, a VMAT2 ligand, to the vesicular membrane with an
IC50 value of 0.90 µM (Teng et al., 1998; Teng et al., 1997).
The concern of the use of stimulant medications clearly indicates that
more treatment options are necessary for ADHD. Based on in vitro experiments,
lobeline may be an option (Teng et al., 1998; Teng et al., 1997). However, the
effect of in vivo administration of lobeline on VMAT2 function needs to be
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examined. In order to determine if the mechanism of lobeline on VMAT2 function
is similar to methylphenidate and amphetamine, the effects of methylphenidate
and amphetamine on VMAT2 function were also investigated. Previous research
in our lab found that after in vivo administration of lobeline, methylphenidate, and
amphetamine, only methylphenidate altered DAT function. This led us to believe
that VMAT2 may possibly be the primary target involved in the mechanism of
action of these agents. Therefore, the goal of the present study was to elucidate
the effect of acute and repeated in vivo administration of lobeline on VMAT2
function and compare its effect to the effects of methylphenidate and
amphetamine. Such experiments are helpful in providing more insight into the
mechanism of action of all these agents.
B.

Methods

Materials.
[3H]DA (3,4-ethyl-2[N-[3H]dihydroxyphenylethylamine; Specific Activity 28
Ci/mmol) was purchased from PerkinElmer Life Sciences Inc. (Boston, MA). LAscorbic acid, bovine serum albumin (BSA), catechol, α-D-glucose, N-(2hydroxyethyl)piperazine-N’-(2-ethanesulfonic

acid)

(HEPES),

nomifensine

maleate, pargyline hydrochloride, sucrose, methylphenidate hydrochloride,
amphetamine hydrochloride, and 3-hydroxytyramine hydrochloride DA were
obtained from Sigma Chemical Co. (St. Louis, MO). Lobeline was purchased
from ICN Biomedicals (Costa Mesa, CA). All other chemicals used in the in vitro
assay buffers were purchased from Fisher Scientific (Pittsburgh, PA).
Subjects.
Adult male Sprague-Dawley rats (200-220g body weight upon arrival)
were obtained from Harlan Inc. (Indianapolis, IN). Animals were housed two per
cage with free access to food and water in the Division of Lab Animal Resources,
University of Kentucky. Experimental protocols were in concordance with the NIH
1996 Guide for the Care and Use of Laboratory Animals and were approved by
the Institutional Animal Care and Use Committee at the University of Kentucky.
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Drug Administration.
In the current study, rats were randomly assigned to 3 treatment groups
(lobeline,

methylphenidate,

and

amphetamine)

for

acute

and

repeated

administration. Lobeline, methylphenidate, and amphetamine were administered
by subcutaneous (sc) injection in a volume of 1 ml/kg body weight and expressed
as the salt weights. The rats in the lobeline treatment group were injected acutely
with lobeline (1, 3, and 10 mg/kg) and repeatedly for 7 days with lobeline (3
mg/kg). The rats in the methylphenidate treatment group were injected acutely (n
= 4-18) with methylphenidate (2.5, 10, and 20 mg/kg) and repeatedly for 7 days
with methylphenidate (2.5 and 10 mg/kg). The rats in the amphetamine treatment
group were injected acutely with amphetamine (0.25, 1.0, and 5.0 mg/kg) and
repeatedly for 7 days with amphetamine (0.25 and 5 mg/kg). Control groups for
the lobeline treatment group were administered saline contemporaneously for all
doses and the methylphenidate and amphetamine treatment groups had
independent saline groups for the individual doses.
Lobeline dose range and time point after injection were chosen based on
previous behavioral studies in which lobeline (1, 3, and 10 mg/kg) were used and
lobeline (3 mg/kg) significantly inhibited methamphetamine self-administration 20
min after injection (Harrod et al., 2001). Methylphenidate dose range and time
point were chosen based on experiments assessing [3H]DA uptake, 60 min after
administration and behavioral studies which concluded that doses of 2.5 and 5.0
of methylphenidate were more clinically relevant (Kuczenski & Segal, 2001;
Wooters et al., 2006). Amphetamine doses range and time point were based on
behavioral studies showing that the low doses of amphetamine (0.25-0.75 mg/kg)
improved stimulus detection performance in rats 30 minutes after injection.
(Grilly, 2000). The doses for the repeated experiments were chosen based on
the effect observed during the acute experiments. If no effect was observed
during the acute experiments, doses were chosen based on previous behavioral
and in vitro studies.
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Vesicle Preparation and [3H]DA Uptake Assay.
The uptake of [3H]DA into striatal synaptic vesicles were determined by
using a previously published method (Erickson et al., 1990). Striata from the rats
were homogenized over a 2-min period in 14ml of 0.32 M sucrose (pH 7.5) with
10 up and down strokes of a Teflon pestle (clearance ~0.009 inches). The
homogenate was centrifuged at 2000 g for 10 min at 4°C, and the resulting
supernatant will be centrifuged at 10,000 g for 30 min at 4°C. Synaptosomes
(buffy coat) were separated from the underlying mitochondria and cellular debris
(reddish pellet) by gentle swirling in 2 ml of 0.32 M sucrose. The enriched
synaptosome fraction (2.0 ml) was subjected to osmotic shock by the addition of
7 ml distilled H2O and homogenized with 5 up and down strokes of the Teflon
pestle. The osmolarity was restored by the addition of 900 µl of 0.25 M HEPES
and 900 µl of 1.0 M neutral potassium-tartrate buffer (pH 7.5) followed by a 20min centrifugation (20,000 g at 4°C). The supernatant was centrifuged for 60 min
(55,000 g at 4°C). Then 1 ml of solution containing 10 mM MgSO4, 0.25 M
HEPES and 1.0 M potassium-tartrate buffer was added to the supernatant and
the suspension was centrifuged (100,000 g for 45 min at 4°C). Immediately
before use, the final pellet was resuspended in the assay buffer (in mM: 25
HEPES, 100 potassium tartrate, 0.05 EGTA, 0.10 EDTA, 2 ATP-Mg++ and 1.7
ascorbic acid, pH 7.4). Aliquots (160 µl containing 8-10 µg protein) of the
resuspension were incubated with 20 µl of drug (final concentrations: nicotine,
0.001-100 µM; lobeline, 0.001-100 µM; tetrabenazine, 0.001-100 µM) and 20 µl
of [3H]DA (final concentration 0.3 µM) for 8 min at 37°C in a total volume of 200
µl. The reaction was terminated by the addition of 2.5 ml of ice-cold assay buffer
containing 2 mM MgSO4. Samples were rapidly filtered through Whatman GF/F
filters using the Brandel cell harvester (Model MP-43RS; Biochemical Research
and Development Laboratories Inc., Gaithersburg, MD). The filters were washed
three times with 4 ml of ice-cold assay buffer containing 2 mM MgSO4. Filters
were previously soaked in 0.5% polyethylenimine (Speiser et al., 1983) solution
for 2 hr at 4 °C. Nonspecific uptake was determined by incubation of duplicate
samples in the presence of R0412-84 (10 µM), a VMAT2 inhibitor. Filters were
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placed into scintillation vials, 10 ml scintillation cocktail were added, and
radioactivity was determined by scintillation spectrometry (Model B1600TR,
Perkin-Elmer Life Sciences, Downers Grove, IL).
C.

Data Analysis.

Kinetic parameters (Vmax and Km) for [3H]DA uptake were determined using
GraphPad Prism software (GraphPad Prism, version 5.02; GraphPad Software,
San Diego, CA). Data are represented as mean values ± S.E.M. To analyze the
kinetic parameters, Vmax and Km for [3H]DA uptake in drug-treated for each drug
at each dose and saline-control groups, separate unpaired Student t-tests were
performed. Log transformed Km values were used for statistical analyses using
the Statistical Packages for the Social Sciences (SPSS; standard version 17,
SPSS Inc., Chicago, IL). Differences were considered significant at p< 0.05. An
individual one-way ANOVA with each dose of methylphenidate, amphetamine
and lobeline serving as an independent group revealed that [3H]DA uptake was
not different among the saline groups across the dose range for each drug
(Tables 9-11). Therefore, the data for the saline-control groups were pooled for
statistical analysis and graphical presentation, which also explains the wide
range of n.Specific [3H]DA uptake for the saline-control groups for acute
methylphenidate 2.5, 10, and 20 mg/kg doses were 19.1 ± 3.6, 23.0 ± 2.7, and
28.0 ± 4.1 pmol/mg/min, respectively, with a pooled mean of 23.8 ± 2.0
pmol/mg/min. Specific [3H]DA uptake for the saline-control groups for

acute

amphetamine 0.25, 1.0, and 5.0 mg/kg doses were 35.3 ± 3.0, 43.1 ± 5.8, and
31.0 ± 3.2 pmol/mg/min, respectively with a pooled mean of 36.0 ± 3.3
pmol/mg/min.
D.

Results

Effects of Acute and Repeated In Vivo Methylphenidate Administration on
Vesicular Monoamine Transporter Function
Kinetic analysis of [3H]DA uptake was performed on synaptosomes after
acute in vivo administration of methylphenidate. Methylphenidate (10, and 20
mg/kg) increased Vmax (53.4 ± 5.0 and 43.4 ± 4.7 pmol/mg/min) for [3H]DA uptake
compared to pooled saline-control (23.8 ± 2.0 pmol/mg/min), respectively. The
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current results show an increase (84-124%) of VMAT2 function, with acute
methylphenidate (10 and 20 mg/kg) having a significantly higher Vmax compared
to control (Fig. 15). Repeated methylphenidate in vivo administration for 7 days
at 2.5 and 10 mg/kg doses had a Vmax of 33.0 ± 1.1 and 52.7 ± 4.0 pmol/mg/min,
respectively, which increased (53% and 145%) VMAT2 function compared to
pooled saline-control with a Vmax of 21.5 ± 1.4 pmol/mg/min (Fig.16). Neither
acute nor repeated methylphenidate in vivo administration had an effect on Km
values (Table 15).
Effects of Acute and Repeated In Vivo Amphetamine Administration on
Vesicular Monoamine Transporter Function
Acute, as well as 7 day-repeated in vivo administration of amphetamine
had no effect on VMAT2 function, (Figs. 17, 18). Specific [3H]DA uptake for
amphetamine 0.25, 1.0, and 5.0 mg/kg doses were 35.3 ± 3.0, 43.1 ± 5.8, and
31.0 ± 3.2 pmol/mg/min, respectively, compared to the pooled saline-control
group with a Vmax of 36.0 ± 3.3 pmol/mg/min. Amphetamine had no effect on Km
values following acute in vivo administration (Table 15); however, repeated in
vivo administration significantly decreased the Km after 7 days (Fig. 19;Table 15).
Effects of Acute and Repeated In Vivo Lobeline Administration on Vesicular
Monoamine Transporter Function
Kinetic analysis of vesicular [3H]DA uptake after acute (Fig. 20) and
repeated (Fig. 20) in vivo administration of lobeline for 7 days showed no effect
on Vmax or Km values (Tables 11 and 15). Specific [3H]DA uptake at VMAT2 for
acute lobeline 1.0, 3.0, and 10.0 mg/kg doses were 29.7 ± 4.5, 33.9 ± 6.9, and
33.7 ± 7.4 pmol/mg/min, respectively, compared to 29.7 ± 5.0 pmol/mg/min for
the pooled saline-control group.
E.

Discussion

In the present study, the effects of acute and repeated in vivo
administration of lobeline on VMAT2 function were determined and compared to
the effects of methylphenidate and amphetamine using kinetic analysis of [3H]DA
uptake into striatal vesicles. This work investigating in vivo drug administration,
extends previous work in our laboratory demonstrating that in vitro, lobeline
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inhibits VMAT2 function (Teng et al., 1997). However, the results from these
studies show that lobeline (1, 3, and 10 mg/kg) has no effect on VMAT2 function
20 min after in vivo administration. Previous research using striatal vesicles has
provided evidence that the ability of a compound to alter monoamine uptake in
vitro does not necessarily predict its ability to modulate monoamine transporters
after in vivo administration (Fleckenstein et al., 1999). This may be the case with
in vesicles as well. Thus, it is necessary to conduct in vivo experiments as well
as in vitro experiments.
Another plausible explanation for the lack of effect with lobeline could be
that the time of the effect was not in the timeframe that was used in this study.
The time point was based on behavioral effects observed after in vivo
administration. The pharmacological effect may not coincide with the behavioral
effect, thus no pharmacological effect was seen at the time point in question.
Acute in vivo administration of methylphenidate showed an increase in
VMAT2 function at 10 and 20 mg/kg, but showed no effect with the 2.5 mg/kg
dose. These results suggest that there is a specific range of doses of
methylphenidate that elicit an effect on VMAT2 function. If the dose is too high or
too low, the effect could be lost. This result is consistent with previous results
showing that a single high dose (40 mg/kg s.c.) of methylphenidate increased
vesicular DA uptake accessed 60 minutes after in vivo administration
(Fleckenstein et al., 1999; Sandoval et al., 2002). After 7 days of repeated in
vivo methylphenidate administration, the 2.5 and 20 mg/kg doses showed a
significant increase in Vmax. No tolerance developed with repeated administration
of methylphenidate after 7 days. Methylphenidate administration did not alter the
Km, which suggests that methylphenidate competes with dopamine at VMAT2 in
a noncompetitive manner. Very little is known about VMAT2 regulation and only
the Fleckstein lab to our knowledge has conducted research on how
methylphenidate interacts with VMAT2. However, the interest in VMAT2 as a
target for drugs of abuse is growing based on a current review by Eden and
Weihe (Eiden, 2011).
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Acute and repeated in vivo administration of amphetamine did not alter
VMAT2 function in these studies. The time points chosen in this current study
were based on behavioral observations of amphetamine and the time course of
the neurochemical effects may not correspond with the behavioral effects of
amphetamine on VMAT2 function. A complete time course would allow more
insight as to what the optimal time point should be in order to observe the
maximal pharmacological effect of amphetamine. However, Fon and colleagues
found that VMAT2 was not required for amphetamine to cause DA release in an
in vitro measure of amphetamine in VMAT2 knock-out mice with an absence of
vesicular monoamine stores (Fon et al., 1997). This finding may be difficult to
relate to methylphenidate, since methylphenidate does not release DA. Based on
this evidence and what is already known about amphetamine, the current results
of this study showing amphetamine did not alter VMAT2 function are intriguing to
say the least.
The current results suggest that methylphenidate acts differently than
lobeline and amphetamine, in reference to the effects observed on VMAT2
function. The observation that amphetamine and methylphenidate influence
VMAT2 differently at the time point and doses used in this study may be rather
surprising since both drugs have been shown to target VMAT2 (Greydanus et al.,
2007; Thanos et al., 2007). However, the data in these studies could be a result
of the difference in their mechanisms of action.
Overall, the results of the present study, have demonstrated that
methylphenidate affects VMAT2 function differently than amphetamine and
lobeline after in vivo administration. These changes in VMAT2 function are
interesting considering that little is known as to how methylphenidate interacts
with VMAT2. These findings suggest that methylphenidate increases VMAT2
function, which decreases the amount of DA in the cytosol. These results also
imply the VMAT2 is a target of methylphenidate and that VMAT2 could be
involved in the etiology of ADHD.
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Although lobeline did not alter VMAT2 function in the present study,
additional evidence suggests that lobeline could still be evaluated as a potential
treatment option for ADHD. Lobeline has been found to improve retention
performance 24 hours after injection in spatial discrimination water maze (Decker
et al., 1993). Furthermore, Levin et al. showed lobeline enhanced learning on the
post-acquisition working memory performance in the radial-arm maze (Levin et
al., 2003). Previous work has also demonstrated that lobeline may be an
effective smoking cessation agent by showing that lobeline acts as a nicotinic
antagonist by inhibiting nicotine-evoked DA release and nicotine-evoked
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Rb+

efflux (Miller et al., 2000). Lobeline has been used as an over-the-counter
smoking cessation agent in the past in the US (Nunn-Thompson & Simon, 1989;
Prignot, 1989) and numerous human studies have been conducted to determine
efficacy of lobeline as a smoking cessation agent, although its use is still
debatable (Dwoskin & Crooks, 2002). This characteristic gives lobeline an added
benefit to the currently used ADHD treatments because it has been shown that
there is a higher rate of smoking in people who have ADHD compared to those
who do not (Milberger et al., 1997). Furthermore, lobeline does not have typical
stimulant side-effects such as abuse liability.
In conclusion, there is evidence to warrant more investigation into the
mechanism of action of these agents because it is still unclear as to how they
elicit their pharmacological effects. Therefore, additional experiments need to be
conducted to elucidate the pharmacological effects of lobeline, methylphenidate,
and amphetamine. Ultimately, studies of this nature may help in the discovery of
new treatment options for ADHD that improve behavioral symptoms while
reducing detrimental drug side-effects.
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TABLE 9. Acute saline-treated control groups did not differ between MPD
doses for VMAT2 experiments. Acute independent saline-treated controls did
not vary between MPD doses during VMAT2 experiments based on results of a
one-way ANOVA (F2,15 = 1.428, p>0.05), with the Vmax as the dependent
variable. This demonstrates that the saline-treated control groups did not differ
over time or between treatment groups. aData are presented as mean ± S.E.M
for n = 4-8 rats/group.

ACUTE
MPD (mg/kg)

Vmax
pmol/min/mg

MPD 2.5 (n= 4)

19 ± 3.6

MPD 10 (n= 8)

23 ± 2.7

MPD 20 (n= 6)

28 ± 4.1

POOLED MEAN

24 ± 1.8a
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TABLE 10. Acute saline-treated control groups did not differ between
AMPH doses for VMAT2 experiments. Acute independent saline-treated
controls did not vary between AMPH doses during VMAT2 experiments based on
results of a one-way ANOVA (F2,13 = 3.076, p>0.05), with the Vmax as the
dependent variable. This demonstrates that the saline-treated control groups did
not differ over time or between treatment groups. aData are presented as mean ±
S.E.M for n = 5-6 rats/group.

ACUTE
AMPH (mg/kg)

Vmax
pmol/min/mg

AMPH 0.25 (n= 5)

35 ± 3.0

AMPH 1.0 (n= 5)

43 ± 5.8

AMPH 5.0 (n= 6)

29 ± 3.3

POOLED MEAN

36 ± 3.3a
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TABLE 11. Acute saline-treated control groups did not differ between LOB
doses for VMAT2 experiments. Acute independent saline-treated controls did
not vary between LOB doses (1, 3, and 10 mg/kg) during VMAT2 experiments
based on results of a one-way ANOVA (F3,27 = 0.1494, p>0.05), with the Vmax as
the dependent variable. This demonstrates that the saline-treated control groups
did not differ over time or between treatment groups. aData are presented as
mean ± S.E.M for n = 7 rats/group.

ACUTE
LOB (mg/kg)

Vmax
pmol/min/mg

POOLED MEAN

30 ± 5.0a
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TABLE 12. Repeated 7-day saline-treated control groups did not differ
between MPD doses for VMAT2 experiments. The 7-day independent salinetreated controls were used for both MPD doses during VMAT2 experiments.
Therefore, no ANOVA was performed. aData are presented as mean ± S.E.M for
n = 8 rats/group.

7-day
MPD (mg/kg)

Vmax
pmol/min/mg

POOLED MEAN

22 ± 1.4a
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TABLE 13. Repeated 7-day saline-treated control groups did not differ
between AMPH doses for VMAT2 experiments. The 7-day independent salinetreated controls were used for both AMPH doses during VMAT2 experiments.
Therefore, no ANOVA was performed. aData are presented as mean ± S.E.M for
n = 5 rats/group.

7-day
AMPH (mg/kg)

Vmax
pmol/min/mg

POOLED MEAN

30 ± 5.3a
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TABLE 14. Repeated 7-day saline-treated control groups did not differ
between LOB doses for VMAT2 experiments. The 7-day independent salinetreated controls were used for both LOB doses during VMAT2 experiments.
Therefore, no ANOVA was performed. aData are presented as mean ± S.E.M for
n = 5 rats/group.

7-day
LOB (mg/kg)

Vmax
pmol/min/mg

POOLED MEAN

24 ± 2.5a
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Figure 15. Acute MPD increased VMAT2 function. Rats were injected acutely
once daily with MPD (0, 2.5, 10.0, and 20 mg/kg; open bars). Control (0; black
bar) represents saline-treated control group. An independent control group was
administered saline contemporaneously with each MPD dose (open bars) for the
acute treatment group. Vmax is represented in pmol/min/mg. Data are presented
as mean ± S.E.M for n = 4 -18 rats/group (Data were pooled for control groups).
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Figure 16. Repeated 7-day MPD increased VMAT2 function. Rats were
injected repeatedly once daily with MPD (0; black bar; 2.5, and 10.0 mg/kg;
open bars). Repeated MPD (2.5and 10 mg/kg for 7 days) increased [3H]DA
uptake (***p<0.001 for 2.5 and 10.0 mg/kg group compared to control). Vmax is
represented in pmol/min/mg. Data are presented as mean ± S.E.M for n = 6-8
rats/group.
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Figure 17. Acute AMPH did not alter VMAT2 function. Rats were injected
acutely once daily with AMPH (0, 0.25, 1.0, and 5.0 mg/kg). Control (0; black bar)
represents saline-treated control group. An independent control group was
administered saline contemporaneously with each AMPH dose (open bars) for
the acute treatment group. Vmax is represented in pmol/min/mg. Acute AMPH
had no effect on striatal [3H]DA uptake 30 min after administration. Data are
presented as mean ± S.E.M for n=4-12 rats/group (Data were pooled for control
groups).
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Figure 18. Repeated 7-day AMPH did not alter VMAT2 function. Rats were
injected repeatedly once daily for 7 days AMPH (0, 0.25, and 5.0 mg/kg; open
bar). Control (0; black bar) represents saline-treated control group. Vmax is
represented in pmol/min/mg. Repeated AMPH (7 days) did not alter striatal
[3H]DA uptake. Data are presented as mean ± S.E.M for n = 5 rats/group.
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Figure 19. Repeated 7-day AMPH decreased Km for VMAT2. Rats were
injected repeatedly once daily with AMPH (0, 0.25, and 5.0 mg/kg; open bars) for
7 days. Control (0; black bar) represents saline-treated control group. Repeated
AMPH (5 mg/kg) decreased Km (0.12 ± 0.01) compared to control (0.24 ± 0.05).
Data are presented as mean ± S.E.M of the log transform of Km for n = 5
rats/group.
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Figure 20. Acute LOB did not alter VMAT2 function. Rats were injected
acutely once daily with LOB (0, 1.0, 3.0, and 10.0 mg/kg) Control (0; black bar)
represents saline-treated control group. A control group was administered saline
contemporaneously for all LOB doses (open bars) for the acute treatment group.
Vmax is represented in pmol/min/mg. Acute LOB did not alter striatal [3H]DA
uptake 20 min after injection. Data are presented as mean ± S.E.M for n = 7-8
rats/group.).
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Figure 21. Repeated LOB did not alter VMAT2 function. Rats were injected
repeatedly once daily for 7 days LOB (0 and 3.0 mg/kg). Vesicles were prepared
20 min post-injection. Control (0; black bar) represents saline-treated control
group. A control group was administered saline contemporaneously for LOB 3
mg/kg dose (open bar) for the7-day treatment group. Vmax is represented in
pmol/min/mg. Repeated LOB for 7 days did not alter [3H]DA uptake. Data are
presented as mean ± S.E.M for n=5-7 rats/group.).
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Table 15. Km values for [3H]DA uptake at VMAT2 were only
altered by the AMPH (7-day treatment) regimen.

ACUTE
MPD
(mg/kg)
0
2.5
10
20

Km
(Mick et
al)
11 ± 1.0
12 ± 3.0
12 ± 3.0
9.0 ± 0.4

7-DAY
MPD
(mg/kg)
0
2.5
10

ACUTE
AMPH
(mg/kg)
0
0.25

Km
(Mick et
al)
11 ± 3.0
9.0 ± 2.0

7-DAY
AMPH
(mg/kg)
0
0.25

1
5

10 ± 1.0
10 ± 2.0

5

ACUTE
Lobeline
(mg/kg)
0
1
3
10

Km
(Mick et
al)
20 ± 4.0
21 ± 4.0
13 ± 1.0
13 ± 3.0

Km ((Mick
et al)
13 ± 1.0
10 ± 1.0
12 ± 1.0

Km (Mick et
al)
24 ± 5.0
18 ± 4.0

12 ± 1.0

7-DAY
Lobeline Km (Mick et
al)
(mg/kg)
0
15 ± 3.0
3
11 ± 2.0

a

Data are presented as mean ± S.E.M for n = 4-18 rats/treatment group. ANOVA
(F(6,48) = 3.21, p> 0.05 revealed that Km values were not different among
independent control groups across the given treatments, and thus, these data for
the saline-treated groups for each treatment group were pooled for statistical
analysis.
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V. Chapter Five
Discussion and Conclusions
A.

Summary
ADHD is a psychiatric disorder that has a worldwide impact. ADHD has

become more of a focus in research due to the increasing number of children
and adults being diagnosed with ADHD and there is still much to be learned
about the safety issues of ADHD medications (Meijer et al., 2009). This increase
in ADHD research, has also led to a need to develop novel agents without the
harmful side effects associated with the current therapies used to treat ADHD.
The first line therapy for ADHD consists of stimulants, namely methylphenidate
and amphetamine. Amphetamine is a DAT substrate, which competes with DA
for DAT and also reverses the transport of dopamine causing release of
dopamine, where as methylphenidate binds to DAT and inhibits DAT function,
without releasing DA (Bannon et al., 2000; Seiden et al., 1993; Solanto, 2002;
Sonders et al., 1997). These agents also interact with VMAT2, which is the
transporter responsible for moving

cytoplasmic dopamine into the synaptic

vesicles

release

for

storage

and

future

(Yelin

&

Schuldiner,

2002).

Methylphenidate has been shown to rapidly and reversibly increase VMAT2
binding and vesicular uptake of dopamine (Sandoval et al., 2001). Amphetamine
has been found to displace the VMAT2 ligand tetrabenazine with a relatively low
(µM) affinity for VMAT2, which suggest amphetamine may be a substrate of
VMAT2 (Gonzalez et al., 1994).
Lobeline, a major alkaloidal component of the Indian tobacco plant, has
been shown in previous in vitro studies performed in our laboratory, to interact
with DAT and VMAT2. For instance, lobeline binds to and inhibits (IC50 value ≈
40-100 µM) DAT, inhibiting DA uptake (Miller et al., 2004; Teng et al., 1997).
Lobeline also inhibits [3H]DA uptake into vesicles with an IC50 value of 0.88 µM
and inhibits the binding of [3H]dihydrotetrabenazine, a VMAT2 ligand, to the
vesicular membrane with an IC50 value of 0.90 µM (Teng et al., 1998; Teng et al.,
1997). However, lobeline may not have any abuse liability based on results from
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behavioral studies, that showed lobeline was not self-administered by rats, nor
did it substitute for d-methamphetamine (Harrod et al., 2003).
The purpose of this dissertation research was to examine the effects of
acute and repeated in vivo administration of a compound called lobeline on
dopamine and vesicular monoamine transporter functions and compare those
effects with the effects of methylphenidate and amphetamine to warrant further
investigation of lobeline as a potential treatment option for ADHD. The
experiments for this dissertation research were conducted in the striatum, a
region of the brain rich in dopamine and is also suggested to be involved in
executive function and motor response associated with ADHD (Dinn et al., 2001;
Volkow et al., 2001; Wilens, 2008).
The first aim of this dissertation research was to determine the effect of
lobeline on DAT function after acute and repeated in vivo administration using
[3H]DA uptake assay and compare its effects with the effects of methylphenidate
and amphetamine. The novel findings from these experiments showed an
increase of DAT function (~60%), with acute methylphenidate (5 and 20 mg/kg)
having

a

significantly

higher

Vmax

compared

to

control.

Repeated

methylphenidate administration for 7 days at 2.5 and 20 mg/kg doses also
increased DAT function (36% and 48%) compared to pooled saline-control.
Neither acute nor repeated methylphenidate in vivo administration had an effect
on Km values. Acute, as well as repeated (7 or 14 days) in vivo administration of
amphetamine and lobeline had no effect on DAT function. Amphetamine and
lobeline had no effect on Km values following acute or repeated in vivo
administration. The results of these experiments do not support the hypothesis
that lobeline would decrease DAT function in vivo as observed in the in vitro
experiments. To our knowledge, this is the first report of the effects of DAT and
VMAT2

function

after

acute

and

repeated

in

vivo

administration

of

methylphenidate, amphetamine, and lobeline.
The second aim was to determine the effect of lobeline on VMAT2
function after acute and repeated in vivo administration and compared its effects
to methylphenidate and amphetamine. Acute in vivo administration of
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methylphenidate showed an increase in VMAT2 function at 10 and 20 mg/kg.
After 7 days of repeated in vivo methylphenidate administration, the 2.5 and 20
mg/kg

doses

showed

a

significant

increase

in

Vmax.

Methylphenidate

administration did not alter the Km. Acute and repeated in vivo administration of
amphetamine did not alter VMAT2 function in these studies. Amphetamine had
no effect on Km values following acute in vivo administration; however, repeated
in vivo administration significantly decreased the Km after 7 days. Acute and
repeated in vivo administration of lobeline did not alter VMAT2 function or Km in
these studies. In summary, all three compounds act differently at this site. The
results of these experiments did not support the hypothesis that lobeline would
decrease VMAT2 function as seen in the previous in vitro studies.
The third aim was to determine if the underlying mechanism of the
methylphenidate-induced increase of DAT function was due to DAT trafficking
using biotinylation and western blot analysis. The biotinylation and western blot
assay revealed that methylphenidate given acutely, slightly but not significantly
decreased intracellular DAT expression with no change in total or surface DAT
expression. However, in vivo administration of methylphenidate after 7 days
significantly decreased intracellular DAT expression, where only ~ 20 %

of

intracellular DAT was found compared to control, without a change in the total or
surface DAT expression. These results agree with the hypothesis that DAT
trafficking was responsible for the methylphenidate-induced increase in DAT
function, but in a different manner since there was no increase in surface DAT
expression. Nevertheless, the significant decrease in intracellular DAT caused by
methylphenidate administration for 7 days does suggest that methylphenidate
redistributes DAT, which means that some type of trafficking is involved and that
this effect is time-dependent.
B.

Potential Mechanism for the Methylphenidate-Induced Increase in
DAT Function
Methylphenidate is a potent DAT inhibitor, which results in an increase in

extracellular dopamine (Easton et al., 2007; Ferris et al., 1972; Richelson &
Pfenning, 1984). Other studies have investigated the effect methylphenidate has
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on DAT density and occupancy (Muneoka et al., 2006; Spencer et al., 2006;
Volkow et al., 1998; Volkow et al., 2007; Wilcox et al., 2008). The results from the
current work revealed that methylphenidate increased DAT function rather than
inhibited DAT function. Specifically, acute methylphenidate (5.0 and 20 mg/kg)
increased DAT function by ~60% and repeated methylphenidate (2.5 and 20
mg/kg) increased DAT function by 36% and 48% respectively. However,
repeated in vivo administration of methylphenidate (2.5, 5.0, or 20 mg/kg) after
14 days did not alter DAT function. These findings suggest that the effect of
methylphenidate is lost between 7 and 14 days and is time-dependent. This
observation may be due to the compensatory effect of the potent inhibition of
methylphenidate on DAT function. As methylphenidate inhibits DAT function, the
system may respond by upregulating the existing DAT in order to compensate for
the lack of DAT function. Overtime the compensatory effect could become less,
thus causing methylphenidate to have no effect on DAT function, which was
observed in the 14-day experiments.
Another potential explanation could be the involvement dopamine
transporter phosphorylation and protein-protein interactions. A study investigating
the effect of methylphenidate on dopamine-and cAMP-regulated phosphoprotein,
Mr 32kDa (DARPP-32) phosphorylation using neostriatal slices found that
methylphenidate increased (DARPP-32) phosphorylation in adult (6-8-week old)
slices but not young (14-15-and 21-22-day old) slices (Fukui, 2003).

The

phosphorylation state of DARPP-32 is involved in the mechanism for integrating
information coming from dopamine neurons, multiple brain regions, utilizing
various neurotransmitters, neuromodulators, neuropides and steroid hormones
(Svenningsson et al., 2004). This finding suggests that age is an important factor
to consider when determining the effect of methylphenidate on phosphorylation.
Vaughan’s group conducted a more recent study to determine if certain DAT
blockers, including methylphenidate, had an effect on basal and phorbol 12
myristate 13 acetate (PMA) (Li et al)-stimulated DAT phosphorylation (Gorentla &
Vaughan, 2005). PMA is a PKC activator and PKC regulates DAT activity and
phosphorylation. The authors exposed rDAT LLC-PK1 cells to methylphenidate
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(10 µM) for 30 minutes and found that methylphenidate had no effect on basal or
PMA-stimulated phosphorylation. This evidence suggests that methylphenidate
does not cause DAT phosphorylation, thus no decrease in DAT function with
methylphenidate was observed. Taken together, these data imply that DAT
function can be regulated by various mechanisms and more work is required to
elucidate the intricacies of these mechanisms.
1.

Methylphenidate increase in DAT Function is trafficking
dependent

Several lines of evidence suggest that psychostimulants are involved in
the regulation of DAT at the level of surface expression (Zhu & Reith, 2008). In
the current study, methylphenidate decreased intracellular DAT without altering
total or surface DAT. DAT function is regulated by numerous cellular signaling
pathways, including PKC, tyrosine kinases, phosphatases, calcium and
calmodulin-dependent kinases, and protein kinase A (PKA), which strongly
modulate DAT expression on the plasma membrane (Melikian, 2004; Robinson,
2002; Vaughan, 2004; Zahniser & Doolen, 2001). G protein-coupled receptors
(GPCRs), enzymatic modification such as phosphorylation or ubiquitination, and
protein-protein interactions between DAT and other scaffolding proteins have
also been found to be involved in the regulation of DAT (Schmitt et al., 2010).
Methylphenidate may have caused the phosphorylation of DAT, thus making
DAT unrecognizable to the DAT antibodies used in the western blot analysis.
Ubiquitination is the covalent attachment of the small soluble protein ubiquitin to
the ε-amino moiety of lysine residues in target cellular proteins. This process
affects DAT cell surface expression and membrane trafficking of transporter
(Schmitt et al., 2010). A possible mechanism mediating the methylphenidateinduced decrease in intracellular DAT could be D3 receptor activation. Zapata et
al conducted an experiment using hEK and neuro2A cells, found a significant
increase in cell surface DAT parallel to a significant increase in DAT function
after brief D3 receptor stimulation (Zapata et al., 2007). This result suggests D3
activation increases DAT redistribution from the intracellular compartment to the
cell surface. This finding is consistent with our results where methylphenidate
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caused the same DAT redistribution from the intracellular compartment based on
the significant decrease in intracellular DAT that was observed. However,
prolonged D3 receptor activation had the opposite effect, causing a decrease in
cell surface DAT. In addition, this study also found that the D3 activation requires
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)
activation. This suggests that there are multiple mechanisms and pathways that
may be involved in the methylphenidate-induced decrease of intracellular DAT.
Another possible explanation could be the involvement of PKA and PKC.
Activation or inhibition of PKC, PI3K, and members of the MAPK family can
cause transport membrane redistribution, although specific kinases responsible
for

direct

phosphorylation

are

still

unknown.

One

report

found

that

methylphenidate had no effect on PKC activator-induced down-regulation of DAT
function (Gorentla & Vaughan, 2005), however results from a previous study
showed that methylphenidate decreased PKA levels when given repeatedly for
five days (Crawford et al., 1998). These results demonstrate that the mechanism
behind the regulation of DAT by methylphenidate is still under debate and further
investigation is needed to gain a clearer picture of how methylphenidate
regulates DAT. In addition, Wagner et al., observed a significant increase in Vmax
in rats with a controlled cortical impact (CCI) that received a daily injection of
methylphenidate (5 mg/kg) for 14 days, but there was no change in total tissue or
membrane bound DAT expression compared to the CCI rats that received saline
(Wagner et al., 2009). These findings demonstrate that methylphenidate has the
ability to increase the Vmax without altering total of surface DAT expression, which
is consistent with the results of this current study. A more recent study examined
the long-term effects on striatal DAT density of a 2-week methylphenidate
treatment given to SHR rats and WKY rats (Roessner et al., 2010).
Methylphenidate was given through drinking water and was adjusted to about 2
mg/kg/day based on daily monitoring of amounts consumed by the two rats per
cage and their body weight. Methylphenidate significantly decreased [3H]GBR
binding in SHR and WKY models at post-natal day 90 when compared to
controls.

This

study

demonstrates
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that

long-term

administration

of

methylphenidate reduced the striatal DAT density in both rat strains. However,
this finding reveals that methylphenidate caused a decrease in the amount of
DAT, but the effect on DAT function after in vivo administration of
methylphenidate was not assessed. Due to a time constraint, the 14-day
experiment on DAT trafficking could not be performed, however based on the
results from the 7-day experiment, it is speculated that methylphenidate may
cause a decrease in surface DAT in regards to DAT trafficking because the
effect of methylphenidate on DAT function was no longer observed after 14 days.
One study found that prolonged D3 receptor stimulation can cause a decrease in
DAT function and a decrease in DAT cell surface expression (Zapata et al.,
2007). In addition, a study has shown that methylphenidate interacts with the D3
receptors (Andersen et al., 2008), adding credence to the theorized results for
the 14-day experiment.
This current work, to our knowledge, is the first to report the effect of acute
and repeated in vivo administration of methylphenidate on DAT function.

In

summary, with DAT being a part of such a dynamic system, there is evidence
that

collectively

suggests

that

multiple

pathways

exist

to

regulate

neurotransmitter transport function (Samuel et al., 2005).
There have also been other examples where there was an increase in DAT
function, but no change in DAT expression. For instance, one report found that
nicotine increased Vmax for [3H]DA uptake, however no increase in cell surface
DAT expression was seen (Middleton et al., 2007). In addition, subfractionation
experiments revealed no difference in dopamine transporter levels in total and
plasma membrane fractions. Furthermore, another study reported that insulin
increased NET function without a change in transport cellular localization
(Apparsundaram et al., 2001). Taken together, these results suggest that it is
possible to have an increase in DAT function with no change in total DAT
expression, which is what the present study found.
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C.

Potential

Mechanism

for

the

Methylphenidate-Induced

Increase in VMAT2 Function
The results of the VMAT2 experiments with methylphenidate are
consistent with previous results showing that a single 40 mg/kg s.c. injection of
methylphenidate increased vesicular DA uptake (Fleckenstein et al., 1999;
Sandoval et al., 2002). The latter study also revealed that D1 and D2 receptor
activity may also by involved in the increase in VMAT2 function by
methylphenidate, since pretreatment with SCH23390, a D1 receptor antagonist
and

eticlopride,

a

D2

methylphenidate-induced

receptor
increases

antagonist
in

both,

VMAT2

completely

function.

inhibited

Furthermore,

methylphenidate may indirectly act as a DA agonist (Wilens, 2008). This may
also explain the increase of VMAT2 function because if methylphenidate acts as
a DA agonist, it could activate both pre and post synaptic D2 DA receptors, thus
indirectly causing an increase in VMAT2 function in order to remove the DA in
the cytosol, which would increase the activation of the D2 DA receptors.
Previous reports have shown that methylphenidate (40 mg/kg) can
increase VMAT2 function accessed 60 minutes after in vivo administration
(Sandoval et al., 2002). Based on the present results, it is very likely that
methylphenidate may be interacting with vesicles in the same way as its
interactions with synaptosomes, since methylphenidate increased both VMAT2
and DAT function. Methylphenidate administration did not alter the Km, which
suggests that methylphenidate competes with dopamine at VMAT2 in a
noncompetitive manner. The current results suggest that methylphenidate acts
differently than lobeline and amphetamine, in reference to the effects observed
on VMAT2 function. The observation that amphetamine and methylphenidate
influence VMAT2 differently at the time point and doses used in this study maybe
rather surprising since both drugs have been shown to target VMAT2
(Greydanus et al., 2007; Thanos et al., 2007).

However, the data in these

studies could be a result of the difference in their mechanisms of action. This
could possibly explain our observations of an increase in DAT and VMAT2
function by methylphenidate and no effect by amphetamine. The data produced
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from this dissertation research are the first to show that in vivo administration of
methylphenidate increased DAT and VMAT2 function. A recent review on
VMAT2 regulation suggest that the altered sensitivity to the locomotor activity
effects of cocaine, amphetamine, and alcohol in VMAT2-knockout mice is tied
closely to the expression of VMAT2 (Takahashi et al., 1997). This review also
states that by gaining a better understanding of VMAT2 dynamics may open the
door to improved pharmacotherapies used to treat psychiatric disorders and
addiction. In addition, methylphenidate was shown to decrease the intracellular
DAT expression, implying that methylphenidate does redistribute DAT. Initially,
methylphenidate was thought to have a more direct and less complicated
mechanism of action based on previous studies. However, the novel results from
this research demonstrate that the mechanism of action of methylphenidate may
be more complicated than previously thought.
D.

Implications

The results of this dissertation work imply that methylphenidate interacts
with DAT in a different manner than amphetamine and lobeline. Based on the
current results showing that lobeline had no effect on DAT and VMAT2 function,
lobeline does not appear to be a plausible treatment option for ADHD. The lack
of effect on DAT and VMAT2 function observed with lobeline could be that the
behavioral

effect,

which

was

the

decreased

self-administration

of

methamphetamine observed in the behavioral study, may involve an interaction
with the α4β2 nAChR and not due to DAT or VMAT2 involvement. However,
lobeline, an analogue of lobeline, causes this same behavioral effect and has
little or no affinity for α4β2* or α7* nAChRs (Miller et al., 2004; Zheng et al.,
2005). Therefore, the cause of the behavioral effect of lobeline requires
additional research to determine what receptors and transporter proteins are
involved in eliciting the behavioral effect of lobeline.
However, amphetamine, an effective treatment for ADHD, had no effect
either. Therefore, additional information is needed to determine if lobeline is
actually a potential treatment option for ADHD. Furthermore, Levin et al. showed
lobeline enhanced learning on the post-acquisition working memory performance
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in the radial-arm maze (Levin et al., 2003). In addition, lobeline has been found to
improve retention performance 24 hours after injection in spatial discrimination
water maze (Decker et al., 1993). Previous work has also demonstrated that
lobeline may be an effective smoking cessation agent by showing that lobeline
acts as a nicotinic antagonist by inhibiting nicotine-evoked DA release and
nicotine-evoked

86

Rb+ efflux (Miller et al., 2000). Lobeline has been used as an

over-the-counter smoking cessation agent in the past in the US (Nunn-Thompson
& Simon, 1989; Prignot, 1989) and numerous human studies have been
conducted to determine efficacy of lobeline as a smoking cessation agent,
although its use is still debatable (Dwoskin & Crooks, 2002). This characteristic
gives lobeline an additional advantage to the currently used ADHD treatments
because it has been shown that there is a higher rate of smoking in people who
have ADHD compared to those who do not (Milberger et al., 1997). Another
benefit of lobeline is that it does not have typical stimulant side-effects such as
abuse liability (Harrod et al., 2003).
In addition, this study unexpectedly found that amphetamine had no effect
on DAT function. However, there have been behavioral reports that have
demonstrated a difference in effect between methylphenidate and amphetamine.
For example, a previous study discovered that 5 mg/kg of amphetamine
produced more sniffing over a 2-hour observation period than rats receiving
either saline or 30 mg/kg of methylphenidate (Roffman & Raskin, 1997).

In

addition, methylphenidate-treated rats exhibited significantly higher total gnawing
than saline or amphetamine-treated rats. Moreover, another study found that
amphetamine and methylphenidate had differential effects on enriched
environmental condition (EC) and impoverished condition (IC) rats. Amphetamine
increased impulsivity choice in EC rats, however methylphenidate had no
significant effect in EC rats (Perry et al., 2008). The authors hypothesized that
the differences in DAT function in mPFC may be associated with these results
because EC rats show a decreased DAT function in mPFC, but not in striatum or
nucleus accumbens, implying that EC rats could have higher levels of
extracellular DA in the mPFC than IC rats (Zhu et al., 2004; Zhu et al., 2005).
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Biochemical studies have also obtained similar results. For instance, one
study found that methylphenidate may interact with a domain on DAT that is
distinct from that of amphetamine due to their different affinities observed with
mutant DAT (Dar et al., 2005).

In addition, Schiffer et al., found that

amphetamine increased extracellular DA more than methylphenidate using
microdialysis, suggesting that the differences between these agents in
modulating extracellular DA may be based on their differences in their molecular
mechanisms, i.e., amphetamine also causes release of DA and methylphenidate
does not (Schiffer et al., 2006). The differential effects of amphetamine and
methylphenidate have been recorded in the clinical setting as well. Borcherding
conducted a study with 45 hyperactive boys and found that subjects taking
amphetamine had increased cleaning and checking behaviors similar to
childhood-onset Obsessive-Compulsive Disorder (OCD). On the other hand, the
subjects that were given methylphenidate displayed perfectionistic and detailoriented behavior, as well as abnormal movements and compulsive behavior
(Borcherding et al., 1990). Taken together, the results of the preclinical
behavioral and biochemical studies, as well as the clinical findings, suggest that
methylphenidate and amphetamine may interact at DAT in different manners to
cause these differential effects.
This research has also led to clinical implications. Based on the preclinical
data of lobeline, a clinical trial was conducted using lobeline. The clinical trial was
a single small-N pilot study to determine the ability of lobeline to decrease ADHD
symptoms in adults. The study was a double-blind, double-dummy, placebocontrolled, within-subject design. Inclusion criteria for the study included being
healthy individuals between 21 and 45 yrs old, with childhood histories and
current symptoms of ADHD (meet diagnostic criteria on the clinical interview and
CAARS) and able to stop current medications for 7 days prior to the clinical trial.
Females were either nonchildbearing (tubal ligation or total hysterectomy) or of
childbearing potential using one or more of the following barrier methods of
contraception: male or female condoms (with spermicide), diaphragm (with
spermicide) and/or intrauterine device (with/without spermicide). No other
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contraceptives were acceptable. Subjects must have a body mass index (BMI)
between 18 and 30 and be willing and able to give written consent. Subjects must
have no medical contraindications determined by the following: an adequate
medical history, a physical examination including vital signs, 12-lead ECG, CBC
with differential and liver functions and urinalysis and a negative drug test
(barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids,
ethanol) at screening and at the time of each admission to the GCRC and CO ≤ 8.
Salivary cotinine was collected and assessed at baseline to determine whether or
not the subject was using smokeless tobacco included being a non-smoker
between the ages of 21-45, in good general health, no current drug use, and
having a history of childhood ADHD symptoms and current ADHD symptoms.
Medical and psychiatric evaluations were conducted. The medical evaluation
consisted of a physical examination (conducted by the PI) and an EKG reviewed
by an Internist/pediatrician (Dr. C. Feddock) with particular attention to
arrhythmias, prolonged QT or heart block. Subjects provided a urine sample for
drug screening, standard urinalysis and βHCG pregnancy tests (for female
subjects). A blood sample was drawn for a complete blood count with differential
and liver function tests. Subjects will undergo breath sample analysis on-site with
an Alco-Sensor Intoximeter and an Innovative Medical CO Monitor. To qualify for
the study, subjects must be non-smokers and CO must be ≤ 8 ppm.
The psychiatric assessment included a structured clinical interview based on
the DSM-IV (SCID) supplemented with ADHD symptoms from the KSADS-E
(Wilens et al, 2003). In addition, the Conners Adult Rating Scale (CAARS) will be
completed. These measures assessed the presence of ADHD and degree of
symptomatology. The Shipley Institute of Living Test was obtained to determine
an estimate of intellectual functioning.
Exclusion criteria included regular use of drugs of abuse, current use of
psychiatric medications other than short acting medications for ADHD, having an
abnormal EKG or hypertension (blood pressure over 150/90 on two consecutive
measures over 15 min when the subject is at rest), being pregnancy, having
current medical difficulties or legal problems, regular use of prescription medicine
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that cannot be discontinued and current use of nicotine and active suicidal
behaviors.
The acute effects of LOB on indices of attention, impulsivity and working
memory were the primary outcomes measures to be assessed; outcomes will be
compared to results obtained with placebo and with the positive control
comparator, methylphenidate, a medication with efficacy for this disorder.
Secondary outcome measures will include physiological and subjective drug effect
reports to provide additional information on safety, abuse liability and tolerability
(e.g., appetite, sleep, side effects).
The first subject was consented on July 30, 2008 and the final subject
consented on October 8, 2009. A total of 42 subjects were enrolled in the study
and screened at intake (18 females and 24 males). Out of the 42 subjects, only 13
were randomized into the protocol because 29 did not meet the inclusion criteria.
Some of the screening failures included elevated BMI, elevated scores on the
Beck Depression Inventory, a CAARS score of >65, 2 positive drug screens,
failure to meet the demands of the protocol (i.e., scheduling conflicts), and family
history of early cardiac death. Out of the 13 subjects that were randomized 4
withdrew, leaving a total of 9 subjects that completed the study. In regards to
demographics of the 13 subjects, 1 was an African American female, 5 were
White females, and 7 were White males. The subjects that withdrew were the
African American female, 1 White female, and 2 White males.
The results of the study showed that lobeline did not have a significant
effect on reducing ADHD symptoms using the outcomes assessed in this trial.
However, it was also difficult to observe a significant effect with methylphenidate,
suggesting that the testing parameters may not have been most appropriate to
use. In addition, various subjects complained of a bitter taste and a burning
sensation with the administration of lobeline sublingual tablet. This adverse effect
could have played a role in the lack of effect observed with lobeline, causing the
subjects to become distracted by the bitter taste or burning sensation. Therefore,
if the subjects were distracted, they might have performed worse on the tests
used to assess for improved attention after administration of lobeline. To
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determine if the adverse effects affected the results of the study, another study
should be conducted with a different dosage form of lobeline, such as a
transdermal patch to alleviate the adverse effect of the bitter taste and burning
sensation. This additional study would confirm if lobeline is able to reduce ADHD
symptoms and provide an overall perspective of the clinical implications of
lobeline as a treatment option for ADHD.
E.

Limitations

One limitation was the choice of using adult rats for the study rather than
adolescent rats, since ADHD is known to be a childhood disorder. However, adult
rats were used to obtain preliminary results as to how lobeline interacts with DAT
and VMAT2 in normal adult rats. Just as clinical studies use healthy subjects to
investigate

the

characteristics

of

an

investigational

drug,

such

as

pharmacokinetics and side effects, we used normal adult rats to gain knowledge
as to how lobeline interacts with DAT and VMAT2. In fact, using adults rats may
not be an actual limitation since ADHD has been shown to persist into adulthood
and more cases of adult ADHD are being diagnosed (American Psychiatric
Association, 2000; de Graaf et al., 2008).
Another limitation was only examining one region of the brain. The
striatum was initially chosen based on the support that DAT is highly expressed
in the striatum (Ciliax et al., 1999). However, recent research focused on the
PFC and reports that it is an essential region of the brain that governs and
maintains attention (Arnsten et al., 2009). For example, improved PFC cognitive
function, i.e., spatial working memory, in monkeys was observed with the optimal
dose of methylphenidate and amphetamine (Gamo et al., 2010). This same study
also stated that PFC function is vastly controlled by DA and NE. In addition, the
authors found that the regulation of the PFC is altered in many ADHD patients.
Based on this increasing amount of evidence, it is necessary to conduct studies
in the PFC to gain a better understanding of the mechanisms of actions of
lobeline, methylphenidate, and amphetamine in this brain region.
The use of individual doses for the chronic studies could be a limitation as
well. The chronic doses were to be based on the effective acute doses. However,
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amphetamine and lobeline did not have an effect in the actue experiments.
Therefore, the doses chosen for the chronic studies for these compounds were
based on behavioral studies. Since a complete dose-response was used for
acute studies, it would be more beneficial to also conduct a complete doseresponse with the chronic studies as well. This would ensure a more complete
picture as to how the compounds interact with the various targets. Determining
the dose-response relationship is imperative when studying different compounds
and their effects on certain targets because it provides vital information as to how
the dose affects the primary outcome measure. Therefore, to address this
limitation it would be prudent to include a dose-response for the chronic studies
as well.
F.

Future Directions

The experiments completed in this dissertation examined the effects of
acute and repeated in vivo administration of lobeline, methylphenidate, and
amphetamine on DAT function in the striatum. Further studies are needed to
investigate the effects of acute and repeated in vivo administration of lobeline,
methylphenidate, and amphetamine on DAT function in the PFC since the PFC is
also widely studied because of its involvement in the regulation of behavior,
attention, affect, motor and cognitive control (Arnsten, 2006; Kieling et al., 2008).
Numerous studies have considered the PFC as a region of interest in examining
the pathophysiology of ADHD (Barkley et al., 1992; Goldman-Rakic, 1996;
Robbins, 1996).
Due to the recent addition of atomoxetine, a selective NET inhibitor, as a
treatment option for ADHD, it is important to determine the effects lobeline has
on this transporter function as well. Impaired regulation of NE neurotransmission
is suggested to contribute to ADHD (Beane & Marrocco, 2004). Studies have
shown, using microdialysis that methylphenidate and amphetamine substantially
increased NE and DA efflux within the PFC to enhance cognitive function
(Berridge et al., 2006; Berridge & Stalnaker, 2002). Methylphenidate also has an
affinity for NET (Andersen, 1989; Easton et al., 2007; Kuczenski & Segal, 1997;
Richelson & Pfenning, 1984). One report even suggests that methylphenidate
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has a higher affinity for NET than DAT (Eshleman et al., 1999). Moreover, a
preclinical study found that methylphenidate-treated rats (0.5 mg/kg, ip) produced
a maximal increase in NE levels significantly larger than the increase of DA in the
PFC (Berridge et al., 2006). Furthermore, the first in vivo study in humans
showed that clinically relevant doses of methylphenidate occupy significant levels
of NET. The results from this study imply that the therapeutic effect of
methylphenidate in ADHD may be modulated via NET inhibition as well as DAT
(Hannestad et al., 2010). A recent review also stated that the majority of drugs
shown to be effective in treating ADHD have important effects on NE
transmission (Del Campo et al., 2011). Thus, there is overwhelming evidence
that NET is an important target that needs to be investigated to determine the
effect lobeline may have on it.
Another suggested future study involves investigating the effects of acute
and repeated in vivo administration of lobeline, methylphenidate, and
amphetamine on DAT and VMAT2 function in adolescent rats as well. Studies
have indicated that age plays a major role in response to ADHD medications due
to the fact that the adolescent brain is still undergoing development, which makes
it more sensitive to the effects of these medications (Canese et al., 2009; Yang et
al., 2003; Yang et al., 2006).
Furthermore, in order to validate the use of lobeline for the treatment of
ADHD, it would be useful to determine if lobeline is effective in reducing the
symptoms of ADHD found in an ADHD rat model. Based on the review of the
literature, convergent evidence suggests that the SHR is one of the best animal
ADHD models (Heal et al., 2008; McCarty et al., 1980; Sagvolden, 2000). Thus, it
would be worthwhile to investigate the effect lobeline has on SHR rats and to
compare its effect to the effects of methylphenidate and amphetamine.
In conclusion, this dissertation research has provided new insights into the
mechanism of action of lobeline and how it interacts with DAT and VMAT2. This
work also extended previous findings as to how methylphenidate interacts with
DAT and VMAT2. Further studies are needed to gain a better understanding of
the exact mechanism responsible for the increase in DAT function caused by
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methylphenidate. Based on the current results showing that lobeline had no
effect on DAT and VMAT2 function, lobeline does not appear to be a plausible
treatment option for ADHD. However, amphetamine, an effective treatment for
ADHD, had no effect either. Therefore, more experiments are warranted in order
to elucidate the mechanism of lobeline and the other compounds. Ultimately,
these additional studies may offer leads for developing related novel and more
effective neuropharmacologic therapeutic agents for ADHD and other psychiatric
disorders. Furthermore, we did find exciting new data that showed that acute and
repeated methylphenidate increased DAT and VMAT2 function after in vivo
administration. These data provide evidence that VMAT2 is also an important
target worthy of further research for additional novel therapeutic compounds.
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